Optimizing the Treatment of Acute Promyelocytic Leukemia: A Maintenance-Free Strategy for Complete Remission

Optimizing the Treatment of Acute Promyelocytic Leukemia: A Maintenance-Free Strategy for Complete Remission | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Optimizing the Treatment of Acute Promyelocytic Leukemia: A Maintenance-Free Strategy for Complete Remission Muhammad Kamruzzaman, Sanghita Banik Proma, Mohit Kumar Pramanik, and 2 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4204216/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background: Acute promyelocytic leukemia (APL) is a distinct variant of acute myeloid leukemia (AML), comprising 5–10% of all AML cases. Characterized by the t(15;17) chromosomal translocation, APL presents a unique challenge due to its associated bleeding manifestations and coagulopathy, emphasizing the need for urgent and specialized management. Methods: This prospective open-label pilot study enrolled ten newly diagnosed APL patients, stratified based on the Sanz risk score. Low and intermediate-risk patients underwent ATRA-ATO induction therapy, followed by consolidation therapy. High-risk patients received additional Daunorubicin or Mitoxantrone alongside ATRA-ATO induction. The study evaluated patient characteristics, clinical findings, laboratory results, and treatment outcomes, focusing on complete remission (CR) after induction therapy and disease-free survival (DFS) at 3 years. Results: The study observed a 100% CR rate after induction therapy, with favorable 3-year DFS and event-free survival (EFS). No treatment failures, mortality, or relapses were reported. Laboratory findings and clinical outcomes were consistent with established characteristics of APL. The absence of maintenance therapy minimized associated toxicities, supporting the safety and efficacy of the chemotherapy-free ATRA-ATO approach. Conclusion: This pilot study underscores the potential paradigm shift in APL management by demonstrating the safety and efficacy of a chemotherapy-free ATRA-ATO strategy. The results align with the 2023 National Comprehensive Cancer Network (NCCN) update, endorsing the ATRA-ATO regimen for APL. The ongoing nature of the research emphasizes its contribution to evolving APL management practices, encouraging further comprehensive evaluations on a broader scale. Acute Promyelocytic Leukemia (APL) All-trans Retinoic Acid(ATRA) Arsenic Trioxide (ATO) Complete Remission Introduction Acute promyelocytic leukemia (APL) is a distinct variant of acute myeloid leukemia (AML), with an incidence of 5–10% of all AML cases 1 . APL origins from a chromosomal translocation, typically t(15;17) (q22;q12-21), which results in the merging of the promyelocytic leukemia (PML) gene with the retinoic acid receptor alpha (RARA) gene 2 . The characteristic symptom of APL is the associated bleeding manifestation (coagulopathy), which leads to a significant incidence of both hemorrhage and thrombosis. As hemorrhage has been identified as the primary cause of early mortality in APL 3 , 4 , 5 , managing the case as a medical emergency is crucial to prevent its complications and fatality 6 . Until 2017, due to the clinical heterogeneity between APL and AML, APL was traditionally treated using standard AML-directed chemotherapeutic induction regimens that caused high rates of relapse and early mortality 7 , 8 . The APL treatment was revolutionized due to the introduction of all-trans retinoic acid (ATRA) along with other components, decreasing the 5-year mortality rate from 82–36% 9 . Because of advancements in the treatment of this disease, APL is now considered the most curable form of leukemia. The established standard of care in treating APL involves combining ATRA with chemotherapy, achieving a complete remission (CR) rate ranging from 90–95%, and long-term survivals up to 80% 10–14 . Despite these high CR rates, there were still notable challenges found such as induction mortality being at 10% and relapse rates between 20% and 30% 10,15,16 . Initially, in cases where relapse occurred following ATRA-chemotherapy treatment protocols, arsenic trioxide (ATO) was incorporated, which showed a favorable outcome 17 – 19 . Subsequently, in 2004, the use of an ATRA-ATO combination therapy for newly diagnosed APL was reported, demonstrating curative effects in 90% of patients 16 , 20 . Multiple clinical trials have evaluated ATRA- and ATO-based induction regimens, establishing the safety and efficacy of this combination. It has been documented to be superior to ATRA plus chemotherapy, particularly in patients classified as low to intermediate risk 12 , 16 , 18 , 21 – 23 . These results have significantly altered frontline practices, resulting in integrating intravenous ATO with ATRA with or without chemotherapy in most current induction regimens. This treatment protocol has increased the CR rates ranging from 90–100%, as well as long-term survival rates of 86–97% 12,14,20,23,24 . Although high-risk patients were more difficult to treat, an exploratory study by the MD Anderson Cancer Center suggested that the addition of a de-escalating cytotoxic regimen such as Gemtuzumab ozogamicin (GO) makes their treatment feasible 18 . Given the physical and financial strain of maintenance doses for APL patients in our country, we sought a course of action to treat APL without requiring a maintenance dose. In addition, life-threatening complications like myelosuppression and cardiotoxicity were found in previous studies where chemotherapy was included 16 , 20 , increasing the burden on patients. The potential for overtreatment in low-risk to intermediate-risk patients due to inadequate risk stratification further raised concerns 25 . Considering these factors, we systematically reviewed the clinical trials, selecting two protocols without maintenance dosage and successful remission. Emphasizing minimal use of cytotoxic chemotherapy, we opted for the approach used in the study by Abaza et al., which involved no cytotoxic chemotherapy in low and intermediate-risk patients and a single dose during induction in high-risk patients. The shifts in the demographics and epidemiology of the condition of APL are becoming evident along with the evolution of therapeutic options. The changing landscape is highlighting the emergence of ethnic disparities in APL incidence over time. In our pilot study, we aim to account for these factors and overcome the limitations of conventional management of APL. The focus is on developing tailored strategies to alleviate the burden of maintenance dose and complications of cytotoxic chemotherapy. Our study aims to lay the foundation for a comprehensive evaluation of APL management on a broader scale, with the goal of minimizing associated toxicities and costs while enhancing therapeutic efficacy and tolerance. The primary objective is to investigate the potential replacement or reduction of chemotherapy in consolidation therapy through the application of the ATRA-ATO combination in APL patients following Sanz risk stratification. Materials and Methods Study Design: This is a prospective open-label pilot study conducted on ten patients newly diagnosed with acute promyelocytic leukemia seeking treatment in the Department of Hematology at Sir Salimullah Medical College Mitford Hospital. The study has been ongoing since August 2020, during the COVID-19 period. By June 2023, 14 patients had successfully reached the primary endpoint of our study protocol and were incorporated into this pilot study. Initial screening was done based on morphological diagnosis, but the confirmation of the PML-RARA fusion gene through RT-PCR was necessary for subsequent enrollment. Patients were then stratified into three risk groups based on the Sanz risk score, with seven falling into the low (WBC count ≤ 10 × 10^9/L and platelet count > 40 × 10^9/L) and intermediate risk (WBC count ≤ 10 × 10^9/L and platelet count ≤ 40 × 10^9/L) categories, while three were classified as high-risk patients (WBC count ≥ 10 × 10^9 cells per L). Treatment Regimen: This study followed the treatment regimen outlined in the clinical trial conducted by Abaza et al in 2017 24 . All patients underwent ATRA-ATO–based induction therapy, with ATRA (45 mg/m 2 ) and ATO (0.15 mg/kg/day) administered during the induction protocol for 45 to 60 days in low and intermediate-risk patients. This was followed by three cycles of consolidation therapy with ATRA + ATO. For high-risk patients, two received Daunorubicin (45 mg/m 2 ), and one received Mitoxantrone (12 mg/m 2 ) as a single dose alongside ATRA + ATO in induction. Subsequently, four consolidation courses of ATO (0.15 mg/kg/day, five days per week, every alternate month over 7 months) and ATRA (45 mg/m 2 , fifteen days on & fifteen days off for 7 months) were administered, with follow-up recommendations provided. Supportive Measures: Standard guidelines were followed for hydration, infection control, prevention measures, management of hyperleukocytosis, correction of the prolonged QT interval, and monitoring for hematologic and nonhematologic toxic effects. At the earliest manifestations of suspected differentiation syndrome, ATRA was temporarily discontinued, and intravenous dexamethasone was administered at a dose of 10 mg every 12 hours until the disappearance of signs and symptoms for a minimum of 3 days. To prevent ATO complications, ECG, serum electrolytes, and serum magnesium were monitored twice weekly. If QT prolongation was identified (> 500 ms, uncorrected), ATO administration was halted for 6 days and resumed only when the QT interval was below 460 ms, with serum potassium exceeding 4 mEq/L, and serum magnesium surpassing 1.8 mg/dl. Primary End Point: The primary endpoint of our study was complete remission (CR) after induction therapy. Secondary endpoints included marrow complete remission (mCR) after consolidation therapy, disease-free survival (DFS), and event-free survival (EFS) after 3 years and early death. All these criteria were defined according to the recommendation of the International Working Group 26 . Results Table 1 Patient characteristics at the time of diagnosis: Characteristics Number of patients Age 45 years 3 Sex Male 6 Female 8 Sanz Risk Category Low-risk 0 Intermediate Risk 9 High-Risk 5 Table 2 Clinical findings of patients at the time of diagnosis: Clinical Findings Number of patients Generalized weakness 14 Fever 10 Features of bleeding Gum bleeding 6 Hematuria 2 Purpura and ecchymosis 2 Bony tenderness 0 DIC (disseminated intravascular coagulation) 8 Other co-morbidities 5 Table 3 Laboratory findings of patients at the time of diagnosis: Laboratory Findings Number of patients Hemoglobin% < 7 gm/dl 7 7–10 gm/dl 7 Thrombocytopenia Mild (1,00,000–1,50,000/mm 3 ) 3 Moderate (50,000–99,000/mm 3 ) 1 Severe (< 50,000/mm 3 ) 9 Total WBC count < 10,000 mm 3 11 Leukemic cells in peripheral blood 10 Table 5 Primary and secondary endpoint outcomes: Endpoints Number of patients Complete remission after induction therapy 14 Complete remission on Day 35 02 Complete remission on Day 45 07 Complete remission on Day 60 05 Disease-free survival (DFS) after 3 years/ Even-free survival (EFS) after 3 years 14 Treatment Failure 0 Mortality 0 Relapse 0 Discussion In our study, the age range of patients was 20–50 years, aligning with the prevailing pattern where APL is commonly diagnosed in younger adults aged 20–59 years and less frequently in both pediatric and elderly populations 27 . We observed the ratio between males and females was 1:1.5, which is consistent with findings from previous clinical trials and population-based research that showed a comparatively higher frequency of APL in women 28 . It has been suggested that estrogen, a member of the retinoid receptors' superfamily, could potentially work synergistically to impact the binding of the aberrant PML/RARA protein to the RXR receptor 28 . Patients with APL are at high risk for thrombohemorrhagic complications such as disseminated intravascular coagulation (DIC), venous thromboembolism, and bleeding manifestations. Oral bleeding is a common finding in APL and can be an initial evidence of the disease 29 and it was also found prevalent among our patients. The majority of our patients also had DIC as a clinical finding, which was persistent with the higher prevalence of DIC associated with APL compared to other subtypes of acute leukemia 30 . Hematological findings like anemia, thrombocytopenia, leukopenia, and an elevated blast count, are characteristic features of acute promyelocytic leukemia (APL). The blood test reports of our patients were consistent with these typical findings. Severe thrombocytopenia is associated with an increased risk of bleeding and was found in nearly all of our patients 31 . Our study aimed to demonstrate that the use of ATRA and arsenic trioxide in both induction and consolidation therapy is potentially superior compared to the standard ATRA and anthracycline-based chemotherapy in adults with low-to-intermediate-risk APL. The combination of ATRA and ATO has already been proven effective as a frontline treatment for APL. A study by Shen et al, where induction was done with ATRA plus ATO and consolidation by chemotherapy, resulted in complete remission (CR) in 94% of patients 16 . Our study replicates such favorable outcomes while eliminating the use of chemotherapy. Notably, our findings are consistent with recent studies by Lo-Coco et al and Abaza et al. These studies demonstrated the superiority of ATRA plus ATO over ATRA plus chemotherapy in low- to intermediate-risk APL patients. Besides 100% complete remission, we also report a 100% 3-year EFS where Lo-Coco et al. reported 98% and Abaza et al reported 96%, surpassing the 85% EFS observed in the chemotherapy group. To improve outcomes in high-risk patients, we followed the treatment protocol outlined by Burnett et al. To the ATRA-ATO combination, we added Daunorubicin or Mitoxantrone, resulting in a significant improvement of both CR and survival rates compared with previous reports. Mitoxantrone was added in a case involving a patient with cardiac issues, as Daunorubicin was unavailable at that time. Importantly, our high-risk patients achieved complete remission without any maintenance therapy, providing additional evidence of the superiority of this treatment regimen. Beyond the therapeutic advantages, our study also verified the regimen's benefits in substantially minimizing hematological side effects. While common side effects such as differentiation syndrome and QTc prolongation were noted, they were manageable. The primary limitation of this study is its single-center, nonrandomized design. The relatively small sample size is attributed to the fact that the patients included in this pilot study have already met our primary endpoints. In the meantime, in the 2023 update to the guidelines for the management of APL, the National Comprehensive Cancer Network (NCCN) has also recommended the use of the ATRA-ATO regimen for low-risk patients, while suggesting the incorporation of Idarubicin along with the ATRA-ATO regimen for high-risk patients. Nonetheless, it's important to note that our study is ongoing, continually demonstrating the effectiveness of this regimen. Conclusion In conclusion, our pilot study demonstrates the safety and efficacy of the chemotherapy-free ATRA plus ATO approach, with or without GO. This treatment regimen ensures long-term disease-free survival across all risk-group patients while reducing the burden of maintenance medication. Recognizing the substantial impact of this treatment regimen on enhancing the quality of care for APL patients, we have decided to disseminate the results of our pilot study. Further evaluation of our research findings on a larger scale is imperative, and we are actively continuing our study to contribute to the ongoing understanding of APL management. Limitations This is a single-center, nonrandomized study in nature, including the patients who were only treated at our hospital. However, the similarity of results to those reported in previous studies supports the efficacy of this regimen. Declarations Ethics approval and consent to participate: All procedures involving patient samples were approved by the Ethical Committee of Sir Salimullah Medical College Mitford Hospital, and written informed consent was obtained from all patients. Consent for publication: Informed written consent was obtained from all the patients involved in the study. Availability of data and materials: The datasets used and analyzed during the current study are available from the corresponding author upon reasonable request. Competing interests: The authors declare that they have no competing interests. Funding: None. Author Contribution MK conceptualized the study. SBP designed the study and wrote the manuscript. MKP and MA collected the data. MK and MSI revised the manuscript. All the authors have read and reviewed the manuscript. References Gill H, Raghupathy R, Lee CYY, Yung Y, Chu HT, Ni MY et al. Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021. BMC Cancer. 2023;23(1). https://doi.org/10.1186/s12885-023-10612-z . Tallman MS, Altman JK. How I treat acute promyelocytic leukemia. Blood. 2009;114(25):5126–35. https://doi.org/10.1182/blood-2009-07-216457 . Paulson K, Serebrin A, Lambert P, Bergeron J, Everett J, Kew A et al. Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study. British Journal of Haematology. 2014;166(5):660–6. https://doi.org/10.1111/bjh.12931 . Rahmé R, Thomas X, Récher C, Vey N, Delaunay J, Deconinck E et al. Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients. Leukemia. 2014;28(12):2422–4. https://doi.org/10.1038/leu.2014.240 . Yohannan B, Cervoni-Curet F, Rios A. AML-156 Early deaths in patients with newly diagnosed acute promyelocytic leukemia: a Single-Center Retrospective Study from a general hospital. Clinical Lymphoma, Myeloma & Leukemia. 2022;22:S219–20. https://doi.org/10.1016/s2152-2650(22)01233-2 . Sanz MÁ, Fenaux P, Tallman MS, Estey EH, Löwenberg B, Naoe T et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019;133(15):1630–43. https://doi.org/10.1182/blood-2019-01-894980 . Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood. 1990;75(11):2112–7. https://doi.org/10.1182/blood.v75.11.2112.2112 . Watts JM, Tallman MS. Acute promyelocytic leukemia: What is the new standard of care? Blood Reviews. 2014;28(5):205–12. https://doi.org/10.1016/j.blre.2014.07.001 . Chen Y, Kantarjian HM, Wang H, Cortes J, Ravandi F. Acute promyelocytic leukemia: A population-based study on incidence and survival in the United States, 1975‐2008. Cancer. 2012;118(23):5811–8. https://doi.org/10.1002/cncr.27623 . Tallman MS, Andersen J, Schiffer CA, Appelbaum FR, Feusner J, Ogden A et al. All-trans-Retinoic acid in acute promyelocytic leukemia. The New England Journal of Medicine. 1997;337(15):1021–8. https://doi.org/10.1056/nejm199710093371501 . Lengfelder E, Haferlach C, Saußele S, Haferlach T, Schultheis B, Schnittger S et al. High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia. 2009;23(12):2248–58. https://doi.org/10.1038/leu.2009.183 . Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Iacobelli S, Ferrara F et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. The New England Journal of Medicine. 2013;369(2):111–21. https://doi.org/10.1056/nejmoa1300874 . Kelaïdi C, Chevret S, De Botton S, Raffoux E, Guerci A, Thomas X et al. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. Journal of Clinical Oncology. 2009;27(16):2668–76. https://doi.org/10.1200/jco.2008.18.4119 . Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. The Lancet Oncology. 2015;16(13):1295–305. https://doi.org/10.1016/s1470-2045(15)00193-x . De Botton S, Sanz MÁ, Chevret S, Dombret H, Martı́N G, Thomas X et al. Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia. 2005;20(1):35–41. https://doi.org/10.1038/sj.leu.2404006 . Shen ZX, Shi Z, Fang J, Gu BW, Li J, Zhu Y et al. All-trans retinoic acid/As 2 O 3 combination yields a high-quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(15):5328–35. https://doi.org/10.1073/pnas.0400053101 . Jq M, Jm L, Zx S, Sj C, Chen Z. How to manage acute promyelocytic leukemia. Leukemia [Internet]. 2012;26(8):1743–51. https://doi.org/10.1038/leu.2012.57 . Ravandi F, Estey E, Jones D, Faderl S, O’Brien S, Fiorentino J et al. Effective treatment of acute promyelocytic leukemia with All-Trans-Retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. Journal of Clinical Oncology. 2009;27(4):504–10. https://doi.org/10.1200/jco.2008.18.6130 . Raffoux E, Rousselot P, Poupon J, Daniel M, Cassinat B, Delarue R et al. Combined treatment with arsenic trioxide and All-Trans-Retinoic acid in patients with relapsed acute promyelocytic leukemia. Journal of Clinical Oncology. 2003;21(12):2326–34. https://doi.org/10.1200/jco.2003.01.149 . Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(9):3342–7. https://doi.org/10.1073/pnas.0813280106 . Wang G, Li W, Cui J, Gao S, Cheng Y, Jiang Z et al. An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all‐trans retinoic acid. Hematological Oncology. 2004;22(2):63–71. https://doi.org/10.1002/hon.728 . Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovšek S, Jones D et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006;107(9):3469–73. https://doi.org/10.1182/blood-2005-10-4006 . Iland H, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012;120(8):1570–80. https://doi.org/10.1182/blood-2012-02-410746 . Abaza Y, Kantarjian HM, Garcia-Manero G, Estey E, Borthakur G, Jabbour E et al. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017;129(10):1275–83. https://doi.org/10.1182/blood-2016-09-736686 . Sanz MÁ, Lo Coco F, Martı́N G, Avvisati G, Rayón C, Barbui T et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96(4):1247–53. https://doi.org/10.1182/blood.v96.4.1247 . Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Journal of Clinical Oncology. 2003;21(24):4642–9. https://doi.org/10.1200/jco.2003.04.036 . Avvisati G, Mele A, Ma S, Vegna ML, Pasquini P, Mandelli F. Epidemiology of acute promyelocytic leukemia in Italy. Annals of Oncology. 1991;2(6):405–8. https://doi.org/10.1093/oxfordjournals.annonc.a057974 . Douer D. The epidemiology of acute promyelocytic leukaemia. Best Practice & Research Clinical Haematology. 2003;16(3):357–67. https://doi.org/10.1016/s1521-6926(03)00065-3 . Bennett JS, Lin TL, Venkatesh P, Male H, Byrd KP. Acute promyelocytic leukemia: A single institution’s experience. Journal of Clinical Oncology. 2022;40(16_suppl):e19001. https://doi.org/10.1200/jco.2022.40.16_suppl.e19001 . Shahmarvand N, Oak J, Cascio MJ, Alcasid M, Goodman EH, Medeiros BC et al. A study of disseminated intravascular coagulation in acute leukemia reveals markedly elevated D-dimer levels are a sensitive indicator of acute promyelocytic leukemia. International Journal of Laboratory Hematology. 2017;39(4):375–83. https://doi.org/10.1111/ijlh.12636 . Salah MB, Bchir M, Berred R, Kharrat R, Abdennebi YB, Aissaouï L et al. PB1802: Acute Promyelocytic Leukemia and thrombosis: How to identify the high-risk patients? HemaSphere. 2022;6:1682–3. https://doi.org/10.1097/01.hs9.0000850060.85301.70 . Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4204216","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":286521613,"identity":"cbb33ba0-5f66-41af-b7be-93d63c1d02fe","order_by":0,"name":"Muhammad Kamruzzaman","email":"","orcid":"","institution":"Sir Salimullah Medical College Mitford Hospital","correspondingAuthor":false,"prefix":"","firstName":"Muhammad","middleName":"","lastName":"Kamruzzaman","suffix":""},{"id":286521614,"identity":"fc50552b-bc7d-4639-85b2-67fee4af3ced","order_by":1,"name":"Sanghita Banik Proma","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA8UlEQVRIiWNgGAWjYLACxgYJBgb2xsYHQDYPH7FaJBh4DjcbgLSwEamFQYJBIr1NAsQhqMWc//Czh193WNTx9xxsq/yaYyfDxsD88NENPFosZ6SZG8uekZCQON7Ydlt2WzLQYWzGxjl4tBjcYDCTlmwD+uXMwbbbktuYgVp42KTxajl//BtYi/yNxLZiyW31RGg5kGMm+RGoxQCohfHjtsOEtVjOyCmTZmyTkNx45mCzNOO24zxszAT8Ys5/fJvkz7Y6frnj7Q8//txWbc/P3vzwMV6HATEzD5QDYTDjUQ7TwvgDyoEzRsEoGAWjYBQgAwB4KUeYs3JURwAAAABJRU5ErkJggg==","orcid":"","institution":"Oxford Bangladesh Sepsis Research","correspondingAuthor":true,"prefix":"","firstName":"Sanghita","middleName":"Banik","lastName":"Proma","suffix":""},{"id":286521615,"identity":"afc9ec9f-b5df-4748-8e93-3c8b51bfa425","order_by":2,"name":"Mohit Kumar Pramanik","email":"","orcid":"","institution":"Sir Salimullah Medical College Mitford Hospital","correspondingAuthor":false,"prefix":"","firstName":"Mohit","middleName":"Kumar","lastName":"Pramanik","suffix":""},{"id":286521616,"identity":"845f339e-6d1d-475e-8b54-b8cbc2678582","order_by":3,"name":"Marzia Afrin","email":"","orcid":"","institution":"Sir Salimullah Medical College Mitford Hospital","correspondingAuthor":false,"prefix":"","firstName":"Marzia","middleName":"","lastName":"Afrin","suffix":""},{"id":286521617,"identity":"dafb0164-743d-475d-a4ef-3f25a3b161a0","order_by":4,"name":"Md. Sirajul Islam","email":"","orcid":"","institution":"Sir Salimullah Medical College Mitford Hospital","correspondingAuthor":false,"prefix":"","firstName":"Md.","middleName":"Sirajul","lastName":"Islam","suffix":""}],"badges":[],"createdAt":"2024-04-02 06:14:37","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4204216/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4204216/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":54383218,"identity":"9be49606-eb40-42b2-83d6-1c7a03b48473","added_by":"auto","created_at":"2024-04-09 16:23:21","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":329951,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4204216/v1/a1166198-53b5-49c0-9461-35f5851a436f.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Optimizing the Treatment of Acute Promyelocytic Leukemia: A Maintenance-Free Strategy for Complete Remission","fulltext":[{"header":"Introduction","content":"\u003cp\u003eAcute promyelocytic leukemia (APL) is a distinct variant of acute myeloid leukemia (AML), with an incidence of 5\u0026ndash;10% of all AML cases\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u003c/sup\u003e. APL origins from a chromosomal translocation, typically t(15;17) (q22;q12-21), which results in the merging of the promyelocytic leukemia (PML) gene with the retinoic acid receptor alpha (RARA) gene\u003csup\u003e\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e\u003c/sup\u003e. The characteristic symptom of APL is the associated bleeding manifestation (coagulopathy), which leads to a significant incidence of both hemorrhage and thrombosis. As hemorrhage has been identified as the primary cause of early mortality in APL\u003csup\u003e\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e,\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e,\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e\u003c/sup\u003e, managing the case as a medical emergency is crucial to prevent its complications and fatality\u003csup\u003e\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eUntil 2017, due to the clinical heterogeneity between APL and AML, APL was traditionally treated using standard AML-directed chemotherapeutic induction regimens that caused high rates of relapse and early mortality\u003csup\u003e\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e,\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e. The APL treatment was revolutionized due to the introduction of all-trans retinoic acid (ATRA) along with other components, decreasing the 5-year mortality rate from 82\u0026ndash;36%\u003csup\u003e9\u003c/sup\u003e. Because of advancements in the treatment of this disease, APL is now considered the most curable form of leukemia. The established standard of care in treating APL involves combining ATRA with chemotherapy, achieving a complete remission (CR) rate ranging from 90\u0026ndash;95%, and long-term survivals up to 80%\u003csup\u003e10\u0026ndash;14\u003c/sup\u003e. Despite these high CR rates, there were still notable challenges found such as induction mortality being at 10% and relapse rates between 20% and 30%\u003csup\u003e10,15,16\u003c/sup\u003e. Initially, in cases where relapse occurred following ATRA-chemotherapy treatment protocols, arsenic trioxide (ATO) was incorporated, which showed a favorable outcome\u003csup\u003e\u003cspan additionalcitationids=\"CR18\" citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u003c/sup\u003e. Subsequently, in 2004, the use of an ATRA-ATO combination therapy for newly diagnosed APL was reported, demonstrating curative effects in 90% of patients\u003csup\u003e\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e, \u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u003c/sup\u003e. Multiple clinical trials have evaluated ATRA- and ATO-based induction regimens, establishing the safety and efficacy of this combination. It has been documented to be superior to ATRA plus chemotherapy, particularly in patients classified as low to intermediate risk\u003csup\u003e\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e, \u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e, \u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e, \u003cspan additionalcitationids=\"CR22\" citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e. These results have significantly altered frontline practices, resulting in integrating intravenous ATO with ATRA with or without chemotherapy in most current induction regimens. This treatment protocol has increased the CR rates ranging from 90\u0026ndash;100%, as well as long-term survival rates of 86\u0026ndash;97%\u003csup\u003e12,14,20,23,24\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eAlthough high-risk patients were more difficult to treat, an exploratory study by the MD Anderson Cancer Center suggested that the addition of a de-escalating cytotoxic regimen such as Gemtuzumab ozogamicin (GO) makes their treatment feasible\u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eGiven the physical and financial strain of maintenance doses for APL patients in our country, we sought a course of action to treat APL without requiring a maintenance dose. In addition, life-threatening complications like myelosuppression and cardiotoxicity were found in previous studies where chemotherapy was included\u003csup\u003e\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e,\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u003c/sup\u003e, increasing the burden on patients. The potential for overtreatment in low-risk to intermediate-risk patients due to inadequate risk stratification further raised concerns\u003csup\u003e\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u003c/sup\u003e. Considering these factors, we systematically reviewed the clinical trials, selecting two protocols without maintenance dosage and successful remission. Emphasizing minimal use of cytotoxic chemotherapy, we opted for the approach used in the study by Abaza et al., which involved no cytotoxic chemotherapy in low and intermediate-risk patients and a single dose during induction in high-risk patients.\u003c/p\u003e \u003cp\u003eThe shifts in the demographics and epidemiology of the condition of APL are becoming evident along with the evolution of therapeutic options. The changing landscape is highlighting the emergence of ethnic disparities in APL incidence over time. In our pilot study, we aim to account for these factors and overcome the limitations of conventional management of APL. The focus is on developing tailored strategies to alleviate the burden of maintenance dose and complications of cytotoxic chemotherapy. Our study aims to lay the foundation for a comprehensive evaluation of APL management on a broader scale, with the goal of minimizing associated toxicities and costs while enhancing therapeutic efficacy and tolerance. The primary objective is to investigate the potential replacement or reduction of chemotherapy in consolidation therapy through the application of the ATRA-ATO combination in APL patients following Sanz risk stratification.\u003c/p\u003e"},{"header":"Materials and Methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eStudy Design:\u003c/h2\u003e \u003cp\u003eThis is a prospective open-label pilot study conducted on ten patients newly diagnosed with acute promyelocytic leukemia seeking treatment in the Department of Hematology at Sir Salimullah Medical College Mitford Hospital. The study has been ongoing since August 2020, during the COVID-19 period. By June 2023, 14 patients had successfully reached the primary endpoint of our study protocol and were incorporated into this pilot study.\u003c/p\u003e \u003cp\u003eInitial screening was done based on morphological diagnosis, but the confirmation of the PML-RARA fusion gene through RT-PCR was necessary for subsequent enrollment. Patients were then stratified into three risk groups based on the Sanz risk score, with seven falling into the low (WBC count\u0026thinsp;\u0026le;\u0026thinsp;10 \u0026times; 10^9/L and platelet count\u0026thinsp;\u0026gt;\u0026thinsp;40 \u0026times; 10^9/L) and intermediate risk (WBC count\u0026thinsp;\u0026le;\u0026thinsp;10 \u0026times; 10^9/L and platelet count\u0026thinsp;\u0026le;\u0026thinsp;40 \u0026times; 10^9/L) categories, while three were classified as high-risk patients (WBC count\u0026thinsp;\u0026ge;\u0026thinsp;10 \u0026times; 10^9 cells per L).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003eTreatment Regimen:\u003c/h2\u003e \u003cp\u003eThis study followed the treatment regimen outlined in the clinical trial conducted by Abaza et al in 2017\u003csup\u003e24\u003c/sup\u003e. All patients underwent ATRA-ATO\u0026ndash;based induction therapy, with ATRA (45 mg/m\u003csup\u003e2\u003c/sup\u003e) and ATO (0.15 mg/kg/day) administered during the induction protocol for 45 to 60 days in low and intermediate-risk patients. This was followed by three cycles of consolidation therapy with ATRA\u0026thinsp;+\u0026thinsp;ATO. For high-risk patients, two received Daunorubicin (45 mg/m\u003csup\u003e2\u003c/sup\u003e), and one received Mitoxantrone (12 mg/m\u003csup\u003e2\u003c/sup\u003e) as a single dose alongside ATRA\u0026thinsp;+\u0026thinsp;ATO in induction. Subsequently, four consolidation courses of ATO (0.15 mg/kg/day, five days per week, every alternate month over 7 months) and ATRA (45 mg/m\u003csup\u003e2\u003c/sup\u003e, fifteen days on \u0026amp; fifteen days off for 7 months) were administered, with follow-up recommendations provided.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003eSupportive Measures:\u003c/h2\u003e \u003cp\u003e Standard guidelines were followed for hydration, infection control, prevention measures, management of hyperleukocytosis, correction of the prolonged QT interval, and monitoring for hematologic and nonhematologic toxic effects. At the earliest manifestations of suspected differentiation syndrome, ATRA was temporarily discontinued, and intravenous dexamethasone was administered at a dose of 10 mg every 12 hours until the disappearance of signs and symptoms for a minimum of 3 days. To prevent ATO complications, ECG, serum electrolytes, and serum magnesium were monitored twice weekly. If QT prolongation was identified (\u0026gt;\u0026thinsp;500 ms, uncorrected), ATO administration was halted for 6 days and resumed only when the QT interval was below 460 ms, with serum potassium exceeding 4 mEq/L, and serum magnesium surpassing 1.8 mg/dl.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003ePrimary End Point:\u003c/h2\u003e \u003cp\u003eThe primary endpoint of our study was complete remission (CR) after induction therapy. Secondary endpoints included marrow complete remission (mCR) after consolidation therapy, disease-free survival (DFS), and event-free survival (EFS) after 3 years and early death. All these criteria were defined according to the recommendation of the International Working Group\u003csup\u003e\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003c/div\u003e"},{"header":"Results","content":"\u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003ePatient characteristics at the time of diagnosis:\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"3\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eCharacteristics\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNumber of patients\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"2\" rowspan=\"3\"\u003e \u003cp\u003eAge\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;25 years\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e25\u0026ndash;45 years\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026gt;\u0026thinsp;45 years\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eSex\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eFemale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"2\" rowspan=\"3\"\u003e \u003cp\u003eSanz Risk Category\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eLow-risk\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eIntermediate Risk\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e9\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHigh-Risk\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eClinical findings of patients at the time of diagnosis:\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"3\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eClinical Findings\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNumber of patients\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eGeneralized weakness\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e14\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eFever\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"2\" rowspan=\"3\"\u003e \u003cp\u003eFeatures of bleeding\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGum bleeding\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHematuria\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePurpura and ecchymosis\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eBony tenderness\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eDIC (disseminated intravascular coagulation)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eOther co-morbidities\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eLaboratory findings of patients at the time of diagnosis:\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"3\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eLaboratory Findings\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNumber of patients\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eHemoglobin%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;7 gm/dl\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e7\u0026ndash;10 gm/dl\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eThrombocytopenia\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMild (1,00,000\u0026ndash;1,50,000/mm\u003csup\u003e3\u003c/sup\u003e)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eModerate\u003c/p\u003e \u003cp\u003e(50,000\u0026ndash;99,000/mm\u003csup\u003e3\u003c/sup\u003e)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSevere\u003c/p\u003e \u003cp\u003e(\u0026lt;\u0026thinsp;50,000/mm\u003csup\u003e3\u003c/sup\u003e)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e9\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eTotal WBC count\u0026thinsp;\u0026lt;\u0026thinsp;10,000 mm\u003csup\u003e\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eLeukemic cells in peripheral blood\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e\u003cimg src=\"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAvIAAAJXCAYAAADxSrARAAAAAXNSR0IArs4c6QAAIABJREFUeF7snQW4VcX3/l+6u7tDkE5FOkRSREK6u0u6pLu7O5WSllBQRESQkBQQaRDphv//Hb/n/i6Xe+HGOffsfc47z+Oj3rP3zJrPmn32O2vWzAnz6tWrV1ARAREQAREQAREQAREQARGwFYEwEvK28peMFQEREAEREAEREAEREAFDQEJeA0EEREAEREAEREAEREAEbEhAQt6GTpPJIiACIiACIiACIiACIiAhrzEgAiIgAiIgAiIgAiIgAjYkICFvQ6fJZBEQAREQAREQAREQARGQkNcYEAEREAEREAEREAEREAEbEpCQt6HTZLIIiIAIiIAIiIAIiIAISMhrDIiACIiACIiACIiACIiADQlIyNvQaTJZBERABERABERABERABCTkNQZEQAREQAREQAREQAREwIYEJORt6DSZLAIiIAIiIAIiIAIiIAIS8hoDIiACIiACIiACIiACImBDAhLyNnSaTBYBERABERABERABERABCXmNAREQAREQAREQAREQARGwIQEJeRs6TSaLgAiIgAiIgAiIgAiIQLCE/IsXL3Djxg08fPjwrQQTJUqEaNGiBXjNlStXMGLECPz777/m3wkSJHjj2j/++AOjRo1C2LBhMXbsWESPHj1EXnv+/DmuX7+OuHHjInLkyO+s69WrV/jnn39w586dt17L+mLFioUwYcK8s05dEHgCI0eOxMGDBzFp0iTEixcv8Dd66ZV8Nvft24cBAwbgk08+QceOHc34rVy5MkqVKoV+/fpZmgyftwcPHhib2ZeoUaMiduzY5rsmTpw4lrH94sWL+OCDDzB69GjUqFEjQLv4PTlnzhxMmDABly5dsoz9MkQEREAERMAzCARLyF+7dg1du3bF3bt3jbjiS/eHH35A8uTJkSdPHjx79syIr8GDBxsBEVD57bff0LNnT0SMGBGzZs3yV8jv3LnTR8DPmDEjxEJ+48aN6NWrl3mxFi5c+J1epIDgJGPv3r1IkSIFnjx5gj179iBChAgoVKiQEe6nTp3CZ599hg4dOiB8+PDvrDOoF1y+fNlMOjhZcFe5evWq6SsnZ6FZNm/ejAsXLqB27doh9n1o2u2utjjhXLduHXr06IHOnTsbIU9hPHHiRLz33ntvfR5DavPLly/x999/I378+EaAB6fwWZo+fboJFPB7gWOeE/zTp0+Dz79VCr/z+P1GEZ8/f35/zSIPjt1hw4Zh7ty5ePr0qVXMlx0iIAIiIAIeQiDYQv7AgQMoUKCAeWn//vvvaNiwIT7++GMMGTLECPkdO3aYF3Hx4sXfiqpbt244efJkgEL+0aNHJopIgRBSIX/27Fn07t3biPLFixcHWshTuKdLlw5p06bFzZs30bRpU8SMGdMIjkiRIplJC6P8ZcqUcbqQpwibN2+eYZ03b163DTuKlo8++ghFixZ1mw1qOHAEzp8/j3LlyplxSiEfWoWTXq4EtG/fHkmTJg1ysxS63bt3NwGCgQMHIkmSJPjrr7/Mc/brr79iy5YtQa7TCjeMHz/eBCz4LKuIgAiIgAiIgDMJBEvIc8mb0SZGpVn8Cnn+jSksvI5C920ltIQ8X6L169dHkyZN0KxZs0ALeS71c2LCvjIizUihbyEfJUoUw4LXvKuvwXHchg0b0L9/f5NaUrBgweBUEeJ7vv/+e8Nt2rRpKFGiRIjrUwWuJeAuIc9Vul9++QVLliwJlpC/f/++mfhXrVrVrPiFCxfOgGJKClfROKG1Y5GQt6PXZLMIiIAI2INAsIS83675J+Qd1zBKx7SZBQsWmGh2woQJzUuaL2vmvVPIHz16FPXq1cPkyZNx5MgRkxLQpk0bkxPrX0T+1q1bRiwsWrTICOsiRYqYVIKMGTP6m6POSQWFcKZMmZAqVSqULVvWR8jzM0b62TYj7+/Kw/VPyDv6yuV/pjAwopg1a1YjwL/66iu0bdvWpB7xM7JipJEMKlSoYCY8K1euNFFHptAwJaFVq1Zo0KABuOrBSQNXEsiNIrpPnz6mHk6SuArC/QO0m2k9zZs3x8yZM01drIeMsmTJAk5GGNkkA0Y1OemoXr26Yc8oKDmyzl27dpl/L1u2zORTU4AwpYYToJ9//tmsvmTPnt34k2lUjkJ/sA9MQRo0aJCxgdeyHoowTgA4IeFY+Pzzz41/mS7BCdCqVatMm8w5Zlv8G/u6fPlypEmTxnxG27nSQ24Uc998840ZH0zNYspCjhw5TNu8n32ikGUElNewsF3Wx3tpD6/nKg/7wpWj4cOHo3z58kiZMqX5OydktDl37txvPMX0F9N9yJL+5gSPvmrZsqXZI0G2P/30k2HElR+mnjFCzfHO9Cj2hX5ZsWKFWcWpUqUKvvzyS8PTUffUqVPNKhWj2hw7FStWNCs9XPnp27evSV/jvhK2QZ/x/zdt2oRx48aZlStyc6StsW1Gs2kv027IjuOJ453+4XjgagvHEK/t1KmTaYt+YFobudIW+piTYaZW8fpGjRq9xobc6Cs+r/Qfc8fZ5xMnThiW27ZtM8Kc/eWYZn/97idxROQ5JmhfsWLFECNGDNPO/PnzzThkOX78uGmLfaat7D+fg2TJkpm+8r/pS66QDR061HxH8N983jgpJdN79+6Z9ukvfs4JOb97WIej0B8cH6yPzwuf3e3bt5vni6k1HOdcpeIqAush/6VLl5oxQV9zfwfTbnwL+TNnzphJMX2ZOHFidOnSxQQWfJfHjx+bezlG2D8+yxy/ZEa/81niM8s0JD7fHBOO1bpjx45hypQpxne0gc8bfcVnh88FP6MvGRTgfWyb/+ZY5XhypEg6xiy/o2k/n7/9+/eb708VERABERAB6xBwuZDni5wv4DFjxhgBxcgaX2azZ882LzIKL74c+XLjS4I57OvXrzdij4KWL1PfqTUUA7yX/27cuLERJRRRTHuhWPGbm0tBwhcQX/61atXCn3/++YaQX7t2LdasWWNecg7hEJCL3ibk2QYFNTfx0ja+VJkSQ2HFfjHNgRv3KIQoqL799lszmaEAb9eunRGTFDBM+6Ho5MSDL3wKIgoEvnwp7pl2wFz9L774wvyNL3xORii6OBHhBmO+iClEyYoTBObpUhAy4sl2+Tn/YY4vhRaFAwVktmzZjPjixIgvcAovinj6kHz8i8hTkNK/rMPRR4oRimn+w4kWRRQ3YXLCxv7Sv5zAsQ/cr8D9BvQz+8LNgaVLlzbCiuKIecbsB1nRTxRlFGPkRWFMIcX/fv/9980EiqKPPj137pwRWAsXLjQilqKFk0mKVQoximDWxzFI0ci+cgLCyRdFOe/zWyiUW7Rogbp16xp2FFicvNBnnBhQQNF+joNcuXKZyRzFMj+nMGfbzFUnA45F+oOTM046OEY4qeCmbk5KOTliqgrrcPSVe07Yz2rVqhkhSyFIm+gbXkufU2iyDw6hRo70H9slX17P5+3HH3809vPZYVv0H4UcRSE3mX/44YdGMH/66admbDAtjWKPffevcFxSsLNO9pXjgqyY5sN7OCGgiKePKPT9Tpo54eQEhOOAEwuO+5o1axoxzFQ2Fj7P9Bf96JhMsQ32h4J19+7dZuxSyPN+Cl32i2ONdXPFgGOmUqVK5juEY8DBn2PRd3FMstlvMuHE4PDhw8YXFNj8N33D8cd26dutW7eaiTxtog98C3muOJAJGXKCRx/6t4H766+/NpMsjiN+l3DSz2eRTOlbfn+yj5zMsx1OrjhmHGOb/ebEg98d/A7ldwS/G3gfnx1OAOgPjj+OCfqDbXH8cE8Cr2E73333nRnDHLv8vuJY4IRARQREQAREwDoEXC7kKZj4QqGI50uQQpWRU0ZSM2fObF7KjHRRqDEaxpcgRS031FIQMLrlW8hTkPElRMHOlyBftqyXYpVCwe/JNxTeFHYUQOnTpzcCxXdEnq6g2KMwpgB+16kzbxPyrItCli9Ivgh5wg7tYzSLwoTts34KCYpaRvoobCnOKQIpPBnl48SGUVtOAvwKeYoBCgdyIDPuQ6AgY3SeL3OKJhaKdoppCiuKWopNTgwoXhihpvCgGCE3irjWrVsbfhRXtI8ig2KHE693CXm2xzo4UaIwypcvnxEZFE+0gyLZkXZEsUphQT6MvFLUcOLGSdzt27fNXgT2wxF9pUClsGFfeQ2FJv1PYUGRwXscm4xZF/lSeHAMUdhQCFEkk4VjbHC88B/2l1FLTrooylgPhSIFMLmx334Lo9L8Oyc8HNu0iz7j5Ij9orDiuKSo5dilTznmGLmlnzneaR99wbYYXeW44GSP/eFkgkKKhWOHEVVGqtk3TjIormkrxSejyhy7nNRQaFLwsVCo0XecLDhy5DmWKMI4cWEhH4o38qOdtI2TKY47CkH+m6Kbwpdi2LGxneOB4jUwQp6+4wSUopTPNvvL554rELSDTPwWXsPIMccGV/E4zrn3hn3kdwg/Z9Sd455inRMTTvbYX06C6HP2m+1xgshCEUy7+eywPo5NClZ+D1H8U8jyO8a/E7HoO17D8ch6+exwzPA54r8dQp5+5Phhf3PmzGnGD/3lW8hzYu8YJ3zeHamJfhlwAkl/s18cE4y+8zuLEx1OHjmeOU7IgpMTfnc52qH4JmMGSRwrkQwc8DuFY47jkt+3bIOrELyG3yf8nsmQIYMxhRM9fl9xjHASxGvIjkEIFREQAREQAWsRcLmQZ3f5MuTLxJH6wpceXzYUCH5z5PmyYoSYQo/L2nzZ+BbyTI2gkONLmwLId2HEypFX6/g7xQTbZSSZEV1Gzf0K+aC4JDBCnjYygklBx+sZCab4oiDxXRj1ZaSRaSV8wbKvFIhkRUHA4+0CEvIUlGREQUOxRaFBwcJINotvIc9oOa/hhMLvqTo8icch5CmgOEHii5xCnlH0oAp5CkIKLhYKKYoxim7fhQKIEwaKMPaboo1RZopKjgn633HakX9CnpOW1atXm3YozBjdp995n18hT/HEz/kPo4++C1NAOGGkkGd7jlQcijNGu/0T8ryfPuVkg6tBFO8UXBTn9BfFMLkxiuu3UBSRNW0nd9+FdrI/9CntYaFQ42SPzwqFL8U+hTzFPcUXC8cHo9YU5Q5h7F+OfEBCngKN5dChQ2bi6BDy7D8FPQUp+8RJA8cz+81Jn3/Fb0Sex1/SH/SvY6WMKRy0l2MxoMg+6+bkhaKcY4irTRSR7KtDTHLs8BmjgOcpPRS8HOcOIZ86dWoT9Wdh8IC82AffhStS7DdXv8jWv+IQ8pxIcKLqdxw7hDzFNCcotMtxghUnGnw+Hak1nDDwO4uR7bcdpco+0F6KfvaPY5f38XuFvqDI5+qA38J0ONbLwIXjaF2uBjH1iww4yaePOG45+eR3D8cyP+f4p798FwY23HlSlr8O0R9FQAREQAReI+ByIc80Db4oKAgpZvmioxh4m5CnmOHnzEXmC8mvkOeLki8zCidHYW4ur/UbUWdUzHdhNI7RRUbfuDztEESBHRfBEfKM5DG9hGLAMdGgSKPNrI/L3xTOFOOMFDPa5kwhT96MhFPwcLLgKOTAl7mrhDwFCyPW9CMjhCycqFGkcUJBFhQQTO1g9JeChznAFG6c5LA4Q8hTGFNE0weOwgg923ekQQVWyDsi/BTwjIBTCFLwUjxxPFJMU2RxzHLiyML+si0KTUanKWwdwtHBg6sDFKMUbUyDYOEY4SSBIp2rEhSnfoU8J06M0jKKz3QKFmcIedZDwc3nhZMS2kw/UuD7faYcTP0KeU6YOVHgWHZMXLh6REFMe/2mslAMc/JOfo7nhCsOTKHhKglFPcU/JwFc+eEEkZ/z+eJqTWCFPPvEZ4GrJ5yAUQAHVAIr5Hk/62UOPifiHBe0j0fcOoQ80274jDMVkN8FFPlvK+wjOXGFj+OLDB2rWZwsOgq5MbrPSTyfK05MHCkwnIhx4stJDz8PSMjz2eBExHeh70L6ux2B/V7VdSIgAiIgAsEj4HIhzxcR0zgcqTNc0uWLOSAhz6VriiC+yJmzSTHjN7WGwomiiZMDigoKYqaPMArt9weoKD58F6aN8D6uBPB6pvdQ1PFlSFHrjNQa3xF59odRO26ApLDlsjtf+BRgjBBSuFJk8uXLiDGjwBRmzhTyFC2MPlIMsW5GR9kuo3IUo64S8uwjGZM3xQR9wwg40wGYCkDxQXFGWxhZpy/q1KljNks6SkiFPIU3hR4jlVzFYT4xfU1hSsHIsROUiDxTe3g9J6T0JaPEnFgy/YEim6svjogno6gcv460Kop1im1G2XkuPkUXeXDTLK9legxXJFg3I8+8l3sbGK0nJ+7f8CvkWSfFIW2hYGQKkzOEPFd82Cb9Qv8wusx2fG8G9fuV41fIU9Dyuec/jmNoKXQ5FjmhYaqH78LnkJM4+oVjwVGY489xxHSikiVLGv78DuAE2LHixYlRYIU8JxOsg3n1nDixMM3GMdn0bVNghTz9QDYUvlxZ4sSUvuV4cQh5/p3PHL//yIbjxr/CXHZubGVggtF58qJfORa4skgG/F7lc8zxy/5wNYWfc7WH362OE644gec+FUb3HSlfviPyTJth+hUnUFw9c6T8MADD1Diu/tAv/B5TdD54L1ndJQIiIAKuJBBiIe/I82WUiS8Yvgx8F0aDGWHnS55CmS9wCjleT2HAFxJFOJfB+bLni4h18OVDse7Imacgo+BkFIsvbL4MeVoFI15MBWFqBsXiu6JcflNr+CKjqGP0jFH+d2125f18uVHY0FbfEweKH+bTOl7YjBIy4soNkBSTFGdkxMkCX46OtBUKCm6MYx/YRzLiZ1wKZx42I5uMzJI1VzWYu8q/s32+7JkXyzooVCkU+dLlBkVG8phSw7aYNkIRxbookigeGRFlNJIpKYzGUTDSZooXRk2Z605h5ciR52Y+vuiZwsT+OwojzhTc3HhJX9JGFgpm+phihsv2THGiiGA0kX2j/WyXKzYUJcxhZySRYtYRweWqCaOKjrxy+op9odhlFJFCjqkejH5z8kNG9CPrZUST6QwUkpzEcCMohTDFEUUbxxj7Sg6c4LAtsuK/mf7Fceo3IknRxNUT9pXjlfs42B4nY+RK39MesuP+B+5B4ISNHLgaQvHGv1GEUvhxgsf0CQovTnJpE1eJOI6YX89oOP+b/Cg2eY4/fcs9D/Q9hRzHDvvIMeDY5Mh6eC0nkRRw9DMZU7CRFftLrrSFqx+MFtMvFJ18Nvn/FMsUeXwmmApFv3MPg18B7hgHfMaZAkTbKProS7Kl3/k3Pit8dtk+J5B+2ZI988z5HPF54eoGxzltInf2kc8O+8m6KOzpI0446Fty4fikSOc45koGn29+xzCKT4HMttkGmdBnrIfjlJMrPnO+C59dtktb+DyQqaNwssR+UWSzbkbMuSmbfmW/yJC8+VywXn4P0p/8jEz5TFDM0/d+f2Ga0XMy4PcZJ7t83smdwQfazO9TPjMcY9wPQdHPccVni38nC8c+Bn6v0hfsM1nQXtrOwIHjGaMt7B+v40SBTDgu6E/WzYkBn2v2JTi/D+DKF5jqFgEREAFvJxBiIc+XGF8WFDB8ITGyyBcrNziyUGTzhcSXGF/efLnzJcf/5kuPR6FRgHLDIwUhX8aOky0cx9Uxz5NRbAo91se2+DLjy5HCjS86LpP73ejqn3P9CnnWy7oCc/wkX2gUeRSPfMFyNYDCxJHSQCHOlykFACcYFDV8KfIFSlFJIcD2mSvPVQbmw7Mux4udaQN8sTNayzop4vhCJyduUOOLlKKGG9fYb/aXETe+fMmEgswh5CkwmXbAnFpGiymA+HKnEObLmbZQzFEQs35OmBitpljnpIbRdPaREw/eTwHA/tBXDoHh4MtJFW1l9JaRUUYGHUyY/8//pxBn/RQ1bJcRRq6OsH7ayeglI9T8hwKJIowpJkwpodCiaObYYDuMEFOIccxQbHCixEJ/8P/Jk7bwGops8qZwoR0U1RQ7jMRSlHA8UthTdJE9/0bOFMj8zLFJ0NFXcqbvmEtOe7iCwEkDfclxT2bkxIkD+0TRSSHI9CH6gBMofkahTNFJP/BZ4X3kwIkcRSVPN+F4oj/Yd95HVo6jEjnmKQRZ+Dc+g3weuKrD/nGSxH5zUkWhz4kJCycEFHDkwueN49Rx8hEFHieb9DFZcCJNP1Gg8lmkjWTCtvzmU7NuToqYokQbOPFkKhBTxSjiOaFk3RzjHD/+5YjTz0zdoaCk/RyHbN9xVCI3Y/J5JSP6mN81/B7hGOGEiBNSMqEw5TjiWOR3CQU/00RoD/vEZ4DPpWMiweeVfnXsF3D4mlw5EeRnnIRxYsaxzhVGPjN8llkHhTcnIRzjjGTzb46VKI47Pnesm/bTbk7UaSMnSJw8kZXv7y72g3Xxu4TXMNWOE0eOb9rClT3ew5UrThrJ1LGCw+eWDDjBYZ0cC47POTHjCiW/j8ifYp2FTDlh4QooOTIFxzHx5ef8zuFkiBN6HT/p7ZJB/RcBEbAagRALeat1SPbYg4BjAkWx5VsUcjWBkyNGkN31A1j2IOg6Kx1imf/mpNJROHnkpI6FolZFBERABERABETAvQQk5N3L32tbZ6SeEWdGkZkC4oiOMoWKUU2mzWgZ3z3Dg5FoTq4o1hnVd5wUw9UzRqGZQkTfqYiACIiACIiACLiXgIS8e/l7betMNWC+LzeCsjBtg6kPjMJz4x7zsB2nvngtJDd1nGlFzEdnXjTTMJjewkkV01K4qZY52H6PeXWTqWpWBERABERABLyagIS8V7vfvZ1nTjRz8/lv5ilzozI3RPt3jKh7LfW+1pmvT99Q1NM3nGgxX5u54ppged94UI9FQAREQASsSUBC3pp+kVUiIAIiIAIiIAIiIAIi8FYCEvIaICIgAiIgAiIgAiIgAiJgQwIS8jZ0mkwWAREQAREQAREQAREQAQl5jQEREAEREAEREAEREAERsCEBCXkbOk0mi4AIiIAIiIAIiIAIiICEvMaACIiACIiACIiACIiACNiQgIS8DZ0mk0VABERABERABERABERAQl5jQAREQAREQAREQAREQARsSEBC3oZOk8kiIAIiIAIiIAIiIAIiICGvMSACIiACIiACIiACIiACNiQgIW9Dp8lkERABERABERABERABEZCQ1xgQAREQAREQAREQAREQARsSkJC3odNksgiIgAiIgAiIgAiIgAhIyGsMiIAIiIAIiIAIiIAIiIANCUjI29BpMlkEREAEREAEREAEREAEJOQ1BkRABERABERABERABETAhgQk5G3oNJksAiIgAiIgAiIgAiIgAhLyGgMiIAIiIAIiIAIiIAIiYEMCEvI2dJpMFgEREAEREAEREAEREAEJeY0BERABERABERABERABEbAhAQl5GzpNJouACIiACIiACIiACIiAhLzGgAiIgAiIgAiIgAiIgAjYkICEvA2dJpNFQAREQAREQAREQAREQEJeY0AEREAEREAEREAEREAEbEhAQt6GTpPJIiACIiACIiACIiACIiAhrzEgAgEQmDFjhtiIgAjYmEDWrFlRqFAhG/dApouACIjA2wlIyGuEiEAABMKGDYvBE2aLjwiIgA0JXL9yCc/uXMWkSZNsaL1MFgEREIHAEZCQDxwnXeWFBMKFC4dfz9/xwp6ryyJgfwJnT/2Bnd/Ml5C3vyvVAxEQgbcQkJDX8BCBAAhIyGtoiIB9CUjI29d3slwERCDwBCTkA89KV3oZAQl5L3O4uutRBCTkPcqd6owIiEAABCTkNTREQBF5jQER8DgCEvIe51J1SAREwB8CEvIaFiIgIa8xIAIeR0BC3uNcqg6JgAhIyGsMiEDgCSi1JvCsdKUIWI2AhLzVPCJ7REAEXEFAEXlXUFWdHkFAQt4j3KhOeCkBCXkvdby6LQJeRkBC3sscru4GnoCEfOBZ6UoRsBoBCXmreUT2iIAIuIKAhLwrqKpOjyAgIe8RblQnvJSAhLyXOl7dFgEvIyAh72UOV3cDT0BCPvCsdKUIWI2AhLzVPCJ7REAEXEFAQt4VVFWnRxCQkPcIN6oTXkpAQt5LHa9ui4CXEZCQ9zKHq7uBJyAhH3hWulIErEZAQt5qHpE9IiACriAgIe8KqqrTIwhIyHuEG9UJLyUgIe+ljle3RcDLCEjIe5nD1d3AE5CQDzwrXSkCViMgIW81j8geERABVxCQkHcFVdXpEQQk5D3CjeqElxKQkPdSx6vbIuBlBCTkvczh6m7gCUjIB56VrhQBqxGQkLeaR2SPCIiAKwhIyLuCqur0CAIS8h7hRnXCSwlIyHup49VtEfAyAhLyXuZwdTfwBCTkA89KV4qA1QhIyFvNI7JHBETAFQQk5F1BVXV6BAEJeY9wozrhpQQk5L3U8eq2CHgZAQl5L3O4uht4AhLygWelK0XAagQk5K3mEdkjAiLgCgIS8q6gqjo9goCEvEe4UZ3wUgIS8l7qeHVbBLyMgIS8lzlc3Q08AQn5wLPSlSJgNQIS8lbziOwRARFwBQEJeVdQVZ0eQUBC3iPcqE54KQEJeS91vLotAl5GQELeyxyu7gaegIR84FnpShGwGgEJeat5RPaIgAi4goCEvCuoqk6PICAh7xFuVCe8lICEvJc6Xt0WAS8jICHvZQ5XdwNPwApC/smTx7h+9TKeP3sWoOFRokZDgoSJES58+MB3LgRX0p4WtSoia448+GrsjHfW9PjxI9y4ehkvXr5EsuSpECFixDfuufL3X+B1jhI2bFhEjRYDsePE9bn+5YsX+Ov8n4gbPz5ixorzznZD84IH9+/hh++2IMN7WZEu43uh2bRT23r16hXYl1s3riF6jFiIlyBhgPW/ePEc1y5fAsdo4qTJwXFopSIhbyVvyBYREAFXEZCQdxVZ1Wt7AlYQ8qdPHMOQnh1w9fLfhuf9+/fw6MF9xIkXH+HDRzB/y/tBYXTsNQhx4wcsuvw64+ihAzj1x1F8XLEqokWPESRfXbp4Hq3rVkG6jFkwKBdgAAAgAElEQVQwesbid967Y/N6DOreDo8ePsDoGUvwYbFSb9xTr3JxHDt8EAkTJzWfPX70EClSp0P5z2qiXJUaiBEzFu78extl8qZHx95DULNB83e264oLKHD3792NHHkKIGmKVD5N7N6+EZ2b1kL1es3QbcAIVzRtBPPeHVuROFlyZH4/JzjZcWZ5+fIlTv9xFKuXzMW6FYtQsVpt9BoyLsAmjv52AF+2ro/Lf/+FCfNWoXCJj51pTojrkpAPMUJVIAIiYAMCEvI2cJJMdA8BKwj5hw/u48/TJ/DkyRO8evkSWzd8je+3b0Lbbv2QOHlKAyZWrNhIlTaDv5HugMiN/qoHVi6chWWbfkTqdBmCBDgoQv7p0yeYMLQfjv1+EKeOH0Gpcp+iz7AJCB/hv0mIo9T4+EP8/dc5IwhZ7t+9g0WzJuHPUyfQbcBIlK5QBffu/ItiOVLhy4Gj3CbkD+7/Eb3bN0GHXoNQpsJnPvbfvnUTB/b9gDTpMiJ95qxB4hnYi9lGyzqVjWBu2u5LRIwUKbC3Buq67RvXYv60/4Q7Bf3HlapiwOhp/t7LSdmXrRvg5LHfcf/eXbMyU6JsxUC1E1oXSciHFmm1IwIi4E4CEvLupK+2LU3ACkLeNyBGTBfPmozVi+dg7OzlSJM+Y7D5jejXFV8vmYclG39A2gyZg1RPUIT8+T9Po1/nFihd7lP8cfQw/jp3FkMmzEaK1GnfEPJXL1/E7iMXff5+7col1CpfGOWq1ETrLn3w5PEjtwv5X/ftQa/2TdC+51f4pHK1IHEL6cW3b91A8y8qonDJsmjWoTsiRYoc0ipfu79EzjSoVL2Oqb9bi7r4qESZAIX82hWLMGlEf1SuXhf87x6DxkjIO9UbqkwEREAEAkdAQj5wnHSVFxKwm5BnfvO5M6ewZvkCfLt6qUlPYY5zmYpVUbV2IyRJlsKkQYzs3w0/fb8DT588RsxYsREuXHh06jsU5avUwPVrV7Bh9VLs3LIel/+6gCjRohnBWr1eUyRIlMSMgsAKedqze9tGcNIwacHXuHzxAnq1b4rOfYei4ue1ECZMGJ9RxYi8XyHPCHzDqmVQsEgJtOnaF08ePw6SkH/x/LmJ6h/57YCJ4C+bNx2//rwHYRAGn9VqgAYtOyJ6jJjGBqat/LxnF1Ytmo2zJ4+bFKa8BQujVqOWyJmvoGE0Z/IYzJs6Fg/u30XUaNERMWIk5C5QyIjYf2/fMpOOdt0HmntYOPE6efx3rFwwC3t2bjX/nzZDJtRv3gEFCxc3exru/nsb/bu2Nr7JX6go5k8fj2OHf0WSZCnRtnt/FC31iUmhWr9qKcYM6mFWJSJEjIQoUaMibrwEZkKXKHFSbN+4BvOmjcOt69cQNXp0s/LRvsdAY8fmdaswuEd7s4pQtVbDAJ9kplu9nzMvLvx5Bo0//xiFipf2V8hfvHAOrepURomylVCgUDH079oS3b+SkPfCr0h1WQREwAIEJOQt4ASZYE0CdhPyVy5dRNcWdfDs6TMULV0OceMnACPiu7Z+i/dz5DGR8JcvX+DMyT8wa+II/LhrO3oMHoMkSVMgVbqMSJg4CZbNnWbELqOy3MB44uhhLJ8/A5Vr1EXLTr2CJOSfPXuK4X274sa1K+g3YrIRnxTm3CTbqffg13Lz/Qr5Z0+fGrsHdGuNZu2/RK3GrfDg3r0gCfnnz59h7pQxZuWBqTy58xdCpizZcOqPI9i64RvTp869h5jPfvvlJ4wa8CWKlPwEmbPlNJMcTgJevniJr8ZOR+p0GY3A5cRk7tQx+OyLBsj3QRHEjB0H6TK9h7OnTqBhlVJo0akXGrbqaDidO3MSfTs1NxOgspU+R5Ro0bFrywYwPYfpRZwE/HPrJgZ0bWUmOeRVqHgZxIuf0KRQcV/EhDkrkT1PftC3zEkfN6Q3suXOj/JVappJVpZsOXHw571mgvR5nUbGJu4lePToAT6tUc/YwZz30QN7oHbj1mjdtc87H7a3CXluSJ46ejB+3LUN05asw8ljRyTk30lUF4iACIiA6whIyLuOrWq2OQG7CfmZE4Zj1aI56Np/OIqXqWAivozKz5gwAsvnTsPE+auNeGTxL7WGEfSL58+alI2ESZKZiPk/N29gcM/2Jg96+tINQRLy3BjapPonqPJFA9Rq1ArAK0wfOxRb1q/GlIVrkDxVGp8RQiF/4dxpk/vNcubkcRz57RfET5AIfYZPNCfB3Ln9T7CE/Pxp433y7KNEiYq7d26jS/O6OHvqOOau3oaUadLh5vWruH71ihH6jtN/Nn6zHBOG9UO/kZPxQZGSxq6AUmuOHzn0hpCfOGIA9u7caiYxmd/PYXhyH0D/Lq2QPGUa9B81xUfI/35wPwaNnYF8hYqaSP8P321Gt5b10K7HAHzR8L8If0CpNQtnTsTkkV9h4bqdyOBPfj5TlI7/ftBskGXk/13lbUKeE57BPTugZaeeKPlJZTMZVET+XUT1uQiIgAi4joCEvOvYqmabE7CbkK9SPDdixY6LUdMXI37CRD70mTLCyHD9Fh180j7eliN/986/OHboV1w4d9ZMBLZuWI0IESJi/prvgiTkN369DNPHDzNC1jGB2LtrG3q0aYjuX402p9E4CoU8I+VshyVZyjQoXqYcajZsYY7WDBM2bLCF/MZvVmDKwm+Q5H+bg1k/o8qMuA+dOBdFSpU1bXK14vSJ4zh59DAePnyIMyePmgh83xGTfU5kCYqQr1W+CB49vI8KVWshWvT/Uni4eXnTmuWIFTsOZq3c7CPkmWIzZ/VWn3SjFy9eoECG+KjTpDU69Bz0ViFPkd62wecm5aZp224oU6EKYsSKHeynLyAh/+DBfRPZ516FnoPHmhUVCflgY9aNIiACIuAUAhLyTsGoSjyRgN2EfJ7UsVHgo2Im8k7bHeXAT3vQu2NT1GnSxghDFn8j8i9f4ocdWzBl1FegmOe54Dy7/eaNa2ZDbFCE/PPnz02eNdNDmKYTNWp00+4/t66bfPFsOfNi/JwVCPs/O/3Lkfc7poIbkd+8dpXJ0fcdjebKxdhBPTF4whwUK1MOPMd+1MDuJsWGZ9STH4Xri+fPgi3kKcSZW8+UJf7bd8lToBB6DhnnI+R5Ss/sVVteuyZXyhjm+M1B42a+VcjzQ65gMCr/x5HfzPnvDVt2wMeVP/c5ojQoz2dAQv63/T+iS4s6aNOtHz4oXMJUeWDfHowd3AutuvRB4eIfI3bceE4/TScotvu+VqfWBJec7hMBEbATAQl5O3lLtoYqAbsJ+WqlCyBylKgYOW2hyW93lO82rTPpEB16foVK1WoHKOS54bNp9U+QIFFStOrc2+R+M996aO9ORugGRcj/ceQQ6lQqhnwfFDZHY/ouJ48fwek/jmD+mh1InymL+ciVQp6bd6cuWvvaue9DenUEU2fGz10JiuphfTqbTb5MbylQuLiZxOzathGDe7QLtpBvVLWMORKUQtyxUdjvAHbkyIdUyLNeRvG5qrFwxkT88N0mTFm8zkyYgloCEvIzJ47ArAkjkDBREkT834k5XGHgHoh4CRIZvl37DUOW7LmD2qRLrpeQdwlWVSoCImAxAhLyFnOIzLEOAbsJeW7sXDB9PFp37WuOBaSIvHHtqtnEyTPOV2z5yQgulvFD+mDJ3KmYtWITsuXKZ/726NFDlPsgCypWrWU2RUaKHAUXz/+Jfl1agifABEXID+/XFWuXLcCslZveEHa7t2/CwK6tzckxtNXVQp6nzXAjKCcnFOg8I71ry3oIGy4sFq7daVJEmtUsb34ga+nGPT6R+0kjB2Lt8gWvCflDv/yE3h2aon6L9qhWt6nPYPUvR37amMHY8PUy9Bo8zpxSw/QgFq5wcD8CU4aCIuT//ecWWtergux5CqB99wFm0uZf4YRkWJ9OGDZ5Pj4qXsbsNeBpPJ/WrI9c+T545wMWkJDn7xkw8u+78LcB+HsElWvUQ+78H5ofyuKPlVmhSMhbwQuyQQREwNUEJORdTVj125aA3YQ8o6Odm9XGoQP7kClrdhM5pYi7d/dfdO47DFVq1vfxBTdTtm9U3Ww4TZYitRHVxcqUR7/OLcE89kqf10aipMmxdsVCXPrrHDJkfj/QQp6bXHneeZiwYbB8848IG/b/0nxoADfQNq5W1hy9uHL7fsSNFz9IEfn33s9pNqg6SoLESdCoVec3BKTj1JrFs6YgfITwxo733s9hBPv1q5fNr9IWK1PBVLN8/kyM6N8VeQt+hMIlymLvrq3mOv56qu8ceZ4uw4nN8d9/w4dFS5k2W3TqiauXL72x2fXWzevo3rqBOb2GKyFc6eB/M7WIp/bwiMigCHnzy7gDu5vJQcGPSuDpsycmV52n8lw4exr5ChXDPzevmxNvwocPj5nLNxr7Fs+ejEnDB5g9Cdw4HFDhj4TduHoF9+/dwy8/7Tan52TPnd+s7jRt/6W/vwCsHHnbfr3JcBEQAQ8hICHvIY5UN5xPwGpCnlFcnvjCM+K5WTRZytRvdJq//rly0WxzdCOPUOSvjFao+oXJnXdsJHXctHDGBHPGODdiMjKeI09+k9O+YPoEHPx5j4le89dLmS9/8cKfPrna/9y6gQFdWiHje9nQutt/EXXfhee2Txja10RpK1St6a9jmP6xae0Kc5pMzrwFTZT71o3rmLp4bYCO5Mk5zb+ogMePHr12Tfz/vxl2wOipr6UT8QKHkGeOfM9BY7B901rs37vbnIBTrV4Tc1Sj77Ji/kxsXr8Kjx8+RLZceVGxWm2zKbZRmy4m/cZRWAdXPyjUeazkFw1bmMkJ88frNm372iZepp2sW7kY321ai6dPniB5ytQoXb4KSpX/1Kx4PLh3F5NHDcLzZ09Nzrzv8nmp/OYXbZt36OHzZ04EZo4fjtMnjpnIfLvuA7Dvhx0mTejvC+fMEZ88C55n5DvSq/Z9vwOTR31ljvHkfoWASvNaFXHz2tU3Pk6VNr05YYd7B/wWHonJlQseuVngo+LOfwhDUKMi8iGAp1tFQARsQ0BC3jaukqGhTcBqQj60+2/39nwLeb+bXe3eN9n/bgIS8u9mpCtEQATsT0BC3v4+VA9cREBC3kVgQ6laCflQAm3RZiTkLeoYmSUCIuBUAhLyTsWpyjyJgIS8vb3JDbqLZk3GlnWrMHb2MiRKkszeHZL1QSIgIR8kXLpYBETApgQk5G3qOJntegIS8q5nrBZEwFUEJORdRVb1ioAIWImAhLyVvCFbLEVAQt5S7pAxIhAkAhLyQcKli0VABGxKQELepo6T2a4nICHvesZqQQRcRUBC3lVkVa8IiICVCEjIW8kbssVSBCTkLeUOGSMCQSIgIR8kXLpYBETApgQk5G3qOJntegIS8q5nrBZEwFUEJORdRVb1ioAIWImAhLyVvCFbLEVAQt5S7pAxIhAkAhLyQcKli0VABGxKQELepo6T2a4nICHvesZqQQRcRUBC3lVkVa8IiICVCEjIW8kbssVSBCTkLeUOGSMCQSIgIR8kXLpYBETApgQk5G3qOJntegIS8q5nrBZEwFUEJORdRVb1ioAIWImAhLyVvCFbLEVAQt5S7pAxIhAkAhLyQcKli0VABGxKQELepo6T2a4nICHvesZqQQRcRUBC3lVkVa8IiICVCEjIW8kbssVSBCTkLeUOGSMCQSIgIR8kXLpYBETApgQk5G3qOJntegIS8q5nrBZEwFUEJORdRVb1ioAIWImAhLyVvCFbLEVAQt5S7pAxIhAkAhLyQcKli0VABGxKQELepo6T2a4nICHvesZqQQRcRUBC3lVkVa8IiICVCEjIW8kbssVSBCTkLeUOGSMCQSIgIR8kXLpYBETApgQk5G3qOJntegIS8q5nrBZEwFUEJORdRVb1ioAIWImAhLyVvCFbLEVAQt5S7pAxIhAkAhLyQcKli0VABGxKQELepo6T2a4nICHvesZqQQRcRUBC3lVkVa8IiICVCEjIW8kbssVSBCTkLeUOGSMCQSIgIR8kXLpYBETApgQk5G3qOJntegIS8q5nrBZEwFUEJORdRVb1ioAIWImAhLyVvCFbLEVAQt5S7pAxIhAkAhLyQcKli0VABGxKQELepo6T2a4nICHvesZqQQRcRUBC3lVkVa8IiICVCEjIW8kbssVSBCTkLeUOGSMCQSIgIR8kXLpYBETApgQk5G3qOJntegLZs2d3fSNqwW0ETp48iQwZMiBs2LBus0ENu5ZAzZo10bNnT9c2otpFQAREwI0EJOTdCF9Ni4AIuI9A+vTpcfjwYUSLFs19RqhlERABERABEQgBAQn5EMDTrSIgAvYlkC1bNuzevRtx48a1bydkuQiIgAiIgFcTkJD3aver8yLgvQSKFCmChQsXIlWqVN4LQT0XAREQARGwNQEJeVu7T8aLgAgEl0DRokUxf/58pE6dOrhV6D4REAEREAERcCsBCXm34lfjIiAC7iJQqlQpTJs2DcyVVxEBERABERABOxKQkLej12SzCIhAiAlUqFABw4cPR9asWUNclyoQAREQAREQAXcQkJB3B3W1KQIi4HYCPJqwS5cuyJs3r9ttkQEiIAIiIAIiEBwCEvLBoaZ7REAEbEfg1KlT6NWrF+7du4dnz57hxIkTiBAhAiJHjmz6UrJkSUyePNl2/ZLBIiACIiAC3ktAQt57fa+ei4BXEaCAr1GjBjZt2vRGv6NHj47169ejWLFiXsVEnRUBERABEbA3AQl5e/tP1ouACASSwMuXL7F27Vq0bNkS165de+2uKlWqYPny5SZCryICIiACIiACdiEgIW8XT8lOERCBEBO4e/cumjdvjmXLlvnUFSVKFGzbtg2FChUKcf2qQAREQAREQARCk4CEfGjSVlsiIAJuJ7Bu3To0btwYN2/eRJgwYVC9enVMmTJFv/Dqds/IABEQAREQgaASkJAPKjFdLwIiYGsC3OjKVJpvv/0WceLEwbhx41C7dm2ECxfO1v2S8e4l8OjRI9y4cQPJkydH2LBh3WuMWhcBEfAaAhLyXuNqddQKBB48eBAiM168eIHHjx+HqI6nT5+aU1tCUihamHMe3BLS+9nuq1ev8PDhw2CZcPjwYXTq1AkZMmRAx44djfgKbgkpT97//Pnz4DZv7nMGz5COzZDeHxJ/+ob35MkT8DkJbuHzFZz76QOu8iRLlgy9e/fGe++9F1wTdJ8IiIAIBJqAhHygUXnHhQsXLsTWrVt9Onvnzp0QdZwCJaQveBrAOkIidkJ6vwNCSHnEjBkzRDzDhw+PqFGjhqiOSJEigf+EpESLFi1EUUeeEhPSqCXTYmLEiBHsbuzbtw+xYsVC/vz5TYpNcAuPrwzJJlneHzFixOA2b+5zBs+Qjs2Q3s/xwHEV0sLng89JcEtw7+fxpitWrED37t0RO3ZsxIsXL7gm6D4REAERCDQBCflAo/KOC48cOWKEPF+oGTNmREhfzkxXCKnwJHluSAzpy9kZqRMhEY7eMYLs00tOyjjBS5o0qX2MlqWWJXDs2DHMmTMHQ4cODfHEzLKdlGEiIAKWIyAhbzmXuN+g8ePHI1WqVKhcuXKIIpXu74ksEAEREIHQIfDHH38YIT9gwACnBC9Cx2q1IgIiYHcCEvJ296AL7JeQdwFUVSkCIuDRBCTkPdq96pwIWJaAhLxlXeM+w6ZNm2aO4qtWrZoi8u5zg1oWARGwEQHmyM+aNQu9evUyey9UREAERCA0CEjIhwZlm7UxY8YMkxvPn7MPySZAm3Vb5oqACIhAsAlQyM+ePRs9e/aUkA82Rd0oAiIQVAIS8kEl5gXXz5s3z5ypzbO1Q3qyiBfgUhdFQAREABLyGgQiIALuICAh7w7qFm9TQt7iDpJ5IiACliNw5swZk1rTrVs3/Uqw5bwjg0TAcwlIyHuub4PdMwp5/ihKs2bNFJEPNkXdKAIi4E0Ezp49a4R8586dET9+fG/quvoqAiLgRgIS8m6Eb9Wmly5das7XbtSokYS8VZ0ku0RABCxFwCHk+YvBCRIksJRtMkYERMBzCUjIe65vg90zCflgo9ONIiACXkrg/PnzmDlzJtq0aYMkSZJ4KQV1WwREILQJSMiHNnEbtLdq1SrcuHHDpNY449dQbdBlmSgCIiACISIgIR8ifLpZBEQgmAQk5IMJzpNv++abb3D58mW0aNFCQt6THa2+iYAIOI3AxYsXMX36dBMASZkypdPqVUUiIAIi8DYCEvIaH28Q2LhxI06cOIH27dtLyGt8iIAIiEAgCFDI8zc4mjZtKiEfCF66RAREwDkEJOSdw9GjapGQ9yh3qjMiIAKhQODvv/82EfnGjRsjderUodCimhABERABQEJeo+ANAtu2bcPBgwfNMWrhw4cXIREQAREQgXcQYDoihXy9evWQLl068RIBERCBUCEgIR8qmO3VyI4dO/Dzzz+ja9euEvL2cp2sFQERcBMBCXk3gVezIuDlBCTkvXwAsPtPnz7FtGnTsH//fty7dw9Xr17FrVu3kCJFCty/fx9x4sTByJEjkSNHDtESAREQARHwh4BDyNetWxfp06cXIxEQAREIFQIS8qGC2fqNrFmzBjVq1DCi3ncJGzYsqlSpgkmTJiFx4sTW74gsFAEREAE3EGAAhAGRmjVrInPmzG6wQE2KgAh4IwEJeW/0uj99fvLkiRHsmzZteu3TuHHjYtSoUSbvU2fKa7CIgAiIgP8EJOQ1MkRABNxBQELeHdQt2ua1a9feiLoXKFAAK1euNGk2KiIgAiIgAhLyGgMiIALWISAhbx1fWMKSRo0aYe7cuT62DB8+HN26dbOEbTJCBERABKxKgL+GPXXqVLOymS1bNquaKbtEQAQ8jICEvIc5NKTdOXDgACpUqABG59OmTYt9+/YhQYIEIa1W94uACIiARxPgAQFTpkxBpUqVdDCAR3tanRMBaxGQkLeWP9xuDU+tYQSem7YYXWrRooXbbZIBIiACImB1Av/8848R8uXKlUPu3Lmtbq7sEwER8BACEvIe4khndmP37t1GyM+ePRtRo0Z1ZtWqSwREQAQ8koCEvEe6VZ0SAcsTCLaQr1+/Pn78+QDCR4hg+U7KQBEQgdcJnD97Go8ePhAWERABJxG4ffu2iciXLVsWefLkcVKtqkYEREAE3k4gREK+VqseSJQ0uRiLgAjYjECdikVx9NCvNrNa5oqAdQncuXMHkydPRsmSJcHTvlREQAREIDQISMiHBmW1IQIWIyAhbzGHyBzbE5CQt70L1QERsCUBCXlbuk1Gi0DICEjIh4yf7hYBvwTu379vfgG7cOHCKFSokACJgAiIQKgQkJAPFcxqRASsRUBC3lr+kDX2J+AQ8h999BH4j4oIiIAIhAYBCfnQoKw2RMBiBCTkLeYQmWN7AhLytnehOiACtiQgIW9Lt8loEQgZAQn5kPHT3SLgl8DDhw9Nag03uhYtWlSAREAERCBUCEjIhwpmNSIC1iIgIW8tf8ga+xN49OgRJk6ciHz58qF48eL275B6IAIiYAsCEvK2cJOMFAHnEpCQdy5P1SYCjx8/NkKeZ8iXKFFCQERABEQgVAhIyIcKZjUiAtYiICFvLX/IGvsTePr0KSZMmIDs2bOjTJky9u+QeiACImALAhLytnCTjBQB5xKQkHcuT9UmAhLyGgMiIALuICAh7w7qalME3ExAQt7NDlDzHkfgxYsXGD9+PDJnzoxy5cp5XP/UIREQAWsSkJC3pl9klQi4lICEvEvxqnIvJOAQ8pkyZUL58uW9kIC6LAIi4A4CEvLuoK42RcDNBCTk3ewANe9xBCTkPc6l6pAI2IKAhLwt3CQjRcC5BCTknctTtYnAq1evTGpN2rRpUalSJQERAREQgVAhICEfKpjViAhYi4CEvLX8IWs8g8C4ceOQOnVqfPrpp57RIfVCBETA8gTcLuRPHv8dMWPFQZJkKSwPy5kGdmr6BR7cv4/pS9f7W+39e3exc8sGJE+VBrnyfeDMpm1bV540sVGncWt07D3Y9OH2P7ewd9c2ZMuZF6nSprdsvx49eoifvv8OESNGxkfFS7/TzhvXrqB13c+QLmNmDJ00953XB+cCCfngUNM9IvB2Ajx+MkWKFKhSpYpQiYAIiECoEHC7kC+YIQHKV/0CfYZNCJUOW6WRdwn5X3/ei9Z1q6BAoWIYP3dFkM0+dvhXHPplHypWq42YsWIH+X4r3uBXyG9auxL9u7RC2y/7oU6TNkEy+feD+3H4wM/4tGY9xIgZK0j3BvXiU38cQbeW9cCl97W7D73z9st//4V2DT9HsuSpg+X7dzYAQEI+MJR0jQgEjcDUqVMRL148VKtWDWHChAnazbpaBERABIJBwO1CPlfKGPisVkMJeT/Ou3/3Dg79+jPiJ0iEzO/nCLJrZ4wbhhnjh2HZpr1InzlrkO+34g1+hfw/N2/gjyOHkDZj5iCv6Ewc3h9zJo/G6u9+QdoMmV3a3UcPH+DY4YMIFz58oFZXJORd6g5VLgIuIyAh7zK0qlgERCAAAhLybhoa74rIh9SsqaMHY/akkVj87Q/IlCVbSKuzxP1+hXxIjBo3pA/mTxuHFVv3IYPFJjoS8iHxrO4VAfcRkJB3H3u1LALeSsDyQv7Cn2ewbuUibFqzEnfv3Eb0GDFRpGRZVKvbBOkzZwF/TY/R5x92bMGsFZt80kh2bf0Wvdo3Mdd16PmVj3/HDu6NY4d+Rf9RU0z+ud9y6+Z1bPxmOXj/5YsXzMdFSn2Cmg2aI3W6jGa59Patm+jepgHey5bLiMBl86bhzInjSJwsBVp37YtipcshfIQI5t5nz55hz47NmD1pNC6cO4MECRKhRoMW2LphNcKHjxBgjvzfF86h+scfoHq9pj72nzp+BK3rfYZm7bvjwrnT2LBqCZ4/f45iZSqgWYcvkTJ1Ovxz6ybGDuqFnVvW48H9e4gbPyEiRIiARm264PPajcAj0g798hNWL56Dg/t/NFHiNOkzoYlMVMkAACAASURBVF6zdijwUTHTv1s3rqNL89rIU7Cw4blgxnjEjZcAi7/9HpvXrsLXS+cZrhu/XobffvkJceMnQI16zVCuSnVsWbca3yybj/N/nkbhEmXRqnNvpMv0ng/mU38cxepFs/HT9zvw5OkTJEyUBDXqN0Opcp8icpQo5jruD2AbS+ZMxaMH95Epaw580bCFsYkpNI4c+RNHD6NVncro/tVolKlY1dx77cplbPh6KX74bjOuXrpoGBcrUx41G7ZA8pSpcf3qFYwd1BPff7cZDx/cR7z4CY2vWnbujcrV6+Dp0yc4uG8vVi+Zg0MHfjbs0mXKgvot2iNvwcJv/Z5g1P3L1vVRr2k7bP32a5w8fgSVPq+FBi07ok39qkiTLiOGTZ5n6mCUfvWSuVizbIHpb7To0VG2UnU0bd8NfoX848ePsHnNCgzu2RE16jdFl37DQ/x9pdSaECNUBSLwBoE5c+YgYsSIqFWrFsKGDStCIiACIuByApYW8jevXzPijQK+VLkqSJw0Ga5e/hvbN65F/ISJMGzSPMSJFw/ffr0cw/p0xvQl65E1Zx4DbdTA7lg2d5oR29xQGjVadDx98gS1yn+E3PkLoXPfYYgUOfIbgNetXIwdm9ahSOlPkDxlGlz66zwWzJiAvB8URtd+wxExUiTcuHYVPdo2xJ3b/wBhwqBY6fKIGTu2EdZ37/yLUdMXIWuO/+w4dGAf+nZqjiTJUqJU+U9x99/b+HnPLhw9dADZcuULUMj/efok6lQogkrV6xihysK87uY1KyBJ8pRInS4DPixaGhcvnMWGVUuNiG7fcxBevXyJc2dOGps3rVmBXkMnIEXqtEiWIpVJP6GIH9a3CzJnzW7sCYMw2PbtN6bu4VPmI+N72YwY7tqiDiggw4cPb0Q22TVp1w1rli/A1NGDzIQqV/5CyJwlG3Zv34jDv/6MD4qUBH1WtHQ5I5IXz56CfB8UwfAp8xAlajRcv3YFXZvXMTnpFT+vhbjxE+Gn77ebSUfLTr1QusJneP7sGVYtno2ZE0bgw6KlkDPfB/j7wp/4ec9unDh6yEw4HEKek4gOjaqja/8RqFD1C8NoxYKZ2L93F4qU/ARJUqTC2VPHsXjWZJQoWxEdew3GkyePce7MKcydPBpbN3yNfiOnIFnK1EiRMg0SJ0uOn/fsxKiBPZA9dz6UKFsJL54/x5b1q3H894MYO2uZmcwFVH7dtwftGlZDosRJkT1PfmTPXQCv8AofFimJdo2qI0nS5Jgwb5W5neNsQNfWaNdjALJkz41/b90wk6yylau9JuRHzViEjd+swOSRA00fyClWnLgh/mKQkA8xQlUgAm8QWLBggflbnTp1JOQ1PkRABEKFgKWFPIXg9LFD0Kn3EJSvWhMRIkTE8+fPsHrxXCNs+g6fiFLlq4CRWYplCq8WnXqaiHnPdo1NZPnOnX8wbtZyvJctJ7gBtPkXFdG5z1BU+aK+v4AZxeWmxMRJkyNM2LBGkDINgyJy2pL/JgQOIU/BPHLqQmTLnd9Ebr/fthG9OjRF575D8WmNeqZ+TjAo5nsNGY/3c+bBy5cvjSgc1KM9YseJF2Qh3/jzsvjk0+po1aW3sfHenX8xcsCX4MrFjOXfIlKk/yYnAaXWDOnVEefPnkLvoROQMk06c+2fp06gR7tGyJW3ILoPGuMj5M+cPI4pi9Yge658CBsunLl21eI5GPNVTzTv0B3V6jZFlKhR8eOubaY/nCj0HT7J1Pv8xXP0bNsYZ04ew8hpi8zKBXPSv14yFwPHzjC54o7VjaG9OxkRO3LaQly/etlsYI0eI4YR2RT9Tx4/xt5dW9GlRV3U9RWR90/IM5odLlw4JEyc1NR/59/bGNGvG65e+guzV23x8XlAqTUU19evXUbvIePNhImFqwhftqpvTpzhBPBtQr75FxVQqVodtP2yP+LEi28uvcLNq36E/OiBPbBs3nSs2r7/jRN3HBH5pMlToXrdJhgzqBeKf1wBjVp3RrToMZzyxSAh7xSMqkQEXiOwePFiPHnyBPXr1zffQyoiIAIi4GoClhbyDauWNqJyzsrNJm3FUf4T7i2MuGnZuZdJTejRthEunD2NdT8cNoK9b+cWRqy2ql3ZpE3Ua94O3ODItJkJc1ciw3vvB8iWKSms48zJP0wkes/OLaaN2Ss3GyHlEPIUijOWfetzOgFFesGMCdC03Zdo2q6bqb9h1TJmw2qvoeOMcGfhRIE58g8fPAiykG9V51N07DUIVWs38rF/wfQJWDRrItZ9fxiRo0R9q5D/vFQBRIgYASU/8ZXKcvcO1q9ajJRp0mPq4rU+Qp4inZMX36cvUMjPmzIGw6csQNYcuU1bXCXp0ryOicQ7+s2/z582HssXzMCgsTORu8CHaPhZGfz91zlUqVkfMWPHMfeS7+5t3+LFi+dYsGYHzp09hc5Na+Hzuo1Ru3Frn7ZfvXqJvGnjvnb8pH9CnnXeu3sHR387gD9PnzAR+F1bN+Dly1dYtH6XDzP/hDz9UrVkPuNjjq2I/5sUcbLEdKFMWbObqPzBn/cace8oiZMkwwdFS5oJZedmtdBt4CiU+7S6z+f+CXnW0bhaWcOckyJG2x2+cwh5smHbTBtq132A00Q8DZOQd/VXq+r3RgIS8t7odfVZBNxLwNJCvmyBzIgUOYqJWjLi7Sgnj/1uhHrRUuVMZJqF0d5pY4dg/jff4c8zJ7FywUyTxtChcQ0kTZYS3QaMQNMa5RA/YWJMXvhNgNQP/PQDJgzrZ6L6MWLFBgXkjatXED9R4jeEfLiw4TB92YbX6uIpPLUatTTpHizVy3xg0mB6DqGQ/7+UiHdtdg0otYZCnisUn9Vq4NPuwhkTMWZQT+z94yqiRov2ViHP4z6Zi86Jkd+IUf5CxdC+x0AfIU9BS2HvuxghP3UsRkxZgCzZc5mPrl25ZIQ8c9Ebt+nic/mC6RPN/oFB42Ygd4FCKPJ+CpODnjJ1WkSIGPG1erNky4Ueg8eCqwDtGlRD3WZtDUffkwi/m139E/J7dmzFlNGDcP/eHRPNf/niJa5e+RvJUqQOlJAvmDGhYZg4SXKEDfd6jitTfRq36YrFsydhx+b/O/8/e+78ZvLGFZrOzWuj+8BRJkXGUfwT8vyMJ+7MGD8c/C2FWLHioHHbLoYh8/h5/GSixMlMdO/xo4fmVCdOJJxVJOSdRVL1iMD/EVi6dCkePnyIBg0aKCKvgSECIhAqBCwt5FvWroxzZ09i2uL1Rgw7yoF9e9C/S0vUbNACdZq0Nn/mxkIK9Wp1mpj0G0bVu/YbhjXLF5pccW4aZQoHNwpyU2NAhVFSClzmU1M4PX3yGJNGfoUDP30fLCFPm5iO03vYBCRImNg0y9xzCt9nT58GKyIfEiFft1JxJE2eEj0Gj/FZIfDLwpEj72wh36beZ0ZUM9XJv43GtIMTGO6L+LjS52jW/ksfIc8oe7HsqYy/35YjX//TEogdNz7adutnjt3kSgrTWE6fOBYoIV+7QhGkz5QVXfsPD/L58syRD4qQZ385seHEdNaEETi4fy9mrdxi2v3vHPlUZuIwqGd747N+IycjTtz/0nVCWiTkQ0pQ94vAmwRWrVqFmzdvokmTJmZ/kYoIiIAIuJqApYX8N0vnmfxmnhhSv0UHs2GSwmzc4N7YsWW9OaXGcQY4RXGt8oWNgKdILFelhhHsJ48dMeKKEdlDB37CtgOnESt2wJsFS+dNjzwFPkKvoeONoGJknjnb165eCpaQHzekt9mM22vIOJN6wnzvNcvnY9aEkeY0lIB+2TWkEfk5k0ZhyujBmL50nTl9xlHGfNUDe3ZuM6IwR54CPn+/eulvc3oLNxG7Sshz8zEj0NxDwIi1Y0WAv9DKFBimqPBXTQd2a2M2fE5dvA4JEycxqUw8SpMbWes2bftWIV8yd1oU/7giOvUebCZQVy5dNJM+/oqu79Qa7iHgOftzV281G2odhXsamPYycMw0ZH4/p8/faQ/3H8RLkDDAZzI4Qt5R2YLp403q14zlG5EoSTKfH4QaPXOxOQmIqUAcP136DvM53SckXw4S8iGhp3tFwH8CEvIaGSIgAqFNwBJCntFG32kDTEGp1bg10qTPiB5tGplTTVKly2hOkTl2+IAR88079DBHETqOeSS4meOHY+qYwUiRKq0RYjnyFsTN61fNr2ryVJWPin/8zl/K5MRhzbL55kQXnuDCYxCZOsKTX/zmyAcmtYbpFlxZuP3PTRT4qDj+OnfGbOzkhCND5vddJuS5gsCjKnm6DCc7FM7MTb908Tx6tWuCixf+RLU6jRE9RiycOHYIP+3egeFT5yP/h0VdJuR5AgwnVRS8ZSp8hjQZMht7dmxeh4YtO5ljKFnInEdoklPu/B+adJsEiZKYTcLvEvKcBPCUmU8qV0Pq9JmwevFsXLt8CWkzvveakN/3ww7jF9bLVJ/KNeqZk3S48bd3x6Ym75/2RIkSzeyX2Ldnp9lb4Xvy4/dhDYqQ79TkC7OZOlf+D80xp1vWrULSFKkwddEa3L1757Vfdn354gUmjRyIhTMnom23/ma/R0iLhHxICep+EXiTwPr163H+/Hm0aNHitXRQsRIBERABVxFwu5Bn6gnP1PZdYsSMbc4fz5Y7Hx49eoj1Kxfju03r8OD+XaRInQ6ly3+KD4uVRuTI/5077ig8KpLnePOXUJu2645ESZKazZQrF83GpjXL0apLH3Ok4dsKUzgWz56MX3783kSMPypWBtFjxsThAz+bE124AZTXTBoxAFGiREWHXoNeq65e5RIo/1lNH1H68uULHP51P1bMn2E2elK88sz177dvxJ3bt9F90H9HS/otjEx3b9PQCF6HwOUxjF91b2eOYCxUvIzPLdzAy9NgJi9c89qRmhTEm75ZbjZtckUj34dFTKoKo8s8A/777zYBCGOEbMlylVG0dHlzZBqP+xw3uA9ix41nNln6Lnt3bsXaFYvQpltfs1GThb+wOn5oH+Qu8NFraUs7t24wvuPZ+uky/neWPNkx1Yk55sxjp5Dm8Z0lPqnkk8pCn23fuMb8fgBzxHnCTa1GrdCnY1MULlnW/DfLX+fOYmifTmjQoqM5A5+FvwOwZPZUk6bC85x5xj6FMCcDXIXwXRjh5xGU9CPP2Wc7LOTMVZQfdmxGuHDhzakyPIKTvyfwtnL+zClzglDDVp3McaWO8u/tWxjZrxuSpUzjs6eD5/jv3bXNnNITLUZMZM+V36w8ceL17z+3MKJfVzPWuZmb5dGDBxjcqyP4o+88ESdhkqRvteVdH0rIv4uQPheBoBOgkD937hxatmwpIR90fLpDBEQgGATcLuSDYbNuEQERCCEBCfkQAtTtIuAPgU2bNuHkyZNo3bq1hLxGiAiIQKgQkJAPFcxqRASsRUBC3lr+kDWeQWDr1q34/fff0a5dO7MiqCICIiACriYgIe9qwqpfBCxIQELegk6RSbYnICFvexeqAyJgOwIS8rZzmQwWgZATkJAPOUPVIAJ+CezevRt79+5F586dESlSJAESAREQAZcTkJB3OWI1IALWIyAhbz2fyCL7E5CQt78P1QMRsBsBCXm7eUz2ioATCEjIOwGiqhABPwQk5DUkREAEQpuAhHxoE1d7ImABAhLyFnCCTPA4Avv27cPmzZvRvXt3RI4c2eP6pw6JgAhYj4CEvPV8IotEwOUEJORdjlgNeCEBCXkvdLq6LAJuJiAh72YHqHkRcAcBCXl3UFebnk7gl19+AX8UqmfPnorIe7qz1T8RsAgBCXmLOEJmiEBoEpCQD03aastbCPz2229YtWoVevfujShRXv/lcW9hoH6KgAiELgEJ+dDlrdZEwBIEJOQt4QYZ4WEEJOQ9zKHqjgjYgICEvA2cFFwTb/9zEz98txnv58yLtBkyB7cat9735PEj3Lx+DXfv3MaLFy8RM1ZsJEySFJEjK9oVEsdIyIeEnu4VAf8JHD9+HHPnzsWAAQMQNWpUYRIBERABlxOQkHc5Ytc38PeFc/hx93YU/7gCEiRK4tPg1g1fo3eHpmjRsScate7sEkPu3vkXu7ZuQKYs2ZEpSzYgTBintfPk8WMsmjUJP32/Ay9fvMCLF8/x9MkTfFypKqp80QCxYsdxWlveVpGEvLd5XP0NDQIS8qFBWW2IgAj4JiAh7wHjYeeW9RjcowOGTpqLfB8W8ekRI/InjhxGqnQZkDR5Spf09PzZ0+jUpCaq1mmMWo1aIowThfyWdasw+queqFqrIcpU/Axhw4bFd5vWGXHfa8g4lPykskv65A2VSsh7g5fVx9AmcPr0aUyePBmDBw9GtGjRQrt5tScCIuCFBCTkPcDp321ai8E9O2DIhNkoWLhEqPbo3JlT6Ni4BqrWaYQ6TVojTJiwTmu/aql8JoVm8oJvEDtuPFPvpYvn0adDMyRLkQoDx85w6sTBaYbboCIJeRs4SSbajsDZs2cxYcIEDBkyRELedt6TwSJgTwIS8qHst8ePH2HqqEG4/c8tlK9SAwtnTsTx339DmLBh8HntxqjduBVi/i9l5OGDB6BI37RmBS5eOIeHD+4hT8GPULNBC+TIkx/hwoXHlNGDsXLBDDDFJVacuIgYKTKKli6HNl374srff6FpjXLo1n8Eylf9wvT02bOn+G3/j/h6yTz89stPpo7U6TKgbrO2ZhLAiPqtG9fRpXlt5ClYGClSp8GK+TPx5+kTSJwsBdp+2R9FSpZF+AgRsHrxXEwbM9j0JWq0aIgaLTpSpc2AAWOmIVas2FizbAG+XjoP9+7dNZ+X+uRTtOrS29ixcuEsDOvTGQPHTEf5z2r664W8aeMge658mLVys4nGszy4fw9jBvXE77/ux4qt+yTkgzl+JeSDCU63icBbCEjIa3iIgAiENgEJ+VAm/ujhA0wcPgC7t29E2DBhULR0eSOkjx0+iA2rl6Bus3ZG7IYPHwH7ftiBWRNGonjZCkiXMQt477ypY41g7jtiEpIkS4ELf57G5nWrsXjWJDRp1w1ZsuVGnHjxkCpNehz7/Te0qVcFnXoPQZUv6pueHtz/I4b36Yz3suVCqXKVTU779m/X4PCBfRg+ZT4yZsmGa1cuo2uLOnj86CHChg2HYh+XR/QYMY0wf/LkMUZMWYD3suXE5b//wq/79mDSiAEoVqY8SpX7FFGiRkP6TFnAdJ/eHZuhbbd+eD9nPty5fQtPnz7BJ59WN3bMnzYOE4b1Q8feQ0wk37/ycf5MJg9+7OzlJgLPQgbjhvTBmmXz8dOpGz4CP5TdaPvmJORt70J1wCIErly5gvv37+PJkye4fPmy2ezaqlUrc/zkixcvkCBBAqRJk0ZBB4v4S2aIgKcRkJAPZY86hPy3Xy/F8MnzkavAh4gUKTLu/nsbzb6ogGdPn2LivFVImiIVbt24hnt37iBlmnQIGy6csXTZvOlYOmcqhk6agyzZc5u/BZRac/jX/W8IeabgUPz3HjYBKVOnM/cz2t6jbSPkzFsQPQaN8RHyFOqjpi/C+znymAj8ri0b0K9rq/8i/P+LogeUWjNpxEDMmTwaq7/7BWnSZ3yD8rUrl3DmxDFkzpYT8eIn9NcLS+dOxYSh/VCk9CcoXKKsSbPZu2sbft6zE1cuXcSv5+9IyAdz/ErIBxOcbhMBPwQWLlxo8uIfPXqE58+f4+rVq0a8cxUxXLhw5gSbKlWqSMhr5IiACLiEgIS8S7AGXKlDyB/cvxdzV281EWxHGTWgO3jSzODxs3w2rVLYnzh6GCeOHcbjx49x9NABHP3tAIZNnotsufIFWch/Xio/IkSMiBJlKyFylP+OR7t/9w7Wr15iovhTF6/1EfJMh5m2ZL2Pfa9evUTBjAnRqksf1G/e3vw9ICH/+8H9aPT5x0iYKAmad+yB0uWrmJWEoJSXL19i09qVmDdlDM6fPYUYsWLjk8rVcP/ePXNKz9b9JxHmfyk3QalX1wIS8hoFIuAcAnfv3kWqVKnw77//vlFh/vz5TYQ+S5YszmlMtYiACIiAHwIS8qE8JBxCnnnqc1ZveU3Iz5s6DkvmTMGgcTORv1BRnDt9EiMHfGlEbJx48U1U/vatm3j18lWwhTyFOJd8kyRPhXDh/4vyO0r+D4uaHHhHak206DGMsPddcqWMgYatOqFd9wFvFfL88NQfRzFz/HAzEaGIb9CiPUpV+AwRIkQINnXuBRjZvxuuXPobM5d/qyhXMElKyAcTnG4TAX8IUKy3aNECT58+9fk0UqRI6NGjB3r16oXw4cOLmwiIgAi4hICEvEuwBlypQ8jv37sLC9buNJtAHaVLizpm4+vo6YtNDjrz1Jk7P2DUVOTIWxARI0XCmuULjTgObkS+bqXi5ijKHoPHIHac/06C8VucJeRZ77Nnz3D6j6OYM2U09u7citmrtiJLtpzBpn7y2O/o2a4xylauhiZtu0rIB5OkhHwwwek2EfCHAFdLK1asiO3bt/t8mjlzZqxatQpZs2YVMxEQARFwGQEJeZeh9b9ih5D/Ztl81KjXFM079kSUqFFx+MDP6NC4OjK89z4mzFtl8sGrlswHprNMW7IBCRP/90NPQ3p1xN6d214T8ru3bcSgHu3Rpe9QfFzpc5+G/cuRH/NVT+zZuRX9RkxGjrz5Afz3A07MOWcefIKEiYMUkb9w7gw6N62NUuUqoVmHHgHmrC+dOw2jBnyJGcs2mNNw9n2/A4vnTEHTdt2QPTfteLPcvHENESJE9PnhJ/7/0J4dcfHCnxgwepqZ7KgEj4CEfPC46S4RCIjAunXrUKdOHdy7d89c0rt3b/Tv39/kyauIgAiIgKsISMi7imwA9TqE/NYNq82JBjzuMU36TDh94hju3fkXM5dvRN4PCpu7F8yYiInD+iLvB0VQ4KPi2LxuJS5fvIAYMWO/JuTPnTlpotRnTx4316bNmBnN2nc3+et+T635+69z6Nm2Mf46dwbV6jZB9Bix8MfRQ/hp93aMnLbIpPQEJSL/7z+3MKxPJ2zftA6FipYyp+B0/2q0OZHm4YP7xp6rly5iy/rVZpIwY/m3iBEzljnphptheexlx16D/aW1aOZkzJ480vxqLH/V9cjBXxApShS07twHVWrVNyJfJXgEJOSDx013iUBABG7duoXWrVtj+fLliBkzJo4ePYoUKVIImAiIgAi4lICEvEvxvlm57xz5gWOmYc3yBfj9t1+Q6b1s+KxWQ2TJnuu1m3hKzffbN5nz33mmeoHCJfD1krlo2u5LpMv0ns+1TFvhKS9c4i3/2RcoV6UGbly9ZH4oqm7TdviwWCmfa3m+/MY1K0y9nEikSJ0WJctWQpHS5UxEnXno44f2Rew4cU3OvO/SoEopVK5RF1Vq/necJQtz4Hke/sXzf6JgkZKo17wddm5ah93fbQJPp4kWLQbez5kH9Zq3R8xYsc09bHv2pFFo12Mg8hQo5K8XLp4/i2Vzp+PE8d/N0ZXZcuZDhc9qIkuO/07rUQk+AQn54LPTnSIQEIEVK1aYoyfr1q2LsWPHCpQIiIAIuJyAhLzLEb/ewNs2u4ayKWrOiwlIyLvP+Zs3b8bhw4fdZ4BadhmB69evm4g88+VTp07tsnZUsXsJMODVtWtX9xqh1kXgfwQk5EN5KEjIhzJwNecvAQl59w2MZs2aIWmGnEjwv30v7rNELYuACASHQIdG1c1BDioiYAUCEvKh7IUnjx9h6ujBOHxwP6YsWoMo/zvLPZTNUHNeTkBC3n0DgEK+Qp3W5ofeVERABOxHIF/aOBLy9nObx1osIe+xrlXHRCBgAhLy7hsdEvLuY6+WRcAZBCTknUFRdTiLgIS8s0iqHhGwEQEJefc5S0LefezVsgg4g4CEvDMoqg5nEZCQdxZJ1SMCNiIgIe8+Z0nIu4+9WhYBZxCQkHcGRdXhLAIS8s4iqXpEwEYEJOTd5ywJefexV8si4AwCEvLOoKg6nEVAQt5ZJFWPCNiIgIS8+5wlIe8+9mpZBJxBQELeGRRVh7MISMg7i6TqEQEbEZCQd5+zJOTdx14ti4AzCEjIO4Oi6nAWAQl5Z5FUPSJgIwIS8u5zloS8+9irZRFwBgEJeWdQVB3OIiAh7yySqkcEbERAQt59zpKQdx97tSwCziAgIe8MiqrDWQQk5J1FUvWIgI0ISMi7z1kS8u5jr5ZFwBkEJOSdQVF1OIuAhLyzSKoeEbARAQl59zlLQt597NWyCDiDgIS8MyiqDmcRCJGQP3bqT0SMFMlZtqgeERCBUCJw5OAvuHf3Tii1pmZ8E5CQ13gQAXsTkJC3t/88zfpgC/nnz5/jxYsXnsZD/fkfgcqVK2PZsmWIEiWKmHgogUiahLvFsxLybsGuRkXAaQQk5J2GUhU5gUCwhbwT2lYVFiZQrlw5rF69WkLewj6SafYkICFvT7/JahFwEJCQ11iwEgEJeSt5w0K2SMhbyBkyxaMISMh7lDvVGS8kICHvhU63cJcl5C3sHHeaJiHvTvpq25MJSMh7snfVN28gICHvDV62Tx8l5O3jq1C1VEI+VHGrMS8iICHvRc5WVz2SgIS8R7rVtp2SkLet61xruIS8a/mqdu8lICHvvb5Xzz2DgIS8Z/jRU3ohIe8pnnRyPyTknQxU1YnA/whIyGsoiIC9CUjI29t/nma9hLynedRJ/ZGQdxJIVSMCfghIyGtIiIC9CUjI29t/nma9hLynedRJ/ZGQdxJIVSMCEvIaAyLgUQQk5D3KnbbvjIS87V3omg5IyLuGq2oVAUXkNQZEwN4EJOTt7T9Ps15C3tM86qT+SMg7CaSqEQFF5DUGRMCjCEjIe5Q7bd8ZCXnbu9A1HZCQdw1X1SoCishrDIiAvQlIyNvbf55mvYS8p3nUSf2RkHcSSFUjAorIawyIgEcRkJD3KHfavjMS8rZ3oWs68P/YuwqwqpYt/EvZ3d2F17zX7u7EAFERQUUUQVRQBAVRRFEUMTFQEbu7u7u7u7sD3lsLzxGQUtmAkgAAIABJREFU9nAOB9Z83/3e8zB7Zs0/s/f+Z82/1hYiHz+4SquCgHjkw66Br1++AMmA5MlTxHhxfPn8GTeuXkSuPPmRKUvWGF8Xk4pfvnxGsmTJYmTPjx8/cPfWdejq6qJA4WIxaV7tdQirZDo6SJ48udr7TqwdCpFPrDOrneMSIq+d8xbvVguRj3eIpYMkikBiJ/IHd2/D1Uvn0aPvwD9m+OrFczh6YDc6dLVEylSp8eb1S6xdthDv375BP4cRMV4R1E6P9o0xYNgotO9iEeProqv4+tULrFmyAB8/fEA/h+HRVcfLF88wpG93pEyZCpPnrYi2vrorvHrxDKsWz8fXL5/Rd3D041G3fTHpb8fGNbh7+8YfVUuXr4hK1WvHpAmV1xEir3JIpcG/QECI/F+Al5gvFSKfmGdXxqZJBBI7kXcZ0AsbVi7G6Xvv/4B51SJ/jB42AFuOXEHW7Dnw8P4duNj1wquXL7Bmz6kYT8v5MyfQ27gF+g9xg3H33jG+LrqKD+7exjBbC7x7+xard5+MrjqeP32MIf3Moaenh5mLN0RbPz4r+HqOQPqMmdCxW0+kSJmKu7p76waG9jMHnTKs2nUi3rqfN80bDx/cg43DCKTLkFGl/fQxbY1zp46hQOGiYdpt3s4YnXtYq7SvmDYmRD6mSEk9dSAgRF4dKGthH0LktXDSxGStQCCxE/lh/S2wac2ySIm8+5D+2Hb8GrJmz4ng4GD8/PkTQDD09PRjPH/xReRja09CIvJmbeojV978GDpqAtKlDyHTIeP5wf8/NvjGeCJ+VbQ174BHD+7Bx385cuXJF9vLo6zfy7gF9HR14Tt/ZZh6JBfS0dFRaV8xbUyIfEyRknrqQECIvDpQ1sI+hMhr4aSJyVqBgBD530SeNOb3bt9gTXrBIsWV8/fzxw88uH8Hb1+/QlBQkPL31KnTIG/Bwrh+5SJ75MkD3LBFOzx9/IA3BJmzZkP2nHnYQx5V+fL5E25eu4zceQvg7dvXePPyJV+bI3de1rzr6OiiYJHfmvf3797y6QHpzfX19ZElaw5kz5U7Qo/8xw/vue1UqVKjSIlSEZpB/d+6fgX5ChbB50+f8PTxQwT9/IEMmbIgZ5680Nc3UF73/ft3PHvyEG9ev8L3b9+QJk1atjNN2nRch34nm90dbfiUo0tPG6ROkxbFDctA30Afd25cg56+/h8afpLdPH3yCBSjQPr5HLnyImPmLMp+X798wdKhnLnz4vWrl3jx7AmPnfrOnCUb1yMJ0r07NzDWZRBePn8Ku2GjkDlrdhQpbsj2ff36BY8f3sebVy+ZdNMGI1fefDAwSI5v377i3u2bLLHKnTd/pNNFRF5fXw9TA9YkmPtbiHyCmQoxBIAQeVkGESIgRF4WhiAQPwgIkf9N5IksDrO1ZCI/NWA1A/79+zcsneeHbRtWQd/AgPXzRHpTp0mHJq07oHsfO7x4/hQ9OzZFrQZN8eP7d9y/cwvPnz5h+YX1IGf8V7VWlN7aKxfOgiQbLdt3xpkTR/Dq5XMUKloCrl5TWSpDgbcKD/CLZ08xc6IHzp8+wbIR8nATSXZwG/cHkX/75hUWz52OhbOnwNLGAd37DIhwEV0+fwY23Y1g1Nmc4wke3rvDZDlrtuww7zsQDZq1Yfs/fvyAretWYMvaFfxv0rp/+vgRhmXLc0wBEeoTRw5g7pTxLD9JkSIl8hcqCl09PQwbMwmpU6fFIKsuSJ8hI3zmLlPacuroQSyZNxNPHj9AcoMUeP36JUoYlkG33v1RzLA011u7LADLA+agUvU6OHlkP4/1y5cvKFexCoa6T+ATFdqw+E+biP27tvAmo1jJf2CQPAUGOI9iPMn2lYvmMZ50OpApcxZYD3JB/kJFmMQP6dedN1Pjps9HsmQRe9eJyH/6+IHxppIxUxbkLVAofm7OGLYqRD6GQEk1tSAgRF4tMCf8Th4/foxPnz4pDbWwsMDUqVORIkVIJgn631y5cvELV4ogIAjEHYGkQuQjC3Y9uGe7UlpDhNzZtieT41lLNzGoF8+ego2ZEVp37Iq2JmZMEMe5Dsaj+3fhPWsxe+4vXzwLs9b1kClzVrQ27oZ6jVvg6eNH8BkzHCVLl8MIr6kcgBpZOX/6OMyNGiF7jlxo19kcVWvVx48f35Ezdz4MtTGHro4uZi4J0bwvD5iN8W5DMN4vEIWLlWQyTScJRUuUCkPkp8xfxXXnTB2PXv0d0bpTV6VWPbwdRLot2jdGthy50dzIBHUaNgNtAubPmMQe7LkrtvEJAW1Q5k33RrXaDdi7TycFe3ds4nEOHTUR7UzM8PnTR/Z42/c0QfZceWA90Blp0qVHlmzZeXPgYNUVqVKnxvTAdWzG4wf3YN21DXvgqW6mrNlAG6qxwweiaIl/YOvkzsR/ReBceLsPRdbsuThwmcZ7eN9OLPCbDNMe1uhlNwTfvn7lgGVnu5549uQxXL2mIVvOXJxJ6PmTx6zPr1a3Ic9lcFAQPn/+xMSd7KF4BKf+FjyfruOnRfpuISJPeGXPmYvtJw8+2WJlPyxKT37c79DorxQiHz1GUkN9CAiRVx/WCbqnI0eOoEGDBvj69SvbScfUlFJNUezs7ODp6RnmtwQ9IDFOEEigCCQVIh/Zpp88swqNfERE3n+aN2Z4e2DN3jPImTsPzyJ5j+dM8cK46QEoX7EqSCPfw6gROpv3Qd/BLuwFJhmH3yRPHNy9HbOWbULadOmjJPLd2zVExy6WGOA8Gga/UjOSVz88kZ/lMxZ+PmMRsH4PSpQqE6bN0Bp5Y7PeGOnYD73shqJjV0v2ikdWiJhadmyKnv0dYGkzWOmN3rh6Kca6DOSNSP2mrdmLHRwcxAReUcgLbtqiNpN4Bzcv5e9Kjbz7BGXAKUlnwhP5ZQGzMW74YMxauhHlK1VTXr984Rws8Z+BMb5z2StPRH7ymOFw956JWg2bMdF++fwZbxhIujNt4W+pS3/zDrxBCK2Rv3XtCgb0NObgWwpK/WM9kH4/6Cf/Hnp84TGjgF2W3iQDXj1/jsA5UxEwyxdVataD59R5SJc+g9rvdCHyaodcOowCASHysjyUCDRt2hRbtmz5A5E8efJg4cKFqF1bM6m+ZIoEgcSEQFIh8pFlrQkd7BoRkV80dzoTyMBN+1H4/3IXKnOnTmAyP3H2YpQq+y8T+Yiy1ixbMAtTx7tj7d7TSJs2PQ7s3oaDe3Yolw8FYrZob8Kk06pzK9gOHclEU1EiIvJ3b16Hi31vPH54D03bdES9xq1YQpIqTRqlR/71y+fsFa9QuTqGefiE0ZpHtHaJyFt3acObCJLXKMqJI/vhNqgvWnYwRS9bR44PIPJM9a9ePIs3r1/j3dvXoJSMlMLTcWTsifyoIbZYtdgfDZu3RfqMmZV937p+Gc8eP8TYaQv4VIOI/LzpEzFu2gIYlimvrEfe/BtXLvFmTFEiIvIUK0AnDCsWzkXZ/6qghZExKGVklqzZoRPKSRSXe3ukQz/Qyc7wsb6oXrdRXJr4q2uEyP8VfHKxihEQIq9iQLW5uStXrqBixYr48OGDchjklTc3N4eXlxcyZFC/50Ob8RTbBYGIEBAi/1sjHxGRv3T+DKw6t0SdRs3RwsgEnz9+xIyJHiwFcZ84k4MooyLyY5ztsfP0LaRPnxHHD+3DiaMHlNOQM1ce9nTfv3srxkSeLn7y6AG2b1wN0pZTcG6VmvVZi0/abUX6ycLFDbF3+yYOwG3Usl2UXubIiPyZ44cxYlAfNG9nwkSeAmynTxiNKxfOoEKl6kiXMRPevHqBtUsD0L5L3Ig8xSRsXrMMbYy7IdOvoFUFQJkyZUGjlkYsy4mKyB/euzNMVqKIiDy1+eH9O1DdI/t34cLZk8ieMzdr5MOfbMT2STFv+iT4T/eGg+s4UBpKdRch8upGXPqLCgEh8rI+wiBgY2ODKVOmKH/LnTs3Zs+ejcaNG4s+XtaKIKACBITIR03kN6xchImjnFHin7J49OAuE2LywpMmO0++AjwDMSHypJ+PrJBGPqYeeUUb5B1/9eI5FvtPx6I50zBxzlIULlZCSeTdJ/ph3AgH3Lx2CV7TAyLNWEPtEZGnzYqNoxtMzK2UZm5euxy0EXHxnMwe8w0rFsFz+CCMn7kQ5f6rwpp7Cvzt3LwW2hqbxckjT/KjmZM8MW/1dvaQR1ZUQeQVbdOG5/Txw/B2d0KD5m1hNWDoX71PJrg7Ydv6FXDx9EWNeo1VcFfGrgkh8rHDS2rHLwJC5OMXX61r/cyZM6hXrx5ev37Ntrdo0QLLli1DypQptW4sYrAgkBARECIfNZEn2cSxg3sQuGEfUqdNS8nVOGNL6JzhmiDyirW0cpE/a8xnLFqHPPkLhvkg1MUzJzF8oBUT7pmL1iNNupAUkeELEXnStNPGxNlzMmeGoYBT0thfOHMS6/adQarUabB6yQKMGzGYJUWkCadCWnbqn75oG1paQ1l4SOvvPGYyp6GkEpFGnjLQ9DFtg8at2mOYxySk+PVspww5lD0nX8HCnP0mNkSevh1w8dwp3sAULflPhGOmUxAnGwsO7O3RbxCfcrgO6oPipcryF3ojiqnYtWU97t25CbPetsq/79+5BXYWxjAsUw5TFqzmwFx1FyHy6kZc+osKASHysj7CIPD+/XsMHToU06dP55zB27dvR82aNQUlQUAQUBECiZ3IR/tlVyc7bDl6lckm5SmnrDUU0Dlj0XpGmDy3JNUw0DdQkkySgBQoXAwduljgn/L/4sqFc+jZqSlsh7qH0biTRn7s8EHYfvIGZ7SJrFBmnF7GzZlAEiFWFJL6UKYV+njS9MC1/LOHkx1uXLuMIsVL4d2bV6DUkXRCQF7zjx/fM5GnvOiK4M9Nq5ZgnJsjZ9JxcBuvHENoW4jI9+rUnLPgULYayh9PueL19A3Qw9oe7Uy6s4789o2rnDGHpDU16zcB5bOndJiXL5yBUeceYYj86sXzMMnDhVNSBgPsxadA0EFWXZE2bTpMWbBKaULgnGlYNt8PmbJmReGihvj58zsT8Rp1G8PCZjAoX/+qxfNAX2xVaOYVF5NG/tiBvThxO8TZQ+X4wb0YYtOD3xkkfXIZOwUGBvpwG9wXRUuW5kwzl8+fgq6ePgaP8GT8bt+4hsFWXTg7D2XUiejjThTjMGWcG8cJkCzq3bs3LNehbD8unj4oWfq3dl9Ft2eMmhEiHyOYpJKaEBAiryagtakbCnglskEEfu7cufyxECmCgCCgGgQSO5HfvXUDLp07zdlkwhci0Ad2b0XXnjbscaYPLJH2nGJxmrXtxKkdp40fhd3bNsB2yEhk/EXGKdCUspXQx56cPCZyekjyGNeo2yhMICblej+0dzu69baNMv0kfQxpZaA/yzIosFNR6ENNW9evZGJOga1USLdOdlOudXoW5slfCLXqNUbqtOk4nSLlSqc86Yr6lC5zw6rF+PDuHZobGUe4oVBo5PvYD0OREoY4efQgb1zKV66OUmUrsEdcUShLDWnM6eNY9LGl/6rWxP4dm1GouCFq1W+irEcEd8+2DZyyMlOW7Ny3ro4O6+EJa8rBH34zcf7U8V/jSoHihqVRukJFztNO5erFczh55IBSM6+4dt3yQA6KtezvEKa9XVvW4drlC0iTNj3HNiA4GLu3rudTAUrXmS17TlSoVA2FipVk0k6bkh2b1iBrthwcsBqRR54+VnXt0nlcuXiW26E0yHkLFObTCU144hUDFiKvmmehtKIaBITIqwbHRNUK5ZO3tbUFpZwsVSriLxMmqgHLYAQBNSKQ2In830BJHvph/S35a6KUgjF0GdirM5M/ylWeK4ovgf5N/+q6NrJgV3X1L/38HQJC5P8OP7latQjEmchTJhNKSSglcSJAgV0RHXUmztEmzVHRp9+lqB8BIfKRY04fGBrp0Bdb1q3gr7NWrd0AXz9/wo7Na3H/9k30tHXkjxNpexEir90zKEReu+cvsVkfZyJvZmaGztZD+UtyUgQBQUC7EOjSsjYH1UlRPwJC5KPG/N3bN9i8dhnrrilLDBXKYFOnUQtUqp44vmVBQaWUnaazhTV/tVWKdiEgRF675iuxWytEPrHPsIxPEIgAASHymlsWQuQ1h730LAioAgEh8qpAUdpQFQJC5FWFpLQjCGgRAkLkNTdZQuQ1h730LAioAgEh8qpAUdpQFQJC5FWFpLQjCGgRAkLkNTdZQuQ1h730LAioAgEh8qpAUdpQFQJC5FWFpLQjCGgRAkLkNTdZQuQ1h730LAioAgEh8qpAUdpQFQJC5FWFpLQjCGgRAkLkNTdZQuQ1h730LAioAgEh8qpAUdpQFQJC5FWFpLQjCGgRAkLkNTdZQuQ1h730LAioAgEh8qpAUdpQFQJC5FWFpLQjCGgRAkLkNTdZQuQ1h730LAioAgEh8qpAUdpQFQJC5FWFpLQjCGgRAkLkNTdZQuQ1h730LAioAgEh8qpAUdpQFQJC5FWFpLQjCGgRAkLkNTdZQuQ1h730LAioAgEh8qpAUdpQFQJC5FWFpLQjCGgRAkLkNTdZQuQ1h730LAioAgEh8qpAUdpQFQJC5FWFpLQjCGgRAkLkNTdZQuQ1h730LAioAgEh8qpAUdpQFQJC5FWFpLQjCGgRAkLkNTdZQuQ1h730LAioAgEh8qpAUdpQFQJC5FWFpLQjCGgRAkLkNTdZQuQ1h730LAioAgEh8qpAUdpQFQJC5H8h6efjiQ/v38PeebSqsI1RO7dvXEXWHLmQJk3aGNWPz0oP793BBHcnGHfvjUrVa8dnV1rb9udPH/HyxTNkz5kb+voGUY7j3q0b8B3nBlMLa5SrWDVBjVmIvOamQ4i85rCXngUBVSAgRF4VKEobqkJAK4n8+uWBGD3MDhsPXkDmrNlVgoVDn2548/ol/JZsVEl7MWlk3YpAuDvaoLuVHfoOHh6TS+K1ztmTR9GvWzsMHD4GbTp1i9e+tLHx4OBgeI9ywsrAuZixaD3KVKgU5TBOHDmAwb1N4eg+AU1atU9QQxYir7npECKvOeylZ0FAFQgIkVcFitKGqhDQSiK/YuEcjHayw46TN7SCyB/YtRUjHW0wxncu/q1SQzl3F8+ewpRxbmhrYoZGLdqpak6jbWfPto0Y7WSL8TMWoux/VZT1hchHDR0R+U2rl2LX1vWwHTIS+QoW5gu2rF2BscMHYXrgWpT4p6yykRNH9mNw7y5C5KNdkUmrghD5pDXfMtrEh4AQ+cQ3p9o8IiHyv2YvPj3yu7duwKihthjpPQPV6zTU+HrZsXENPIYNwJgp/qhco44Q+b+ckfUrFmG8myN8/JejXKiNkRD5vwQ2kV4uRD6RTqwMK8kgIEQ+yUy1Vgw0URD5j+/fYfaU8ShQuBjK/lsZKxbOxrXLF5E3f0GYWdkpPaeKGbl35xZWBc7FlYvnkDV7DnToYol5Mybiw/t3SmnNk0cP4Olsjxr1mqB9lx7KyXx4/w6mjHWDhc1gFCluqPz9xtVLWLV4Hm5cuYR06TOgbuMWaNyqPVYt8gedINy5eR0FixZH+gyZ8F+VGjC17Iu3r19hnKsDjM16o0qtesq2SOKze8sGbNuwCuQFzpOvABo0b4NK1etAR0eH67149hRug63RsVsvpEyVCisX+ePl82coX6kqjydLtoglR0v8Z2Llorm4c+s6ChcriXTpM7Ie3qRHH9y4cpGlNf2HuCFj5izYvHoZvn3/hrqNWqBJ6/ZIlTpNmEV98exJEIm9df0q0mfMiHqNW6Fpmw7KOg/u3cZUL3e0N7XA8UN7cfr4ITRo1gYdulri7ZvX2LR6CU4fP4w3r16huGFptOpoiqIl/vl9/d3bmDHRA2a9bXH75jVsXrMM3759ReUadVn6Qzi/fvkC82f6IEvW7IxpsmTJlNdvXbcSh/buQC+7IcidN7/y91cvnmPaeHfWufe0dVT+vnfHZmxctRhde9qgdPmK/DvNRcCsKciUKQu3v3/nFvbI97YbytcvnD0Fa5bMx73bN1G05D9IkzY9atZrjPZdLUD4kEfe3tkD+gYG2LpuBYKCgnkuGzZvgxQpU2nsISHSGo1BDyHymsNeehYEVIGAEHlVoChtqAqBREHkXzx/imH9LZA6dVqQFzR1mrRIlyEjbl69hFx58mP28s3IliOXkgAP6dsdJ48eRMWqNfHq5Qu8efUC3398ZzKp0MjfvnEN3drUQ5OWRhg2xuc3Yb9yEf3NO8Bj8hxlAOOJw/vh5tAXD+7eRrXa9fH44X0m7r7zVzKx3LhqKXZvXYdGLY2Qv2BR3lhUq9MA1y9fhHWX1hgwbBSMTEM2C8+fPcHwAb1x9MBuFDMsg7Rp04E2CW/fvILr+Glo1aEL17t1/QpMW9TCf1Vq4uSRA8hfuCg+fnjPNrQw6gzHkV6MQ/hycM92bFi5BHu2bWDSnTd/YRQoXBRVa9XH1Uvn0Mu4OTJkzMwE+d/K1XHrxlU8f/oYQ0d5o30XCyVRXr8ikOVCJUqVQY26jUEyoYN7tqFzD2vW2FM5c+IIBlgaI2++grh7+wZKlamAz58/wXPqPAy3742rF8+huVFnpEiRAhtXLcGzJ4+wdOthFC1RSnm9vaUJcufLz3X/q1qLsb176zpMLftxYPKXz58wabQzdm/fiK1HriDZr40ONdCqVjmkz5ARUwNWM+lXlC+fP6OPaSuQlOjU3XfK3/t2bcvrwnboSJiYW/HvN69dhqO1GZP7Vh27YLH/dCyd5wfvWYtQqFhJ7N+1FRSzQQSf/p4zdz7e4FWqURvnTx+HTTcjpMuQAa9evEDFarVw/epFvHz2FCO9Z6KFkYmq7uNYtyNEPtaQqewCIfIqg1IaEgQ0goAQeY3ALp1GgkDiIPLPnmKYrQUTx87m1uhhM4gJsN8kT/aYOo4cj+btjBmCRXOnY/bkcUw2m7bugB8/fmD10vmYOXEME7DYEvl3b1/D02UQLp45Aa8ZC1HMsDS+f/uGowf3IE/eAihQpBgik9acO3X8DyK/wM8X86ZNgN2w0Uz0yANP5Nx1sDWunD+DlTtPIHuu3EoinzZdBlgPdEaztp1gkDw5nO16Mukd7TObbYmoRCWtMTdqxBuagcM9mcg/ffwQzraW0E+eHL7zVkBPTx93b92AY18z3iSN9pmFlKlSczeTPFywY+NqePjO5UBQmo8eRo3YDpcxk1Gq3L9c79GDuyCdfkujzkj7i2DTxsW6SxsO+u3Rd6CSyFu0b4ySZcpj0HBPlq28f/cWPmOGs3d+2dbDyJ2vAJ8KeLk6Yvi4KWjQrDVfe2T/Lm6P5tnUou8fMATM8oW3uxP8Fm9Axeq1eRNUwzAXnzo0atGWx58mbTruZ+JoZ0z2X47ipcooifyEWYuUJzJRSWt6G7eAYZkKGOw6DmUqVMS92zfgbNcLGTJmwuR5KzT2YBIirzHoxSOvOeilZ0FAJQgIkVcJjNKIihBIVESe5BoL1uyEQfIUDM+rl8/RrKohrAY4oXufAfybjZkRgoKDMGLcVKWXnry6jn27g1ILxpbIE8nu06U1bxQsbQYz0Q1fYkPkzdrWR4YMmeDs6cuyH0UJnDMNkzyc4TnFH/WbtlYS+XpNWsFt/HTo6Yf0e3jvDgy3t8K4GQEoH0nKw6iIfB/T1ug7yAUmPaygo6OLH9+/Y6aPJ7ZvWIXl246yRGTn5rWssSfJS9l/fwfLkrfZd6wrHFzHMR5E5MnzTRsNkqVQe6HLu3dv8eThPXz++AkkwyEvPZFuexcPJZEnLzmdWNBpgKJsW78KY1zsYec0Cq07dmEvvX3PzkiVKhXmrNjK1bxcHVhutHjTARQsUvyPObl07jSfaFj2d+Dx7t2+CXaWxjA26wXaYFFgct4CheDpMhCUlpM2CVmz54w1kR9gYcx2UkAzbcpokzfRw5k3Gqt2nlDRbRz7ZoTIxx4zVV0hHnlVISntCAKaQUCIvGZwl14jRiBREfngoGD4LQ2bPrJC/nQwMe+Dwa5jGQHjJtWRK19+DPf0RYZMmZWohA92jam0hmQvJs1qYOSEGWjSukMYjbai8dgQ+cpFsjDpI3t1dfWU9u3cvA5O/XvAecxktGzfWUnk23TsBkf38cp6RFBJEuQzZymq120U4azHNth13vSJmDZhFA5cfMRefzrlmDTaBZmyZEWKFCmVfXz9+gVfv3xhWU/TNh2ZyPfv3h6DRngqJUFUmcgseeQXzZ0GOtH4/u07vn//BopLIAlLaCJva96BsSC5kKKcOnqQNyskRzK3HoCgoCBOC0mSl4B1u9mugb06I1vO3Bg3bX4YHBVtkA0dGlVhbb337EWY4zse+3ZugctYX5D0igKTKRC4fcPKrOvv2d8Rurq6sSbyEWWtoUxFAX6+OHrjhcaeS0LkNQa9eOQ1B730LAioBAEh8iqBURpREQKJnsiXz5cWHbv1ZI03FZKOUCCnqog8aai7tKgNe5cxMDI1Vwajhp6f2BB5knfUadgcQ0ZNYGmHosSGyJOnmaQgNes3URmRJznL0evP+bRj3fJA9niPnxnIuu/wheIC6L/IiDzFMbgOsoZh6fIspSHPN+Fo3LQ6THtYR0vkD+7exvp84+5WTOSpkB7drE19Pn0xLFMe7kP6c1aeCpWqRXqrLF84B4Gzp2LIKG9M9XJD5ep10MmsF19LbVCQL8VDuHhORo16jTnwWKGRj6m0JjIiP2fKeJy+915Ft3HsmxEiH3vMVHWFeORVhaS0IwhoBgEh8prBXXqNGIEkR+SdbHpwBpThY6dwzu/goCBcu3yB86qT1lshrSE5BXnay/xbGeNnBHCGEdJRL5k3kz8IpAh2ffroIQZZmSJ/wSKcLzxtuvTsIaaMNMlTpGDNNck2iBw6e/owSVeUiDTyFFhJuvRhHpNQpEQpJsSUTWfcCAds37gaC9bu4mBQRbBrRB756Ig8bQo8nOzgNmE6E1RFiSyPPHnkQxP5I/t2wc2hH7r1skGGGnVrAAAgAElEQVTH/xNf8lQryscPH3jcenp6kRJ5Is8+Y1ywevcp1rhToew1lh2a8ldQQ3vk+3RuhS49+3H2IdrYfPv2Df7TvBHg54O5K7aFiQPo0LAyt1Wq7L+4eO4Ua+hDZ7EJfws8f/oERvUronbDZjh38ijG+wUiX4FCmDJuJAf+lvynPE4c3oeJs5cgW85ckRJ5CtSl7EO0TipW+/1F3MjST5JHXoh80n0ke3l5YcOGDUkXgEQ+8itXrqBgwYJInjx5Ih9p0h0evfN27dqVdAGQkScoBJIckacsIy52vVCuYhXWmr988QzHD+7FuVPHULJ0OSWRJ+mFfa/OOHviCDp164U8BQrhwpnj2L9zK3vdFUT+29cvmD9zMstE6KNOFJBJKQtPHz/C3l0KGCVv8Qh7K06PWa9pK5b0/Fe1Jq5duvBHsCtlP6GPC1FqyFoNmkLfIDkunD6O3ds2sHRnoEtIRpi/IfLkKR8x0ApFipdC3UbNkTFLVs5+c+Xi2Qi/7BqeyFNGGwpsJZ03SWHIex0UHMxZgigtJo2b0l9G5pHftYU2EgMYC8KMYhu2rFuOnZvWogtlowmlkbfs2BTZsufk9Jxk4/27t7Bx5RIULl4S3rMWhyHqFJg6YlAfGBgkZ/JP3vnoSve2DbjNjJmyYMWOY1x9w8rFHI+go6PHWYgoWxCVyDzyxw7uZTwpwLdGvUYce1G+UjVeU+KRj24G5O+CQOJCoEuXLvDw8EC+fPkS18BkNIKAIJAgEdBKIr9m6QKMHmqLLUev8JddX796Aaf+FjDQN+CP8oQu/xZIHyYl4udPnzjf+5J5M/Du7RvOBd7OpDuTUgp2nbn4t6fs8YN7mDRmOA7t2c7pLCtWrYXqdRti6riRTO7K/QomJQ/6umULsXrpAnz68J5ziVepWRd9Bjkjc5ZsoHSHJMmYN2MS9PUNOEDTot8gzkZDRDW0hpzypB/as4M3BpfPn4G+vj5y5smHpq07onWnruzxp0Lks2Ojqkya7ZzclUMmjXz3/wfMTpqzFNUi+fgUBfeSV5zyr5P3vK1xd3S3HoD7t2+il3ELOLiFBKsqChF5yuqz9/x91shToVSRqxfPY105nz4kT4GcefOjUfO2aNy6Pf/7yoWzsDJtBUe3EM28otAJw/KA2ZxfX0dXF1mz5eBNC3mp2xqbhSHyFJxMMQFvXr3Eob07oauni/pNWsHY3AqFipYIM9efPn5Elxa18PrVS5D0JSpZjeLCBTN9OCsNyaIo/kCxSRps1RW3b1yF77yVPOe/mDxWBM7lUxmvGQHKIFpaN3RKsGjONKRKkxadzHrD1NKa8/Lb9ugIp9ETedOoKOSRD5wzFYevPtPYQ0GkNRqDXjpO5AgIkU/kEyzDEwQSGAJaSeQJQ/KOhpZN0L+phJdShNTjv4SBXlFfcU1k1wPB+NW0su3wfSsaDt9m+LmOqI+YtBXRuH5jEPHYopKUhLc3PI4RXRtXOyO7TmG/whbqM/xckUf/d7CryR/zENG9RHnrKUiYyDMFvcakRLRGIl8Pf649VeIZE3tVUUeIvCpQlDYEgT8RECIvq0IQEATUiYDWEnl1giR9aQaBsET+d9aayKxRBB73GTiMPxgVWruvmREk3F6FyCfcuRHLtBsBIfLaPX9ivSCgbQgIkde2GUtC9tLXYvt2a/uHNCcyCEYM7IMzJw5z/AIFvEqJHAEh8rI6BIH4QcDc3BxOTk4oWrRo/HQgrQoCgoAgEAoBIfKyHBIsAqR5v3bpHPIVKoJMmaOXyVw6fxr0LQHK6qPQ8ifYwWnYMCHyGp4A6T7RItC7d2/Y2Njgn3/+SbRjlIEJAoJAwkFAiHzCmQuxRBBQGwJC5NUGtXSUxBAQIp/EJlyGKwhoGAEh8hqeAOleENAEAkLkNYG69JkUEBAinxRmWcYoCCQcBITIJ5y5EEsEAbUhIERebVBLR0kMASHySWzCZbiCgIYRECKv4QmQ7gUBTSAgRF4TqEufSQEBW1tbmJqaolKlSklhuDJGQUAQ0DACQuQ1PAHSvSCgCQSEyGsCdekzKSBgb2+P9u3bo1q1aklhuDJGQUAQ0DACQuQ1PAHSvSCgCQSEyGsCdekzKSAgRD4pzLKMURBIOAgIkU84cyGWCAJqQ0CIvNqglo6SGAJC5JPYhMtwBQENIyBEXsMTIN0LAppAQIi8JlCXPpMCAkLkk8IsyxgFgYSDgBD5BDAX169chLNdT1y7dB6LNx9EiVJllFbdv3ML/c074M7Na5FaWqFSdbiOn4a8BQqhhmEufPzwXlk3V5586NDVEu1MuiNdhox/tPHq5XOMdrLDrs3rMGPRelSuUSfWiFy5eA7D+lvg1vUrWLr1MIqV/P0hFPptgKUJ7t2+EWm7FavVZvvJVipPHj3A2mULsXHVYtD4kydPgfKVqqKn7RBUqCS601hPUAQXCJFXBYrShiAA3L59Gxs3bsSPHz/w9etXLF++HJUrV0bWrCEfscuWLRssLS1hYGAgcAkCgoAgoHIEhMirHNLYNRgcHIQ1SwLgN3ksXj57gpbtTTFszCTo6OhyQ29ev8TapQvx+tUL/ve1yxdw7uRR1G7YDFmz5+TfcufJh4Yt2iFDpswony8tSpX9F/9Vrcl/u3z+NC6dO40Gzdpwu3p6+mEMvHjuFBz7mOHVi2cwLFsBMxevh66uXowHERQUhOUL52DeNG+8ePYURp27w2HkeOjo6HAb1O665Yt4HFSuXDiLi2dPok6j5sicNTv/lidfQTRq0ZY3GmdPHoWny0C8efWSNwQFi5bg/3/t8nlcv3wBxuZW6G03FGnSpouxjVLxTwSEyMuqEARUg8CXL1+YuJ87d+6PBnV1dWFtbY3x48cLkVcN3NKKICAIhENAiLyGl8T7d28x3s2RifvD+3fx7MkjzAhchxy580Ro2ZqlAZjlMxaeU/1RunzFP+oQke/Wqz8GOI/mv717+wbjRgzGtvWrsGzbERQoXDTMNf7TvHF43y5kyJgJOzevxfLtR1GoaIkYo/L2zWuMHT4IqVOnwe2b1/DuzWv4zl+J7DlzR9jG8oDZWDBzMrxmBKDEP2XD1Pn65TP6mbXH+7dvYGU/FLUbNkeyZMm4zqP7dzFnihe2b1yLAcNGoXWnrsrNQoyNlYpKBITIy2IQBFSHwM6dO9G2bVu8f//7NJRaL1y4MObNm4caNWqorjNpSRAQBASBUAgIkdfwcrh3+yZsuhvBeqAzgoOD4TFsAAYOH4PWHbuqhMhTm/OmT8RkzxGYvmgdqtSoG6bdTk2qoUrNuqhcvS7sLDuhcw9r2Dm5xxiVm9cuY4ClMZPrz58+8aZhsJsXmrftFGsiv2vrerjY9YJFv0Ho1rv/H6cHb9+8Qps6FVC1Vn04jhyP9BFIhWJseBKvKEQ+iS8AGb5KESBZjYmJCVasWKFsl04lzc3N4e3tjXTp5ARRpYBLY4KAIKBEQIi8hhfDknkzsXrxPLhPmsVSkiaVS6BKrXpMVFOmTPWHdbH1yH/79hUzvMfAf9oEbDlyGdlz/fb0H9q7Ay4DemGYhw/qNWmJ9g0rQVdHD35LN8aYJC+c5YuNq5ditM9s9uQ3rlScZT/2Lh5IkSLlH/ZH5ZF3sumBsyePwX2SX6RaeIoloJML94kzWZIjJW4ICJGPG25ylSAQGQLHjh1D06ZN8erVK66SI0cO+Pv7o0mTJgKaICAICALxhoAQ+XiDNvqGyYtjY2aEzFmzwcHNC+nSZ8DE0cNwaM8OjPKZheKGv4NeFa3FhMg3ammEDl0s+JLjh/Zh24aVqNu4JfoOcoGuXoj+/efPn3Cx64nbN65h4uzFyJE7L5bO98PMSWMwzGMS6jdtHe0AyP6+XdsiV958GOjsgTTp0rNM6Pjh/fCYPAeFi5WMFZG36d4ejx/cg/fsxchXoHCE/Xs4DcDh/TsxYWYgihmWjtZGqRAxAkLkZWUIAqpF4N27d3B0dMSsWbP4+UpSm8WLFyN58uSq7UhaEwQEAUEgFAJC5DW4HC6fP4N+3drCZogb2nTqxpacOLwfA3ubYtAIT7RoZ4xkyUKCRmND5NOmy4AMmTKxXp0CsVoamaC3vROy/Aoupbbu3rqBrq3qoK2JGQYMC9HTv3rxHG3r/YtWHUzRb/AIJE+RggNN79y8ruxf38AA+QoWRtp06XHp3Cn0N+8Iu2HuaNHOhOuQl3+oTQ84jfIGbSgUGndFA1F55InIP338ED5zlyFn7rxC5ONxbQqRj0dwpekkiQDJGDdv3ow+ffrg2bNnIN28fN01SS4FGbQgoFYEhMirFe6wnZEefsfG1ejS0wa58uTnP7588QwLZvqgfKVqGOk9AwYGYb05MfHIU+abrr1s8PXLF/iOHYH3795hxLgpKB4qreXC2VMwabQLzKxsUbTE73SR071HI1PmLHDznsFe8T3bNmL8yCFKwylTjr2zB0qX/w8jHfph384tMLXoqyTez54+QoCfLypVrwN37xnQ0Q3JvhNTIn/35nV4+M7FP+X+jXBmHK3NOCDYfaIf8uQXaU1cl68Q+bgiJ9cJApEj8OnTJ2WqyTlz5oCy1kgRBAQBQSA+ERAiH5/oRtH2y+fP0Lp2OXz8+AEheVnCFtLHr9hxDDl/5VZX/DUmRD501pobVy7CslMztO3UDf0cR3BqScqUY9+zM04c3veHx5z6oc0DSWPqNmkZ4d+pDqWabF6tFL59/xax/alSY93eM8icLSTFZEyIPGWzmTfdG0PcJ7A3P6LSqFIx/FupOtdJnzGThmZP+7sVIq/+OSTpxfbt22FkFPHaVr9F0mN8IHD06FHOVpMlS5b4aF7aFAQEAUEgDAJC5DW0IDatXgo3h75w9ZqGpm06hrFiz/aNGDXEFt162aBbb9swf4stkaePQ/mOdcW2DauwbOsRZMmWHaePHcKIQX1g1NkcZlZ2YdqnDzfZWZrgvyo14DjSK9Kc8utWBGLk4H7wmDz7D9K9Y9MaeAyzh2W/gehs0TfGRP7B3dswbVEL5StWg/1wjzA6+TevX2Hu1PFYuzQAg13HoYVRiJRHStwQECIfN9z+5qrHjx9j6NCh8PPzk5zifwOkXCsICAKCgCCgRECIvAYWw5fPn+Bi3xvHDu5lr3V4z/Ljh/cxtJ8554APWLcbqdOkVVoZWyJPF+7dsRmjhvSHkak5LG0GY/4MHyzwm4zFmw4ov6aq6ODD+3fwHuWEI/t2YcG63WF09Yo6nz99ZB386eOHsW7f2T8y3Dx6cBeDrbriy+fPWLCW7E+jtD8qjTxVmuPrhUX+M1CydDlUrVUPGTJm5i/V0oeiNq9Zhq69+qOHtb144/9y3QqR/0sA43C5EPk4gCaXCAJJEIF9+/ahVq1aSXDkMuS4ICBEPi6o/eU1N65eAqVRLFOhEpxGT/yjNcp4MH3CKM7/7rtgFarWrKesQ2R2yriRkX4Qqmrx7OjY1VL5QSi68MWzJ3C26wUKrl2z5xTnqqeMM+OmL4C+ftgvvQYHBWHTmmXwcnNkz3dE+eCvXToPp/4WqFitNnvtw5efP39w3nrSys9YtB6VqtdWVlm7LACzJ3tF+EEoqvTx/Xsc3Lsd29atxOkTh9lOfX0DFC5WAm2MzVCjTkOkTZ/hL2dALhcir/41QESeco0XKlQIt27d+u1N+fXRs7hYFD6YPHQbUf2N6kX394jsie6av7EnsvEntD7/xp6o5vhvsIvOJpnLiJGPDrfo/h6XNRtdm/T3I0eO8NeCI6traGgIJyenuDwy5JpEiIAQ+UQ4qTIkQSA6BITIR4eQ6v8emUeesp1EVaL6u7r/Rnaqu0/BJ+6Yy3xFjV1CxYeyHe3YsQOpUoX9loziXihWrJjqH1DSotYiIERea6dODBcE4o6AEPm4YxfXK0VaE1fk5DpBIGkhQB8Tu3HjBtKEkqUmLQRktLFBQIh8bNCSuoJAIkFAiLz6J1KIvPoxlx4FAW1EQIi8Ns6a5mwWIq857KVnQUBjCAiRVz/0T548gbOzM3x8fJA6dWr1GyA9CgKCgFYgIEReK6YpwRgpRD7BTIUYIgioDwEh8urDWtETEXkXFxd4e3sjbdrfmajUb4n0KAgIAgkZASHyCXl2Ep5tQuQT3pyIRYJAvCMgRD7eIf6jAyHy6sdcehQEtBEBIfLaOGuas1mIvOawl54FAY0hIERe/dALkVc/5tKjIKCNCAiR18ZZ05zNQuQ1h730LAhoDAEh8uqHXoi8+jGXHgUBbURAiLw2zprmbBYirznspWdBQGMICJFXP/TPnj2Dq6sr3N3dkTlzZvUbID0KAoKAViAgRF4rpinBGClEPsFMhRgiCKgPASHy6sNa0ZMQefVjLj0KAtqIgBB5bZw1zdksRF5z2EvPgoDGEBAir37ohcirH3PpURDQRgSEyGvjrGnOZiHymsNeehYENIaAEHn1Qy9EXv2YS4+CgDYiIEReG2dNczYLkdcc9tKzIKAxBITIqx96IfLqx1x6FAS0EQEh8to4a5qzWYi85rCXngUBjSEgRF790AuRVz/m0qMgoI0ICJHXxlnTnM1/ReR/6KVG6jTpNGe99CwICAJxQmDN0gV49uRRnK6Vi+KGwPPnz+Hm5obhw4cjW7ZscWtErhIEBIFEj4AQ+UQ/xSodYJyJ/LVr1/D06VOVGiONJRwEiGzY2dkhU6ZMCccosUSlCNSsWVOl7UljUSPw4sULjBw5EkOHDkXOnDkFLkFAEBAEIkRAiLwsjNggEGciH5tOpK72IdChQwf4+vqCHihSBAFB4O8RECL/9xhKC4JAYkQgODgY9J+i5MqVC9evX0fq1Kn5p2TJkvF/UgSBiBAQIi/rIkIEhMjLwhAE/g6BoKAg3L9/H/fu3QP9/3fv3mH+/PkwMTFBlixZoKOjgwIFCiBv3rx/15FcLQgIAlqNwNq1a+Hl5aUcw+HDh1G1alXlvy0tLdG9e3etHqMYH38ICJGPP2y1umUh8lo9fWJ8AkDg58+fCAgIgIODA96/f88W0W9UdHV1kS5dOsyZMwctWrRIANaKCYKAIKApBGiTX6VKFVy+fPkPE2izv3fvXuTLl09T5km/CRwBIfIJfII0ZZ4QeU0hL/0mJgTIG9+jRw/s3Lnzj2G1adMGgYGBSJUqVWIasoxFEBAEYokAyWpmzJgBa2vrP65UBMjHskmpnoQQECKfhCY7NkMVIh8btKSuIBA5AqNGjQL99/XrV2Ul0rseOnSIvXBSBAFBQBC4cuUKunXrhuPHjyvB+Oeff7Bq1SoULVpUABIEIkVAiLwsjggRECIvC0MQUA0ClHaySZMmOHXqlLJBemGTXl6KICAICAKEAMnuPD094e7uzpt+AwMDDBw4EM7OznJqJ0skSgSEyMsCESIva0AQiGcEFixYADMzM+6FAl3XrFmD6tWrx3Ov0rwgIAhoEwKUqaZVq1Yg73zx4sV5s1+5cmVtGoLYqgEEhMhrAHRt6FI88towS2KjtiDw6dMn1KtXD0ePHmXN/MSJEznYVYogIAgIAgoEKLuVh4cHRowYgf79+7OHPnny5AKQICAeeVkDsUdAiHzsMVPFFT9+/FBFM9JGAkSASHy7du0wa9YsNGvWLAFaKCapAgHKSBTXnN9E5Og/KUkXgQ8fPiB79uw4cuQISpcunXSBSOIjp2cIPUtiUsQjHxOUkmAdc3NzDBkyhI/3pKgHAdJFZs+ZCyVKlVVPh9KLmhEIZpKmoxOzh7OajZPuVIDAk0f3MWmCFygjUVyKt7c3Zs6Zh4yZssTlcrlGEBAEEgEC375+QemSRWMcRyVEPhFMenwMQYh8fKAadZtE5Os2bo5pAWvU37n0GO8IUIq5nz9/QE9PP977kg40g0DgnGmoXq7YXxF53Qx5ULuhnNhoZgalV0FA8wg8efQAi6eNESKv+anQbguEyKt//oTIqx9z6VEQUCUCQuRViaa0JQgkTQSEyCfNeVf5qIXIqxzSaBsUIh8tRFJBEEjQCAiRT9DTI8YJAlqBgBB5rZimhG+kEHn1z5EQefVjLj0KAqpEQIi8KtGUtgSBpImAEPmkOe8qH7UQeZVDGm2DQuSjhUgqCAIJGgEh8gl6esQ4QUArEBAirxXTlPCNFCKv/jkSIq9+zKVHQUCVCAiRVyWa0pYgkDQRECKfNOdd5aMWIq9ySKNtUIh8tBBJBUEgQSMgRD5BT48YJwhoBQJC5LVimhK+kZaWlhgwYABKlSqV8I1NJBYKkU8kEynDSLIICJFPslMvAxcEVIaAEHmVQZm0G+rXrx+6deuGSpUqJW0g1Dh6IfJqBFu6EgTiAQEh8vEAqjQpCCQxBITIJ7EJj6/hCpGPL2Qjb1eIvPoxlx4FAVUiIERelWhKW4JA0kRAiHzSnHeVj1qIvMohjbZBIfLRQiQVBIEEjYAQ+QQ9PWKcIKAVCAiR14ppSvhGCpFX/xwJkVc/5tKjIKBKBITIqxJNaUsQSJoICJFPmvOu8lELkVc5pNE2KEQ+WoikgiCQoBEQIp+gp0eMEwS0AgEh8loxTQnfSCHy6p8jIfLqx1x6FARUiYAQeVWiKW0JAkkTASHySXPeVT5qIfIqhzTaBhMjkf/x/Tt0dHWho6MT7fhVVSE4OJibSpYsmaqa/Kt2fv74wdfr6un9VTuJ+eLYzNmPHz9AM5sQ8RQiH7dV+v37N+jo6EJXVzduDcTxKlp3CeU5ERQUhKCgn9DV1UswNsUR1ni7LDbPCcKSMNVGPIXIx9sSSloNC5FX/3xrmsgfP7QPadOnR4lSZVUy+A/v36F17XJwHuODuo1bqqTN6Br58uUzju7fjffv3qKFkUl01eP97+/evIbr4L74+uUTpgasiff+tLGDt29eY9v6lcieKw9q1W8S5RBev3oBp/4W0Nc3wGT/5QluuEmByF+7dB4vXzxH1Vr1VIb/vwUzoItFXwxwHq2yNqNr6PKFM7h07gzqNm6OTJmzRlc9Xv8eHByEpfNnYWXgXIz3C0T+gkXitT9tbJyf7Qd24/3b6J/ttNkP8JvMz5VJc5che87cWjVkIfJaNV0J11gh8uqfG00T+cpFs6ByjboqI0jxTeQ3rV6K79++oXErI6RImYon7OmjB3Bz6IfbN65i85HLap3EjauWsEetYfN2SJEyJff9+uULuA62xod3bzFnxVa12qMtnZ09eRQ2Zu1RqmwFTA9cqzR7/YpAJuy0CUyeIgX//uLZUwyztUBwUDD8lm5McENMCkTetkdH7NuxGafvvVcZ/vFJ5I8d3ItjB/egay8bpM+QSWnztPHuWLZgFqYGrEapsv+qbCzRNUSOhpNHD6KLZV+ky5CRq5PnOHD2VCbyE+csRcEixaJrJsn9PbJn+8Hd23Dp/GkYm/VG2vQZGBc6CZ47zRtb163A1AWrkCN3Xq3CS4i8Vk1XwjV28ODBaNasGerWrZtwjUxklmmayJfPlxY16zfRGiLfx7Q1fv78AQ/fuciSNbvyAX7/7i18+/oVxUuVUesKsTJpiWS6Ohg1aRYyZ8kmRD6G6H/+9Ak3r11GmrTpUKBwUeVVlh2bIl36jBg+zhcZMmYWIh9DPOO7mnXXNji8d6fWEPnJniMwb/pELN9+FIWLlVTC8+zJI94YEmlOmSp1fMOmbN971DAs9p+OpVsOo1DR4kLkY4g8kfOInu0ewwZgy9rlCFi3B/kLhZxkCJGPIahSLXEj4OjoiIYNG6JBgwaJe6AJaHQJjciTHpGIMulWyQP6M+gnKc+hq6PDuvfwJehniCaRFOqkif/88QNa1ykfRlrDdYL/1C3++PEdyajtcDry322SllXnl4Y2GD9//ESfLq3ZLvdJfsiSLTv09PRZW0o2kxHh26Lj658/g0D/S+PQ0aH/dMPoUcmjTm3S+BQaS7IrKp0/t/vjJ6w6t+I+3SZMR+as2dieN69eKj3ys5dvgWL8ZGdE2k3CPEQrSzYGQydZCNahdbysuU8WYj/1S4JxPcYtGYKDgvCT5uDXGEPmiuITfscL0PXUXjIdnd/2EPbUz69YBur/58+f0Av1G823Yk0QbuHjHtjunz8ZA4W9ivqK8SrWzO+6tI5oHD+475C1FoQfP3+iV6dmSJ8xE4Z5TEKGTJkZz5fPnyk98jOXbGAbaayR4anu2zspeOTDE3maY7p/aT1ToTUQHMna5b//Wieh6/xXKGMYaQ2vmx8//rjvFPcPrYXQRaEvV2jeFfc1rQ+fMS7s7Q7cuB9FipdkO2ntRqZJ53vw13OK+lA8d0Lfgwr7eL2SrdE8G3/fOz/h7T4UyxfOwcJ1e1CoWAklbr898kuQr2ARto/u2siePaFxJNvC35P8LA4K4usVcTqKtn6PkZ7WwYzHn8/C39crnkkh9oTUVY4pgnmiv/FzmGJZfq0LxXz9Xi/0DPn9Hgm5l4NDnkO/4pvCr4PQz/aQZ8tPeDjZYcemNXziSY4A6o/mT+GRn7JgFbLlyImgoOAo8VT3syKq/sQjn5BmQ4ttESKv/slLaET+9LFDTEJNzPvg4tlT2L9rCzE51GrYDFZ2Q5Erb34lSA/v38HMiZ44tHc7/1ahcg00bd0Bo4b2VxJ5egjPn+HDx510fJwrTz7l9Z0aV0O+goXhNSNA+dvVS+cROHsKjh7Ywx52IuvdevXnY9KpXiNx5eJZJv+Zs2Xnh/fYafORO08+uA/tzzrK0DKNxw/vY/Pa5di6dgXoIamnp4vipcqiXWdz1KjbiKUwrKucOZmPvRu2aIut61fiwunjLNtpa2yG7n3sIvTcnTp2CJNGO+Pa5fP80s+SNRt0dPUwbvoCZMuekzF8+ewpuvTsh2UBs3GLvM/p0sO8jz1atDdB8uQhshF62Z44sh9rlizgo2IeW9bsMDI1R8PmbaFvYIC3r1/BdZA1az7z5C+ABX6+SJ0mLfyWbGByv355IA7v28mexu/fvqJcxao8fyVLl+OX9ZvXrzDCvjcKFQn80H8AACAASURBVCuJoiVKMaG4e/M6v+xNLay5L/KC09hHDekPJ49JPI+Kcu7UMYwY2AeW/QahebgYhL3bN2HUUFuMmuTHEi0qVy6cxfCBVsiZOy985i5TtrNk3kzM9vXC+JkLkTV7DnRpWQdNW3WAw0gvnu+Jo4fh9o1r/FKn0w2yb4JfIHvmSVpDXvwOXS1ZikAyKpJMWNgMZlsNkidX/837q8ekSOTv3b4Jo/oVYTXACV++fMKWdSvw4tkTGJapwL9VqFxdGcRKG1u6B1YEzmGvacEixWFkYg4X+17oYtlPqZE/c+IIBlgaY8jICSydUxQ/H0/s27EFAet2K8ke3du0DrasXYGPH97z/dCkdXu0bG+KOVPGY8/2jXj/9g2vQX2D5OjZ34HjZ1YsnMuecXrmFCpagrug+2vfzi1YuzSA72faMOTOmx9N2nRAS6POSinMhTMnMaSvGUwt+uHKpbPYt30TE+8a9ZrAasBQ5C1Q6I81+PTxQ/h6umLfzs0g2SE9x0g6ZmXvhMYtjXizsWT+TJj3GcDSJXq+Udx+y/adYWkzGKlSp1G2eefmNSwPmIMTh/fhy+fP0NPXR+NW7fn+pfuFbKF7jO7J+k1bwX+aN1/bz2EE6jRqgd1b12PLuuV4+vgRPr5/h3wFCsOoiwVqN2jK9w85MRbNnc73YksjE6xfsQgUG/Ht+zc0aNoaPe2G8LPt/OkTcOjTFU1adYCt00ilfV+/fMYgq67IkTM37IaN4jlRlNs3r6Fjw8owtx4I60HO/PPXL18wYlAf3L11HRNnL0GOXHn49yP7d8HZtifsXcagZr1G/Hx59/Y1pgeuw4N7d0CnLYf27mCnEV2jp28AOyd31KzXmIn8hpWLYNF3ELZvXI2rF8+xs6CNcTfGWJ2nMLF9IAmRjy1iUj9CBITIq39hJDQif3jfLgzqbcpEq0Kl6qhUow4/DNcuXYD2XSxgPciFQaIH60hHGw4yNbXoyy+xyxfOYveWdaAAJUWwq4LIb1ixCL7zVyJ3vgJKkMMT+UcP7vGLnDTwRp3NkSVbDu778+eP6GTWG58+foD7kP58fZ+Bw5jg0TE1eQbdHfvj1Yvn8F+1LeTl/OY1e23opUB20/H658+f+GV28+pl9vhWr9uQvdtzpk7AioWzkTJVGjRs3oaJBmkwd21ZjxFeU9Gsbac/Fsa7t2/w4O5tjHTsxy/+3gOGMrEke8h+IvInjx5Azlx50bRNR2TKkhXrlgfi5tVLHNhWsWotbpNIL73MKNiYiEiKFCmxd8dm7Nm2EUPcx6NKzXp49fI5E2l64aVMmRptOnVFMp1kaN7OBAd2bcXOzetQr0lL5M5bAM+ePsLcqRN4vENHefPL9OWLZxhhb4X7d24heYqUaNqmA7Jmz4njh/byy45e9IQvER86TanTqDmGjBzPLz0iXovmTsOKhXMwZcFq3niFLkToyIve2aIvbwrIM08bgpEOfdnztm7fWWTMnIUx6WPaCp8+fcSspZvw/OkTdG/XAPUat8TwcVOYTN0nPB36sua1R9+BSJsuAwoXK8EEnoj8pXOnef0QgSCv/apF/hwfMW56AMpVrKL+m/dXj0mRyN+4ehkmTashb/5CPCd1G7dgTykFG+YvXBQunr7IliMXb8aJqBKpJOJa9t8qeHDvNvZs28DzSZt0RbArEXlb8w4Y7DouTNB6eCJPG9Pxbo7YsWktuva0QZHihiCnAm1mB48YC109fczxHYfN61Zg9KRZyJO/EHLmzsNrnogqkV3vWYv4uq9fv2DpvJmYN30S6jVthbL/VubTHtrY0wa5j/0wmPe153v85JEDsOnensdV7r8qHPh7/cpFrF48H606doHt0N+kVrEYafwkDfGb5ImdW9bB3XsmcucriJx58jL5JiI/dfxIZMqSDY1atOON9pH9u7Fj02oMcZ+A1h27clO0SR/YqzNvjjp1780Elp5jgXOmMq7drGxhYJAcAX6+WODngzRp0qF1xy7sFKAN/M8f3zHJw4U3vUVKlML3X/f14wf3WBZIkkSavwUzfdgmem4QHsVK/oNrly/wvVajXmO4ek3la627tuV7L3DjPmXQMM2nnUVH9LF35r5Dn+ASDp2b1UDWHLnY+ZIufQZOTtC2TgXeiFHMAm3+yIbZvuM4jmHFjmO8cSPnAp3K+a/azu+WB3duY4rXSH5+0bMjZ+58yJ0vP9Knz8hE3n/aBMaTNjmFQj3LqW7zdsYae05E17EQ+egQkr/HCAEh8jGCSaWVEiKRH2DRCZ0trGFmZYf0GTLi1YtnGDXUjonerGWbePwH92xnckkeUvJ0kEeHCBfpFqd4ucWJyPtPnQA/n7FwmzCDXyIkHSECSJuG9BlJZqGH3sYtWKZDGvms2XKwLW9ev/yDyO/fuYUJclvj7uhl68AElgp5tUgOQ8TXxtGVvWNE5OkUYJiHD+o2acEvxBtXL6Fft3aoXL0O3LxnRDrnPTs1Y7vcJ81SavYVwa4Xz57EpNlLUaJ0WSYCJw7vRz+zdujn4MpBb1S83Bxx/tQxuHpNC/EQJksG8jYStrSZGu0zW0nkiUj4LdkIwzLkaQ85nqbNC738smTLxicD5OWaNsEdFOw3dcFq3kAoiDx5+4hE06aL7KHsOuQVL1i0OEaMm8Ivv7EjBoNOZUZOmIFihqV5Q+Ri15NlLrQxCO/RojXhRpuZ/x9t04uSiPzMiWP42PvJw/vwmhnIHr87N67B3KgRexrtXTxw5+b1MEReAXAPo0Y816SRz5gpi5LEEJG/df0Ke/iLGZZhzGkTSeTGbthotO/SQ6X3ZWwaS8pEvnylanAZ68ubSDr9ISK4avE8jJ22AMUNS/NaHm5vxSdrLp6T2cNM9zSdQtH9Fd4jHxMif3D3dt5Ad+xqycGsBslT8D3w/MkjXu/0bzotW+A3GUu3HmZyrCjhifzDe3cw3L43r33X8dOUXmS6N8zaNkCqVKmZeObJX5CJvHWXNuho1gsWfQfyPUGnDZ4uA/Hs6WPMjSKwfbzbECxd4Iclmw8qNfuKYFfaqAwa4YmmrTvyc5SeUQMsjFG05D98wkdl5SJ/jHUZhAmzFqF6nYaMNY152oRROHl4H8b4+nMGKCLyFNDrNHoib4YUUkMizZT9KQ/N0y+J5O5tGzF6qC0/q2nzriDy5AggqSARd3oWfv70EUNtevD456/ewRsDOmGZMHIIXMdPV57eebs74ejBPRg10Y9tD19m0HNh42qM9J4JwzLl2avuZNODTxbIGWRubc940okuPcfI8UPP9tBEXtEm/bZtwyrMX7sLBQuHBAkrNPILZ/myo6Zuk5bKZ7mNmREqVqvFfSfUIkQ+oc6MltklRF79E5YQiTyRJnoQ1m/aWgnIBPeh2LZ+FbYeuxryYgn0ZynEtIVrUKZCJWW98FlrYuORp4cteeWWbT2MnKEkOKFnJaZEfrr3aNDGYMmWQ8ojdGrny+dPTPrJO0/klTxPROQpZRl5hRTHu1S3bd1/kSZdOgSs3R0nIh9R1pr/CmaESQ8rDHQZw212bFSFvYIko6ETASr04ty5eS0yZ8kK0tgrPPJ0IjFn+ZYwtpBmlF7SF06fYM/Zt29f2VNFL8QZi9ez109B5Ok4fvbyzWGuH2ZryaSaiHvh4iX5hMCsbX3+N3m0yHtq2rw27J1Ho2UH0z808iRNIsJEGyEK5NPT14OLXS9Urd2ATwbIw0nymDVLF2DciMGYMn8Ve97iQuQjylpTsXAm9LC2R5+BIcf1mihJmcgbd7fCwOEha5kK3b/9zdtj8tzlLPGigGZ7SxMmv5179AkT9xE+a01MPfIkjfEZMxwL1uzizWZEJaZEnmRj/cyMMGi4J1p1MA3T1Nyp3rxu3Sf6oey/lZjIDuxtyp7yJq3aK+uSd3jdsoXYdvxapMsvKiIfUdaarq3r4tOHD1i58zi3SZuhTWuWopNZL2TKHBJUT/f+mROH8PDuHU63SBt0IvKrl8zHZP9lrLkPXYjo0qkpORg+fviA+3dusuRH8axXEHk6OaQ0r6GlQnQv06mCx+S5qNe0JcuEapfJhyYtjTDKZzZ3U6dMPlSr3YA3AbSZCl+uXDwH2qgTfoQ1narcuXWdx0M20Vjp+eMyoBePk05S40LkI8pa067ef0iVJg3HKCTUIkQ+oc6MltklRF79E6ZNRH7hrCnKrBWL/WfAd6wrZixapzIib9KsBh7dv4sdJ2+yNjyiElMiT6SRjtAPXHqMVKl/Z6eILZEnkrzj5I1IF0ZUHvmIiDxlCSKpDnnaqVQvmZO9RkVKGP4x5tLl/mOCGhWRP35wLx8zE/mnY3QKYiOJSsqUqWJE5L1cHZl8KYg8SVyG9DPnwF3y6i0PmM1SGTolCe3ZDA0IyZdIw0+yhsLFDTnnOxH/DSsX4/jhfeyppJOWU0cPYvXuk3ypqog84dmxW08+LdBUESIflsibt2vIsSokC6PNJXnZu/S0URmRnzV5HKZPGIWDV57wOv8bIk96894mLXmDWbV2/TgT+Tm+XlFm9IkLkb9++SKOXHvGNvU2acEneuQ0SRnqeUZ/y5OvIHrZOvKpQmREnmJPyBlDsTEUN6BnoM9yNjoxiQmRp80GPSsURJ76HeNsz6d3tNEhEupobYaRE/3QqEXbCOeEHBGEdenyFdHbbgi6t2vIz0J61pA3f/Gm/bh66QIHKtNpIsn4VEnk6ZRlx6mbmnpMRNuvEPloIZIKMUFAiHxMUFJtHW0l8muXBWC821DOHlOnYTMlKKTj7tG+8R/SGtKRkvde4eX5+P49urWpx95yRbDrYKsuII0+edoos8PfEPn5MyZhurcH5xP+t0oNZVOkx+zfvQNrKh1cvTjgNSqPfHwTeUq3SDIX94kzWcMbUYmKyBNpIpkNBYwWLWGIH99/gI7qKeAtvEeeXtwB68N6pOh6Otomok6ByORhJ93tEv8ZmLZwLVwG9ORjckc3wipi0vT86WM42/ViWQN93IlkAOSVe3jvLhz7mrHOmCRXVWvVR09bRyHy4SbZ29sbuhnyoHao+0i1T5m/by181hqFRj4ij3xoIk9ByQN7maJhi3YcEKrITPL2zSvUK1eIJWahNfJ0Kkce/jadurHR9PVXCnI/cfiAMtiV4jUonaPvvBVh7u3Qo4ypR5503SQl7Nq7P8t8Qhen/pa4dukcxvjO5XsgKo98fBP5ca4OWLlwLhas3RVpil2S6kRG5CldIz2zSZpG+n66l+lZG/r0VeGRp/uXiLQirSNhMtrJjoNIpwWsRflKVRkmil+y6twSfQcPZ2cAJQBYtHE/MmT8nbc/NJ70bJkzxQuH9uxgGQ1t+MnzT88NmneSaZIs8dGDu3AeM5njYITIR37vJgtWfPP27+9vaSERISBEXv2Tqa1E/uyJI3Ds252lKD7+y1lLTxkfSHNJmQUUwa6UCm3tsoXwcB4A13FT0aydMR/LkpZ24ewpqF6nkZLIb1mzDC72vWFq2Re97YayHpskIpQtoux/lZE2XXrY9ejEWk/yaJNulUpEGnny/pJ9pJ/knPPZQnLOkwyEXro2Q9zQzsQMQT+D/orI06bg44d37JVSZPSJ6oNQ4T3ylGGDiAl5lEmTqkjvSNkuKHtFjly5o/TIN65UnF/spP2kFyhtPOhomrS/4Yk8BfBRPIOZlS3HDFAwL0lrKKPDQBcP3lBQIS8bxRcULmaIU0cP/BF8GP4uobRvnsMHgT7WRURez8AAw8dO4SDkNrXLczDc82dPOMsOBRJTicwjTxpkKhRkrPgyY1QfhBKPvHqeWXEl8pTJhvTMN69f4fgMel7Q2iYdN2VFoWBVBZF/9vgRmlY15PvS1smdvzFAErMJI4eGeJt/Za25cOYEr1sKOiUnAAW9U3wOreeK1Wry79MnjMasyWNZikY6fkUJr5GnvPKkt6fAddoY5C0QEsxNwebD+lugap0G8PCZzVKRvyHyU8a5cfYuijEiIk0lqg9CkbQmtEd+56a1vCm2tHGARb9BytM7ckzQRj9HrrwcCBsZkacPeh07sAfLth/hAGUqJE8ich/eI0+yRAq8VQTL02aHNPL0bFq8+QAH5FMhqR4Ft1LgP3n2m7c1Zq1/5CUYe7ZvhutAK97Uk0ae5Eik2e/btS3IIZA8eUoO+qcgaPo9MiJPJxxkO538/FPuP+4yqjzyJK0Rj7x6nhXSi4YRGDJkCOrXr8+55KWoB4GESOSdbS05BSGlMFMUOpYNLa2h30m3SV82JQJJpOv2zaucgpJ0js5jJvHXOamQV46yuJw/dRyVqtcBZachgk/abQrcCp1+koIv6TPq+QsU5uAt+jrjf1VrYbTPLM5iQyni6MXL3qL/50UnT3Le/AVZ9/765XPMXRmStYYKkWR6KZEOvkgxQ84eQXXILnp5kceHH/5TJ7B8JCKN/If3b7H9ROTSGjpyJm9XgcLFONsFHS3nzpMfroP7/vqya1hNOxFPeuGN8pnFNhLxHtK3O86ePIJmbY2RLXsu3Lx+GYf2bOcgwgbN2vCL2nVgH87aQ5r50GWqlzsCZk1mbaph6QpYuzwAb16+QI48+Vj2FFojf+vGVXz++BHJUyTngNLb168iU9ZsmDJvBWeyUBR64dHc7t2xib30CzfsQ8ZMIR9niqzs2LgGroP78OZj0PAxaGvSnasS4SKCT1r5yfNWcLYKKqSN7d72d9YaRbuL5kxjCQBtIkjvP2aKPwc185ddg4M52Dd0ESKvnucUES0iXoovu5L23bhJNUTukV+HKjVD0pGS5prIOAWtV6hUDbQO8xcsAtKnhybyVHfEQCuWZJX4pyx/a+DB3VscIEuysdDpJz1dBvEGOE3atChZujw/Myil4uLNBzkbDUlmKKidNgOUJaZDVwv28i+ijzL5z+SgUapHZf+urZzhikg9fe2V7rN7d27yc81/5XZlpi3KQkWnC0PdKT1mWI18dB55eo7RJpUyMeXKm49xowwqdPrFGvnZYb/sSkT+xuWLOPxLWkN20nNm3fKF+K9KTb6fPnx4x+k3KTGAjYMrny4GzPLFmsXz2bkSOsMU3YOELWWzolSUNJcU/0Lpbp08JnI8lMIjT84O2tTTCZ5h2QqcOpc2SlMWrFSmmCV7aAO/ZL4fa92pbDh0Ebmi+ZoqBazTs4U08e1MuvMzTvGsps0ObfQoaJ6IPpUQIm/7K2vN72f74b07OIMQBRzTSSaltazXuEWkX3ZlIv/2Ncs2E2oRaU1CnRkts8vd3R2GhoYwMvqdw1fLhqB15mqayFOqSSJNlM6RCj1oZ08ex1lrFJ4O+p2CW4lc0gtQUUiXTRkqSLtJ2V8owLFp6/bwGGbP6SPJi64odAxLaeieP3nMAWr0UqW80vRioxzPikIvj01rlnGblHaybIVKaNC8rTLTA5E72lDQiQA9wPsMckGqVKk4rRzp3+mYN3Shr1FS7mTyCFMWlH8r1+B88eTdV7yMKH3jqWMHOYWk4mui9LeRDnTUHozh46ZGuq7IK0UnC0RKyBNIOZJTpEjFwZ+cpu1XzmRFA5SpgzYvJj36KNukDQ153OjlShsL2sBQnntKj0n6eSIW9IKmF2f4oE4a84pAf/acU9aa/6rU4NMH8r73HeTCqRxDB7s6uo/ndHl3bl1DmfIV0bRtJyZV4QulnJzs6cqpLik4LbpC2XPGjhjE5IvyXyv09DSPc6dN4GBeyslNMh4qVN9z+EDOCmRk+jvjDJ3WUPo7etFTzm0ar4GBAacvpDVGcxS6EJ5EZIgUaKokBY08ebfPHD/Cm10q5Gl3c+jHqQ8pO4qi3Lp2BT6ew/k+pNSFVChLDaVUpSBEun9JI03zRdleSEffrvPvuaPTtqXz/Hj+M2bJipZGpnjz+gXOnjgaxttL637/zq2cTvbNm1coUKgoOx7+rVJTaQsFoFI+ebofTSz6gGJOKOPN7m0beI2GDmyn59PqpQtw7/YNpE5Nm4NynFJS8fVoapSCQ2njbGJuhbK/vOr0O21UKJ2m96zFUS5BCpylXPEkayEZD/VB2bUohaxlf0f+gJGieLk64NXLFyzrURTy4O/aso7bePH8KaeYpM1SrQbN+J6njS79jTKK9bIdojyFVFxPpH/v9o0c6F+sxD+cFtd/ujfPBQUmhw52pRNVOtU8feIwe/CbtekU5nmuaJNOR5xsLPg0khwH0RXaECyZN4NjZ8jrTvMfgu0tjHGxR+GiJWFuPYBPYKjQO4biseh/wz/baQN0YPc2pE6Tjr/3QakmCZ8TRw6yjItIvqJQqmRyHtFJX0ItQuQT6sxomV1C5NU/YZom8uofsfSobgSiyloTkS2UaWja+FFY+j/2zgIsqu1r46+K3Yrd3fnXa7didyt2A6KIKKKAIiKKqKio2GB3d16749rd3WJjfN9a3pnLwNDDMHNm7ee5z713OGfHb5058+61117bfw4WrdvDG3GlhE3AFIS82F/5BMLLWqN19L9/4+jBvRjjYIUhozw0VimUT0v3IxQhr3umJlmjCHn9m12EvP6Zm1qLURXydMgT5dZOlSYtn7hIsbdSRMjLM6BsAlEV8rQReYr7SN7kSuGRqth7ZVOKvdGJkI89tiZVswh5/ZtbhLz+mZtai3wK7zAbjl+nnO4RFVqepw2KI8ZN4RM7pYRPQDzy8oQogQCF7lC6WcpOQwd60f6Y8AqF/HVpVguVa9aFlb0zkibTntVKCWz0MQYR8vqgbAJtiJDXv5FFyOufubQoBHRJQIS8LmlKXULANAmIkDdNu+t81CLkdY40wgpFyEeISC4QAgZNQIS8QZtHOicEjIKACHmjMJPhd1KEvP5tJEJe/8ylRSGgSwIi5HVJU+oSAqZJQIS8adpd56MWIa9zpBFWKEI+QkRygRAwaAIi5A3aPNI5IWAUBETIG4WZDL+THh4eyJs3Lzp06GD4nVVID0XIK8SQMgyTJSBC3mRNLwMXAjojIEJeZyhNu6LJkycjTZo06NnzvwNaTJtI7I9ehHzsM5YWhEBsEhAhH5t0pW4hYBoERMibhp1jfZQi5GMdcagGRMjrn7m0KAR0SUCEvC5pSl1CwDQJiJA3TbvrfNQi5HWONMIKRchHiEguMFIC79++Qbv6ldB/iBNaduhmpKOIuNsi5CNmJFeET+A3HfIAIF68eIIqjghQHv0ta5Zhw8oATJwVAPOMmfXaExHyesWt3MZEyOvftkoQ8t++fsGt61dBwq1E2fJImSq1GiSdFnjp/Gl8CgwME26y5MmRv3AxpEiZCicOH8DPHz/U1yZMlAiZsmRF5mw5kChR4lB10Mv37q3reP7kMQoUKYYMmbLE2Ihfv9B4LuPDu3coWbY8UgQbz48fQbh0/gw+f/wYZjvJU6Tk8SRPkYKvoRMQXz57ihfPn/J98eLHQ4qUqZE9Z26kTW8erf7euXkN9OLHn99/LqnSpOEfH2IQ8jTWe3du4unDB0iRKhUKFy+FhAkTqe/78vkTbl67gnTmGbhPqnL+1DF8/vRJ/f8JzMxgnjETsuXIhSRJIz78Zf6MSVi/fBF8F29Arrz5Q43z9o2rbLf0GTIiX6GiMDMzixaLuL7JkIQ8PWu3b1zDm5cvULRUWaRJm04Dz8WzpxD44X2YyBInSYIChYvxqb6njh5E0Pfv6mvNEpohQ6asfFAQXaet0HP25MF95M5fMMIDhSJjt+/fv4Gek7evXqF4mXJIlTqNxm3/nD2Jjx8+hFlVkqRJeTwp/73vx48fePXiGV48fYyPgYH8XaTva9YcuWCeIVNkuhTqGvoe3rt9E79//WLmqdOk1VoPifXLF87iw7u3yJknL7LnysvXkT3279yCRIkTo0GzNtHqg9wUcwKfPgZi1OC+yJUnH/oPGQl6dsIr375+5d8eekbpnart9ykqvRIhHxVacm2YBETI6//hUIKQv375H4wc3Ae3r1+Bw+iJ6NRzgBokieIRA3vi7s1r/Nnnz5/w+tULpE+fAcmS/xG6OfPkg+0IN+QvVBQVCpjDzCwhMvzrDXn37g1y5y2Atl16o16TlqFelnS6oF3vjjh55AC69B2IIaM8YmxEEurOQ/ri3q0bGOE+Ge269lHX+fHDe37Z37t9gz/79Okj3r5+iXTmGZEsWXL+LE/+QjyePPkL4vu3b9i0egl2bVmPB/duIUnipPziJ88b/eiTp7pyjbpR7jOdvLpu+SLkzJ1PzTVhwoTIna8gajdohnqNW7AYUxWPkXZYu3QBC5axk/1Qunwl9d9I+Lna90fV2hbob+ek/rxZ9VJ4+vghsmXPxZ+9f/cGmbJkR+NW7dGqY3ckT5kqzH4HfnjHpz4WL10O7lPnhrru5fOncOjfBRfOnEDtBk3hMnEGUqfRFJ1RhhJHNxiSkH/y8D6GWXXD5QtnYO3ggt4DHTSoDBvQFTeuXOTPvn79ArJDmnTpkTLln8m3eabMGOw0lu1WrVg2FvKZs2bnv719+xo5cuZB8/Zd0KR1J60neQ7q2Q50MjA9HyPH+yB+/Pgxssr9u7cwwqYHrl48j0FOY9G9/2CN+hz6W+Lm1cv82ZcvX/DqxVOeHKdI8efZpL7TfUVKlOb/37xmGbZvWAWacCRKmAhBP4Lw6+dPFC5eGs3bWaKmReMo93fhzMmY5e0OclpYDXVGL5uhWut4cPc2+nVswhPwbv0HM2cqN65egkM/S5glSoS1e06q7922fiXo/da4VQck/ffdEuXO6fGGoKAgbFwZgCzZcqBCtdpGNzG/efUS7Hp3wLAxXqhet2G45N6+foXVS+Zj67rlSJo0Gab7r0OGTDHz4IuQ1+PDquSmRMjr37rGLuTJy7R13QosWzATr188h1nCRFi796TaY0teKhKDNE4qZ08ewfQJozFgyEj8VaUmf5YoUSIWEIkTJ0GZnClRsVptfpmyeHjzClPHjWIvmt/yLciR+48XS1Vu3bgKu17tWeC/fvkcW49eZg9bWGX2x8VDeAAAIABJREFU5HEsYqkNbYU8/BtWBLBIfv7kEXvjl287rPbO0I/+0yePWKBTOXF4P+ZM9WTRVLZClT/jSZyYJyL0702rl8LHwxnFy5RHlz42SJ8hE37+/IEr/5zFLO9x7NkcPWkWSperGKo7S+bOQDpzczRqGTqLlOvQAdi0agnW7TvD99FKweOH9xEweypuXb+Cntb26NTLSj3xcRnSj0UMrXrUsGiMYaMnIFXqP0L/5rXLcB3SH5Vq1MXA4a7qfjSoWAS00D9zyUb+7OuXz2y7a5cuYOzUOahSs16YnA/v28kTOGfPabBo2lrjOvIak7eeJjgJ4pshf+GiLOTTpove6oT+v7WaLRqSkD/69x5McR8JWmX5+DEQ249d0RCBTx49AHkSqVy7fAHjHG3R3WoI6jRszp/RqggJElpxqZDfnCel42cs5L9RnZPdnfDgzi14z12GEmXKa4CgSYFl05pIlz4DqJ1NB88jdYgVgeA3kPglgV3TokmYJjywaytmeruDJtDU/rZwxnP14jmMHzUEvWwcUKNeI66TJrf0bkmSJCn27dgMj5GDka9gUXTtZ4us2XPh16+fIAE312cCPnx4B/cpc1GhWq1Q/aGVJXo3tO4cOhHEDC83zJ/uhVr1m/DEaIKvP0+YQ5YJzkOxa+t6XrGsULUWRrh78yVkj/t3boJWvPIVLKK+zaZrK/bWe81egoyZY77SGNvfE7JP77YNUeavyrAe5sIC15jK7MkeOLx/F8ZO8ePnPqxCjqtJbiPw+MFdXsUkZxW9I2NqIxHyxvS0GHBfRcjr3zjGLuS/f/sKJ9teLMLoR3vpPF/MCFiH/1WsqhXmkQO74TKkP0aN9+EfvpCFhDx5lL3nLOU/0URhy9plfI/bFD80bd1J45aJrg64dvkf1KzXGAt8J3G9dRu3DNOQf+VLj352I8L0mpEHjMZD4QMkZsjrMm3BKv5x0lZoSZy83aO9fFGlloXGJRRq1KRqCRQtWQZuk/2QKUs2jb+fPXEEvds1RN1GLVgY00QmeKF7S5erBPepc0I1rRLy5x5ohiy9f/cWjtbdcP3KRSzbcpBDkqiohLztiDFYsdAPrl6+6pWA8IQ8CaHNh/5Rt3/ln3Po3KQ6+gwajj4Dh4FCn7SVGRPdEOA3FZsPX+LQqODl6qULGDPUCu269saWtSuQOm1aEfJpsqvFZ0zeQmRnEhY0OZrjMwE+C1aFOeGi1ZCB3VrD3nk8e9lDFhLyFDLgv2Gv+k9HD+yBddeWsHcZj869rDViumdMHAMS3m0se2HR7KmwHjoKTdt0DnM4/8uTBpa9rGE3alyY19B3kSaTOXLng9/U8Zi1ZCMqVtc+CT936hgG92qPYaMnshc7eAl8/w6NqxTnsDCv2YvVYS2qay6dO42uLWqjTPlK8F28PlToWM/WFrwCNX3RmlB9VQn5eat3YGjfzhju5oUGzdtqXPfsyWM0rlwUDZu3w/NnT5C3QGG1kKd3HK18xIsfnyceNGH4EfQdA7u34RW/8dMWsEhMmCixeoXj9+9foDAhciwA8fhzmgioVkCoTno3x0+QQCOM7kdQEH79/sWf0aogtUWhjPRvKgnMEiBBAjMNu5KnnWxA9fP9v34iXrz4MEuYUN0erUYQ436dmrKjZMAQJyRNmpydGVRofBzuFy8eOx2obVUoCvWV+kAODhoLhTvRhDJ+/ARqhn/G843bpEJ1UFgh1Un9Crm34L9x/eQ2aUwRhe61s6iErDlyYpzPfHVYpLYHc/xIO9y/cwsjPX2wZe1y7N22UYR8TF5acq9uCYiQ1y3PyNRm7EL+8YN76N2+Ef9oFylRhsMpGrVsjxFjvfkFG7JER8jv2LQGTgN78gakesFEOsWatqlXARZNWqFzbyvYdG3N4ToL1uwMU2BGJOQp5tG6S0sMdnJH3gKF0K1lXTRra4mhruP5xyBkCU/I0yTAe4wjrByc0bWvrdbHwbJpDf4xGuPth9z5CmhcEx0hTysgu7aswzinwbAe6oz23ftxnSohv+fsbVhZtuBY+DHes9lDHxUhT97+tvUq8AoEhTmofliDd/z79+8YaduL90ZsP35VY0xfPn/mMAT6IfSYNp/Figj5yUigAyH/7s1rdGhYhQV2jboN0aV5bZSrVA0TfBdptVN0hDzFzfft0BhO46awYFcJKPIct7WogP9VqMrfHUeb7nj1/BlW7z6hFnMhvwARCXkKX+jYuBo/ZxWr1UKnxtVQo25jjJ3qx+F3IUt4Qn7r+pUYNag3e+tthrlo/S72aFWPw8c8pi3gCUzwEhkhf+rOW3RuXI3DkuycPZAi2MogTUIWzZoCzxmLsGSer4aQf/HsCay7tkL+gkV49YO+Nz4eLrh04TQ7MmjPC4lQ6hetYNAq5YFd27B59VLcunGF/0YTlAbN26Fp644cUkd1dmtRh/emjJ0yl1dZyEbkACABTA4PEsybVi3Fkb9382oqrbhR3+mdUep/Ffi9RPfQKgetaJQqVwHrV/jj9vWrvJpn2ccGrTp2Q+IkSbF3+yZM83TF08cP2BOfJp05v4snzvRnwU7PTP1mbfD1yyds37iaHT+rdh3n0KFjB/fy6uLZk8f+rKBkzIRaDZqiXZc+vH+GCu0J6tykBvoOcuSV173bN+LD+3e8kkmb6YuV+p96UvHm1Uvs2Lgau7eux+tXL3kchYuVQncrOxQqWkKr7T8GfkDNkjnRrmtfDBszMdyf7ieP7vN+CprMzJvhJUI+MkJHrtEfgRkzZvCXwcrKSn+NmnhLxi7k5033ws7Na+E+ZQ4KFSsJipGlFy15NbRtcIyqkKdYVlrypBjZqfNXaCx5bl6zFONH2bPAr1rLAl6jh2HjqiXsUaMfIm0lIiE/e4oHDu7ezt5/itknjyX9mFGcd/ZceaIk5D2cBjObqfNXhunRpzAIWvIf4z1LHZqjaiQ6Qp7uJY83hcrQjz7VG1zIk9jYsMKfvZvD3SbxakBkhfzzp4+xeM507NqyFi4TaAWintYsG69fvsCowb3ZYzh35TYNZiS2PEfZo8+gYbzyQkvxIuR1I+SXL5yFgDnTMX76AhY4FFtOmysn+S1BQS0CJqpCnsJlKCSKhNf4afNRKlg42J5tGzDcqjtPGuo2bsHPl98UT8xetgl/Vamh9bsYkZBfMnc6VgXMw7hp8ziMZ2i/zry5cMLMAP5uRkXI02rBAl9vfjdUql5Ha3/8pnpizZL5GDV+KmrU04yVj4yQP3vvPeb7emPjysWYumClOkyGwgIH92yPbDlz896Z0UOtNIQ8cbXt3oYn11MXrAKJykf374L2wXz99hW2w0cjbfoMvIGYhC6tehIbi2ZtULLsX+yVP33sEIc4DrAfyfH3JO53blqDCS4O6G3rgLaWvbEqYC5W+PvxigW9L/fv2oLNq5exvejdRo4Rep/ThnkS+rTXgCc2Tna85yJR4iRo0rojTyxolfSfMycxed5y5kn7nu7evI6xjgN5vwHtaSJBTysP9LcBnZshoVlCZMySFfWbtuZN9B17DgA9N/QOpGeJ+kT6g8ION6xcDIsmLTHCfQo7Zeid1qVpDeTIlZcTCdSo15CFPE2KSv+vAhzdJ/NGaHIU0IRpy7rl6NJnIAoXK4l3795i2Txffo9PnrsMWbLnDGV/+n3p3rIuTwp6WA2JlCqhVQYR8pFCJRfpk8CcOXPw6dMn2NnZ6bNZk27LmIU8vYw7NKiMkv/7i0MjyPNCG92c7fpixLgpWjMwREbIk0eJNsBSoWw39INAoRy0GVPliaO40iF9OvIy9eKN+3njHS2P92hdD137DcLA4aP5fopZXTRrqvoZW7FoNnud6B8qtImMNgRShgLyDtF4ylWujhFjJ/MPyN5tGzDW0RYuE315U2bIEp5HfoyDFQ7s3sYrBGHFXFIICsWKj540E6X/VxG+k/5sgKNCn5NHqkrN/0J2yMueLEUK9qyRFytkaA3dR15zEvLJU6bEnBVbNYQ8XU+x9PR3EhjLth7C40d//l9bjDxt5FWJwC+fPvFG3e797dCoZbswM9eQ98zFrh/fR89F8EKex7Rp0/EkgjKJ9GxdX4T85JgLefKmdmleCxkzZcXkuct578WZ44d5xcPWcTQ6dO8f6tmNjJCnFZe8BQvzvZxxKV489LQeirqNmqs97fRMjHGwZjG5fv8Z9sRSHDF5UGkDqfOE6Xw/CVTaF6IqNPGgZ4S8+KpC3nL6TpIg69iwCvIUKARP30UcdkarAbQZkUJxWnfqEWo84XnkaZ9NwJxpWLHjCAoW0e6VpU2r/rN9+NmsadEI9N1UFfLukmeXJp+qQqKZVrRUoTX03aIsOiNte/OGfxKqVCj8gpwMs5dtZm95REJeXX/n5qBMKhQjrwpPo82/FGZIG0pdJkxXJwwgEU6rhxR/TxM5mjRQNjGvMcPZLjYOrrw/oGGLdrB1dOPng1ZwaL8Ke5fjx+fQFpqo0cb8qfNWsLhXCfnTxw+xQ4KcA/QOpoxWfdo35hCanv9u7qUYeZrwlKlQBQOHjVZvhn704B4LeXpn+y3bzCuP1B71jxIHUD/oPaHa/0TvYZoU/nPuJF9PqyMk5C2bVGf+Q109kTFzVg6v8ZsyHgf37sC0hat5YzO/++z7o3qdhjyBUa2iHju4D0NoI6ubl9ZUuOTBdxtuwytNtJE7MkWEfGQoyTV6JyBCXu/IeRNorfqNMXPxBv03HsMWD+/fCfs+nfmHuuG/MaEU09m6TjnUadQCto5j1JlcVE1FRsiTR6hYqbKc3YGyw7Tp3Is3b9LGIlUhT6N9305o07mnhgelWY3SHN8+btp8ZMyUBVcunucfF1WhHw/yViX4d2me0vMt23YY6dKb8yTE0aYH/0CqQnjecrhCZQ4XsrJ3DpWSLFJCfu0u5MlXUCvt6RPGsHeLhDx5r5rXKKO+jmNc41Ms6n9x6BsOnEPmrNnCF/LXrsDFvj+HBqkyxqhCa1TCn0INKNaTltEbNG0NV/sBWoX8h7dv8FfVmqDlaoq7r2XRmO2qbTOfquOUhYPaq1qrvkYYA62WkGfUa3YAx/5TESEPUEhjTENrTh87COsurTDE2YO/E6rSqEpxlC1fiT2WIdMiRkbI0z6RMn9VwsvnzzjbTdM2HdHfbiR7VlWFslXR96Za7foccqUqFPZGEwESgBT68fjRA7Su/WcCTYW+ixR+FzxMZsvhixxaQZvIB3RujpEeU9GifVf1PQ0rF0XFqrXhMHqCRppbuiByQv4oChYprvW7SB77xXOmYbibN/5XqSqaVi2pvi7o+5/N7RSnrirr9p3md01wIf/u7WvQplbyqAds2ofADx/g6WyP929ew3fJBp5Ex0TIkyi369MRTu6TWZQHL3OnTcT29SvhNmUOipf+H/+JPOmO1t1BYpreG0u2HER68z/hKhS2Q5MrCuW5ceUSx6CfO3WUkxOQMCZhrRLytBq3aP0ejfb+lzs1Wnbszt57KhEJeQpvof0JqkIe8hY1y6JF+y7oN9iRPf6qQqsaE1yGYty0Bfz7SEK+W/Pa6DvYUSMTE02waI8S7eOgDF7HD+3nMEwKKQu+CkUOHQoLoqxc9FsSsqxf7g/vsSN4JZm8/ZEpIuQjQ0mu0TsBEfJ6R260Qp42PZHnnZZGq9drhJQp/+R3Jq8O/QjTxldvv6Vqz7qKbGSEfPDNrrRpjpZKKcsNZYwgEU4bq+izudMmcPaHtOn+E/hnjh/Ct29f+celWp0GoUI/wgqtoQ1dI2y649DenXwf5XmnQpvOThzZzz9+U+atCLUsG56Q9x7rhPXLFsLVayanztRWbHu0BcUCu02eHcprH53QGvpxJv5jhtmgQ7e+vMxOJaSQDwz8gBHW3VmcD3WdAP9ZU7QK+eCbXSkDD20ubtGhKwYOc+XYWG1F5ZHPV7goxkz6E9rz4ukT9GhjwZ7FoS6e6tvchtnwJsI+tsM43zdl9TG2EtdZayiEydvNkUMnKFtLqtT/pfE8cXgfe87H+cxTr0Kp+EZGyAff7Ep7PqZ7usKytw3HG9MKHG0qJBE0ZdxI3iiaPsN/KfjOnz4GErYOrp6ceSnkhsSwQmtoPDTJpMxRteo3VWdXon4fP7SXPfaeMxZyKF/wEp6QJ5E7c9JY/i6ScNRWKB0qnR9BYo42qAcvkQmtUU2SiQdl96GYdgobI+FOApRyxMdUyNP7k8JwKIMXidXgRZuQp/ZoZZBsTSsfk/yWgs7toHLh9An4jHfmkBMKl6GY+ccP7rOdIiPkKTEBJSygFSAqURXytIpQu0wedgxY9hmokao0KkKeUqqu3XuKHSEUpkgTF0r9G/JMEdrg27w9pRgNnWSBPfLDbODo7s17oiJTRMhHhpJco3cCIuT1jtxohTwdgEI/KLSEW6HqnzSSqkLeH9pw6eg2iT3ZwUtUhTz9OAztZ/lvGrbFnPmFYrApFpNi8VVp81Rt0PLtyoA57MWjH0/apBW8hCXkSXzSJlcKIyhfqbrGPffv3uYQG1p5CL7Zli4KT8iTd8imWyu07dwLg5zcQoWikIju074RqtdpwPnqQ6bNjI6QJy/nrMkenDN+3qrtarETUshT3ynGlTKQUJgRxelSvHzI9JMhs9bQJlZaDaEsPBRSpa2Q92vU4D4s8lQx8pTn376fJYcnqHJ8070vnz/hzBq0OY5CnLSFTOj/Wxm1FuNayFPu+OHW3Tj8pGrt+hqdp/hkioPuO2g4OvToryGWoirkqWL7vp3x8P4dDt+gVIkkAie5OeL6pQu8mTGkWKcUqjS5oHAYCkMJXsIS8g/v3+V4+NSp06JyTc0zFl48e4pt61fAxsEFbbr01qgvPCF/7uQx9GxjwSuHozynqUNSVBXQ959ipCkWnzachjx4KipCnjZy2/XpgDRp06PsX5V5T4Gnrz9y5MoTYyFPNqOc8xTO0uHfjeyqMTha98Dd29d5EznZhmLnly2cjc2rl3As/YZVizk+nrzo5BDp3bYBx6oTD94EGi8eAvx8OGWuPoQ8hU12alKNY+x59fbfc0VoPLRxdqX/HM66RBOW8DzywYU8ZQIbOag3ZyYLvpIT0TeaQqL6tGskMfIRgZK/Gz4BEfL6t5GxhtasWOTHL9sZ/mtDbdKkDaoUqpEpc1beiBoTIU8e5t1b1sF9xCD2ptVp2IxjPkfY9uSsLCFf1hQrTB4wOkV1wkx/9cFSqj6EJeQpfpayqVB6u+CHJdF9dLIkharkzJVXnVNbVV94Qp4mFVaWzXH31g3+gWjRoRvnzKdCudjdR9jiwd07mDR7MYevhCxRFfI0waG4eorzrd3wTyyp6pAqbUKeVjamT3DFsvnkNf+NLn1pb4FmHvmQQp5in/t3aoau/QehS28brdlQKL555KBeOHnkbxy+8oSHRUv4dCDOn3R5/xViQB55OkSnQJHioeyl/29k1FuMayFP3sTxzvYYN3Ue7yMJXmhSRd9FCmGZMne5hr2iI+TJpg4DurDwokOf6LtBq0rtu/bl3OwhhTzFHdOz7uEznzdrRkbI0zPsNcYR3rOXhPpeUNgHjYe8yhTHTeJTVcIT8hQ2MqhHW1y6cIZD8Tr26K/Or3/n5nVMcLHHqWOHmJEqB33wvkZFyNOqpLfbCKxaPI8nL+ThtXZw5olWVDzy9n064cnjB5zpRpU4gMZPnuNnFP6yaI06rpyyuNB3vHrdRrzBnVZLKD/+wB5t0LJ9N071Oty6+5/MNV6+nMWlYcUiHBo0cfZiXnGkvQ60ykphNtET8p85Fp684fYunuqJmypGPmRoDdlkgutQHNm/m1ckVeeKkB1pHwDF8av2P0VWyNMkk1LbUugkbWwN7hyhTf0UW6/t5F16d9Yrlx/N23VhPpEp4pGPDCW5Ru8ERMjrHblReuRJlFFKMoqn3Hb0SihoJKYnuDpw5gHKQU7ZGFQlYo98Kt5UqsojT/eRABw9dACH1CxYuxPk5SPhvXDtLuTMk1+jfcpxvGbpQniOGoJpi9aiai3NQ4vox4s8WaqQE7qZsh+Qh59ypG89cinUeGhVgCYSdNLiliOXON5XVSjzA2V10JZHnq6hWFn6Ab1+5R8WqXTyKsWdknigVJGUUYRCebQVignNW7CI1h8W4kEx56qDraiPdMAPTXwo9SCFy9CPlqrQD+Pmtctw7r7mcfYk9Hq1bYCH9+6ESs1HrCjGOXgeeRICtPmXTuqds3Ib0qZLr7XvdIgPbR7cdPACb8wLq/RqU583AMqBUNHLI0/fNdp3sHvrBmw8eD7UChSJM8oes3CmN6f7C57tJUIhX8CcBV/wPPL0vJCQJOETsGk/e8cnj3Viz2nwLDYqe1O/hlt1Y3FJqRGDC+8GFQrzih1NClSFPMRTx43kDYx0mBVtigxeKGyOxkuZW9YfOIdc/26Kp2vCE/L0dzrXgfLMU0x4WvMMyFegCG8mvXXtMocE0r4aWpXSVmiTLaUbJHEYsvh6uWHejEka362L505x+kdaQSRhqPqecqjLv1lrKIyDijprTa48vJ9AVbZvWAlnu3686knfQ9eJvuxZ/3v3Nn7/vnrxnEOAOMvNg7v8fqEVMNq/QhPmTo2rI3GSxBg/fSF/dptWHVrUYbFKm4qXLZiFOT6eKFexGkr+rwLv1SFGdEr1f0L+LW+Sff4kdIx8yNAaCrckFvRuplW+L/Q74OvPSQNI4BcpXjqUY4f2XYx2sOLN0ZTthqZlt29e5Rz081Zv53AZKjQZ7Nq8NsfS9wp2WjHFyAf3yNO19BntUzBLaIYmrTsjfvx4OLRvJyc+mL96p9ZsanRfx4ZVee8HhaGFXD0KbnPaX7RjwypQml3i/ubVCxQtUQbJUqTkrD6UlSc6RQ6Eig41uScUARHy+n8ojNEjTxvflsybwanA2liGPumQKJ44fABrl85Hq049NE5RpY1x9KPXsXt/raEZFKdKm5QoZlpVyHND8bJHD+yG95xlWLZwFr59+cInl2p74dIGWfJKU/aZxiFCe7RZmH6kaDz0o9GyYzetDwEdhLNu+ULOMxw8nd71yxcQ4DcNnXtbo2jJslrvpY2ih/bt4KwblKGBYssLFi2ORi3ahzqpNrJPIMVD048TTQaoUBx07rwFULFGHZQqW4G9WcELLVNTFpOQKyQUj7xvxyZsW7cCHXsM0DjVktJnfg/6jtFeM9VV0WSKhMSmVYv5RNo0YQj5Q3t38MmuFF7VpE3YWSAoiwmF1nQOw5aR5RGX18WlR57ijKn9lKlTs/340J0QhUTlioWzYdGsNWrU/XPiKRUKyZkybhR/RytpOWSJNg3SngU6/ElVaC8JpTWkVTKKjaZJ8/Onj2DZ25oFYMhCmyQpEwqFblA7IT32Ia+nzeUk0ilbE024tV1PGVPoeW7cuiOnLFQVOtPCx9MFbS17oXxl7SkvaSJ6aM92nDz6NwthEpk0uaGwIG0pLSPzXNE5F/u2bwr13aLJdspUaTjEj7LJUKHxLV8wE1lz5FbH6pMNacMsOTwo45aq0HeN3kvnTx5jHgPsR6nzqpOwpYn8w3u32etcpGQZPixPlXf9/OnjnG6TRKXqcCyqj0LuKIyI3q8U+rN22UJ+L9EBU5SylxwNdLpp74HDOPc8TRRXBszlk3WDb2SmPlJqXgp7Ce4UoZWCFf5zcOfGVT5Bt4f1EH5H+Yx3Yb70zg5ZyIlAp05T2kl6b1F6SdrIS+8zVXnx9DE8/t95RJOQ4AcJnjt5FIvnTudMQ8EP3Lty4Sz2bNuIG1cv8ruRMhXRfSH3VQTvC63I0h4pWh2gPoRVqK+0N4wOsQpeaLJFrEOGX0bmGaJrRMhHlpRcFy4BEfL6f0CMUcjrn5K0aGwEaPLSq219ZMmWk721YZ0Aa2zj0tbfuBTySuAnYxAChkCAVmqG9OmEQSPceKUookmnrvssQl7XRE20PhHy+je8CHn9M5cW9UNgjs8E9gDSITzR9Xbqp6cxa0WEfMz4yd1CwBAIUJgVrSJS6CSFe1F2JH0WEfL6pK3gtkjIf/z4EUOGRO5kMwWj0NvQRMjrDbU0pGcCge/foVPjaujS1xbtuvbRc+v6a06EvP5YS0tCILYIUAjQ9o2rOY0rhSAG32MUW20Gr1eEvD4om0AbS5Yswa1btzB69J9TMaXEPgER8rHPWFoQArFJQIR8bNKVuoWAaRAQIW8ado71UYqQj3XEoRoQIa9/5tKiENAlARHyuqQpdQkB0yQgQt407a7zUYuQ1znSCCsUIR8hIrlACBg0ARHyBm0e6ZwQMAoCIuSNwkyG30kR8vq3kQh5/TOXFoWALgmIkNclTalLCJgmARHypml3nY9ahLzOkUZYoQj5CBHJBULAoAmIkDdo80jnhIBREBAhbxRmMvxOipDXv41EyOufubQoBHRJQIS8LmlKXULANAmIkDdNu+t81CLkdY40wgpFyEeISC4QAgZNQIS8QZtHOicEjIKACHmjMJPhd1KEvP5tJEJe/8ylRSGgSwIi5HVJU+oSAqZJQIS8adpd56MWIa9zpBFWKEI+QkRygRAwaAIi5A3aPNI5IWAUBETIG4WZDL+Tq1evxpkzZ+Dp6Wn4nVVID0XIK8SQMgyTJSBC3mRNLwMXAjojIEJeZyhNu6INGzbg4MGDmDx5smmD0OPoScibZ8iIXHnz67FVaUoICAFdEXj98gVm+U5HixYtolUlvW99ZsxEylSpo3W/3CQEhIDxEwj6/h0Vy5eFv79/pAYT7/fv378jdaVcZFIERMiblLllsHoiQCtdr1+/Rt++fRE/fnw9tSrNCAEhYEwEsmTJgps3byJFihTG1G3paxwRECEfR+ANvVkR8oZuIemfMRLYtGkTHjx4gH79+iFhwoTGOATpsxAQArFMoFixYti9ezeyZs0ayy1J9UogIEJeCVaMhTGIkI8FqFKlyRPYtm0be9r69++PxIkTmzwPASAEhEBoAtWrV4efnx+KFCkieISn4v6VAAAgAElEQVRAhAREyEeIyDQvECFvmnaXUccuAfKyXbp0iYV80qRJY7cxqV0ICAGjJFCvXj14e3ujZMmSRtl/6bR+CYiQ1y9vo2lNhLzRmEo6akQEaAP58ePHYWVlJfGvRmQ36aoQ0CeB3r17o127drCwsNBns9KWkRIQIW+khovtbouQj23CUr8pEjhx4gT27t0La2trpE4tmUlM8RmQMQuBiAgMGTIE1apVQ8uWLSO6VP4uBCBCXh4CrQREyMuDIQR0T4DOZti+fTtsbGyQJk0a3TcgNQoBIWD0BJycnFCqVCm0b9/e6MciA4h9AiLkY5+xUbawc+dOrF27FnPmzDHK/kunhYAhErhw4QJoktyzZ0/2yL97947/Ld55Q7SW9EkIxA2BSZMm8TuhT58+cdMBadWoCIiQNypz6a+ztClvxYoVmD9/vv4alZaEgMIIBAUFwd3dHRs3bsSbN2/w4cMHfPnyBd+/f+eRpkyZEtOnT0eXLl0kr7zCbC/DEQJRIUDvBNWxPosWLcLbt29ha2vLVdDntDlezp6IClHTuVaEvOnYOkojFSEfJVxysRAIk8CxY8fQsWNH3L9/X+OaePHioWrVqjxZLlCggBAUAkLARAn8+PEDrq6uuHz5Mk/0KUXt+/fvOfyO/j9t2rS8tyZz5swmSkiGHR4BEfLyfKgJrFmzBj9//uT/pxR5hw4dwoABA0AvGfIsNmnSBObm5kJMCAiBKBCg78/o0aMxbtw4jbuSJEkCNzc30Ma2BAkSRKFGuVQICAElEfj16xemTJmCUaNG4evXr6GG5uPjo/bOK2ncMhbdEBAhrxuOiqjF3t4e/v7+PBYSH/RCoSOiaVmvePHi2Lp1q6TMU4SlZRBRIfD8+XP2kJH3PLqFlsnLlSuHO3fuqKvImDEjp6LMkydPdKuV+4SAEFAIAXrHUNpJSlEbvOTMmZMdaxSGJ0UIaCMgQl6eCzUBWsojjzuJ+OCF4vImTpwIOzs7idGT58XkCFBozJIlS+Dr6xujsa9fvx5t2rQBed+o0KFQs2bNilGdcrMQEALKITBz5kwMHz4cHz9+VA9q6NCh8PLyUs4gZSQ6JyBCXudIjbtCeomQaA9eypcvj4CAABQuXNi4Bye9FwLRIECxqZTFKeT3IqpV0UbXrl278sZXin2lCYJ8p6JKUa4XAsolQBvi6SAoeudQyZo1K2e5ot9gKUIgLAIi5OXZ0CBw8eJFtG7dmkMJqNBOeUdHRwwbNgwU0ytFCJgaAV0JefLEk4jv168fmjdvjrlz55oaShmvEBACERDYs2cP6tWrx6vflKaWvPFy5oQ8NuERECEvz4cGAYqLd3Z2BuWxpZI/f37OJ1+yZEkhJQRMkoCuhDzBo7zxtFTevXv3GMXcm6QhZNBCwAQI0IS/U6dOIEFPm1zpvynDlRQhIB55eQYiTYCW/Elo3Lhxg3fK08tEihAwVQJbtmzB6dOnOfOMLgotn6dKlQpmZma6qE7qEAJCQGEEXr58CSsrK85kkz17doWNToajawLikdc1UQXUR6kmafl/8+bNOHDgAAIDA/Hq1SutI9PmKZDPoNWDEpZXJeTnkb2ODBIT1truj2x9Srk3Mgz37duHq1evwsbGJtR3ILK8ImvTyNZnSPwj25fIsFYBjiwvXbdtjO3GlGtMxqyAnzuDHAJliqNsWZI33iDNY3CdEiFvcCYxjA7RUfIk4nv16oUdO3aEOsyGeqk6hS66PY7J/aZ0rymNNabPVWywunLlCofEVK5cOdxHPTbajsx3y5TaNaWxxvS7ENP7w2MdXPyr/lvbZ8EnGRH9PeSERJ9tRNS3iP4eVt+jcl9UrtXWHol+CwsLJEuWLDKvDblGQQREyCvImLocCsXpffv2jTe7Bi/hvdwj+pGNrXsj84MVV30zxnZjylNpY6aVqYcPH/LhaOGVuBp3RPYy1H4Zar9NkVdUbRGckeq/Q/47ZJ3h/T0m96ra0dan4H2I7N/DG1tEY4rJvdHpa/B7MmXKhJo1a0rIni6FkJHUJULeSAwl3RQCQiBuCFDqVcrrTDGrUoSAEBACQkAIGBIBEfKGZA3pixAQAgZHQIS8wZlEOiQEhIAQEAL/EhAhL4+CEBACQiAcAvPmzeO/0vHpUoSAEBACQkAIGBIBEfKGZA3pixAQAgZHYPbs2bxXpFu3bgbXN+mQEBACQkAImDYBEfKmbX8ZvRAQAhEQECEvj4gQEAJCQAgYKgER8oZqGemXEBACcULgy5cv+PDhA6dXpUObFixYgJQpU/IJi3RseqJEifgfOW0xTswjjQoBISAEhEAwAiLk5XEQAkJACAQjQCevOjo64sWLFyzY6YRjys2cL18+JEiQAIULF+ZUlKlTpxZuQkAICAEhIATilIAI+TjFL40LASFgaAToDAU6xXXWrFmhukYeehL5Tk5Ooc5YMLRxSH+EgBAQAkJA+QREyCvfxjJCISAEokggMDAQ6dOnR1BQkMadRYoUwcKFC1GhQoUo1iiXCwEhIASEgBDQPQER8rpnKjUKASGgAAIjR46Eh4eHeiQJEybE4MGD+TPyzEsRAkJACAgBIRDXBETIx7UFpH0hIAQMksDdu3dRo0YNPHz4kPuXNWtW7Nq1C8WKFTPI/kqnhIAQEAJCwPQIiJA3PZvLiIWAEIgEgW/fvmH06NHw9PTkq4cPH87eeMpcI0UICAEhIASEgCEQECFvCFaQPggBIWCQBPbs2QNLS0ve2HrhwgWkSpXKIPspnRICQkAICAHTJCBC3jTtLqMWAkIgEgTev38POzs7lCtXDlZWVpG4Qy4RAkJACAgBIaA/AiLk9cdaWlIoge3bt2P37t0KHZ0M68yZM8iVKxfMzc0FhkIJjB07FsmTJ1fo6GRYQkAIKJmACHklW1fGphcCzs7OMEuTFYWKldRLe9KIEBACuiMwddwobFm/WiZqukMqNQkBIaBHAiLk9QhbmlImARLyectUR5nylZQ5QBmVEFAwAYf+XbDcf64IeQXbWIYmBJRMQIS8kq0rY9MLARHyesEsjQiBWCEgQj5WsEqlQkAI6ImACHk9gZZmlEtAhLxybSsjUz4BEfLKt7GMUAgomYAIeSVbV8amFwIi5PWCWRoRArFCQIR8rGCVSoWAENATARHyegItzSiXgAh55dpWRqZ8AiLklW9jGaEQUDIBEfJKtq6MTS8ERMjrBbM0IgRihYAI+VjBKpUKASGgJwIi5PUEWppRLgER8sq1rYxM+QREyCvfxjJCIaBkAiLklWxdGZteCIiQ1wtmaUQIxAoBEfKxglUqFQJCQE8ERMjrCbQ0o1wCIuSVa1sZmfIJiJBXvo1lhEJAyQREyCvZujI2vRAQIa8XzNKIEIgVAiLkYwWrVCoEhICeCIiQ1xNoaUa5BETIK9e2MjLlExAhr3wbywiFgJIJiJBXsnVlbHohIEJeL5ilESEQKwREyMcKVqlUCAgBPREQIa8n0NKMcgmIkFeubWVkyicgQl75NpYRCgElExAhr2Trytj0QsBUhfzv37/x+ME9PHvyEMVLl0OSpMmY95cvn/H71y8kS54iXP4/goJw4sgBFCpaAuYZM+vEVkFB3/H92zckS5Yc8eLH10md0ank86ePOH3sEPIWLILsOXNHpwqTuIdsRTajZyVevHjhjvnVi2e4df0qipYojVRp0uqMjwh5naGUioSAEIgDAiLk4wC6NKksAjEV8p8+BuLCmRO4fOEM3r99gxSpUiNn7nwoVa4isuXIZbCwfv38iSXzfbFp1RL4LFiFbDlz4/27t1i7dAGePLqPUeOnhdv3D+/foWWt/2HUeB/Uqt8kxuP88eMHtm9YhTPHD8NmmIvOJgfR6diNq5fQpVkt2Di4oEvfgdGpQvH3fPv6FZvXLuPn3t55PFKkTBXumHdtXgef8S5w95mLMuUr6YyPCHmdoZSKhIAQiAMCIuTjALo0qSwCMRHy796+xuzJHtizbQN+/fqFnLnz4/27N6DP06XPgLV7TxksrJ8/fyLAzwebVi/FtEWrkSNXXrx68RzuI2xx99Z1bPz7fKwJ+SXzZmDv9k2YONMfGTJl4XaCvn/HzEljsXX9SsxfsxM5cuWJdXbXr1yEr5cbuva1RblK1dTtXbl4Dj1a1kP/ISPRw8ou1vthjA3QqsVUD2cc2rsTy7YdQtp06XkYNBlbOn8m2zZrsInstvUrMX3CaLj7zMP/KlTR2ZBFyOsMpVQkBIRAHBAQIR8H0KVJZRGIrpAnIezj4Yzli2ajh9UQWNmPUoO5deMqVi6cjZHjfQwWljYhH5XOxsQjP85pMHZsXI2AjfuRJ3/BqDSr02spfGbU4D4Y5DQWDZu3FSGvA7oLfL0xe4oH/NfvRZESpdU1ipDXAVypQggIAcURECGvOJPKgPRNILpC/ubVy+jWsg4atWjHQjBlqtThdv3dm9fs6X775jXMzMw4dCRX3vxIniLlv/dRzPp9vHr5HHnzF8bjR/fx5OF9JEmSFPkKFUGmLNk06v8Tc3wFnz99QpIkSZAjdz7kyJ1Xfc3bN6+4vXdv3mhtT5uQp/CWG1cuIuj7Nw4NCl7u3b6Jxw/ugq6hMBxacWhrUVEjtIbqfP70MV8X+OED953GmDlbDiRIkID7evXSeSyYMQlnTx7BoBFjkTFzVhQtWYbH9/D+Hbx4+hglypRH4iRJ1c0HfniPe7dv4OXzZ1xP2vTmyJ2vIFKlTvPfeF+/ws1rl5G/cFEQa+pvwoSJkCtvPmTPmQfxEyTQGM+dm9exd/tGLJs/E01ad0SZvyojnXkGFC1RBrduXGGPfL/BI9CwRVvcvX2DY/ezZMuBPPkLIVHixBp1Bbct/S1r9pzIW6Cw+prPHz/izInDKFCkON69fYNnjx8gY+ZsPO7v37/j4b3bzO3rly9IlSYN8uQrhPQZMqrv//TxI/MqVrIsvn79jHu3buD7928wz5gF+QsV4f0NP34E4dqlf0Ch6oWKlWKbq8rjh/f5WShZ9i8NZvR38qyfPXEUmbJk5f6pCvF+/vQJi3EV50+fPuLqxXNse+JPjN++folS/6uA3wCuXbqAlYv8sHPzGgx0HMPciVfuvPmxfeNq9siP8Z7NnOnZjh8/AXLnL4hsOXIiXrzo7YkQj7y+35jSnhAQArokIEJelzSlLpMkEF0hP228C4elOHlMQe0GzcJld/70cVA4yY3LF/m6oB/fkSRJMtSyaIzOvW1YtFFozvKFs7Fn63oULFoC504exZfPn/HpUyCKFC+N0ZNmIUOmP5tKaZPqxNHD8Prlc54Q0HWFi5WE3ahx/He6d+l8X9y4culPe0HfkTRpMtRq2Ayde1qxkNIm5MnLPn6kHV6+eIZ5q7arx3T80D7M8h7H7dIeABJ2FarWwrrli9RCnvpP1630n4OgoCAkNEvI/UuaPDlshrmy2Hvx9AmWLZiFnVvW4NXzZyyeaaNkhx4DUL5iVfj7+bCnftqiNcicNTu3T5MVuufM8UP4+eMnfuM3i/nS5Sqhn50jsuX4sxn1yIHdmOjqgErV6+DKP+dAY/nw7i1y5SuA4WO8ULh4KQ0bbV6zHGuXzsfVSxeQr2BhnlCQkLXsbYPHD++hW4s6qFClJrf3+sVzPH/2hFmTuK9VvzESJPgjlG9evcT9JuGbJm16BAZ+4M/bdemNxq068H/T5KhHaws0adURl/85i4+BH5A6bTrMWrIBW9Yux87Na5E8eQr8+PkTNEGjvRXD3SapGVAIUO+2DdCyQzfm8ebVC7x98wZJkiaBZR8bNG/XBbTnYZqnK86dOo6ZS9YjbTpz9XjHDLPG0QN7MG/1jlAhS69fvkD7BpVRoFBRzFq2SX3PyEG9cero33CfOhd/VanJn188dwqu9gPQfYAd6jdrDb8p43Hi0H6+j3isWDgbW9Ytx/27tzgOnia3Fk1bo36TVjzGSWMcUalGHWZFMfZvXr9EvoJFMNLDB7nzFYjW+0eEfLSwyU1CQAgYCAER8gZiCOmG8RKIrpC36doKz548wvjpCzQ8mSFJvHz+FCNseuLW9ctwnTSLPagkSDetXsKid9AIN7Tu3JOzfpDYpzjxLNlywt7FE7ny5MO+HZswb7oXb7rsO8iRq5/l7Y5Fs30wf/V2jkMO+vaNPaIkfl88e4rhVl1ZTLlM9GWRSu1tWBWANYvnw26kOwtCuj5kjDzF93s42bF3eNH6PdwWCdihfTvj6eMHLOpIOF+7fAGeo+xB7l/VZlfKYrNi0Wz2stawaISkSZPj/p2b8B7rhIJFi8NlwgyePNDm4Emjh2Pfzs2YEbAOOfPkQ/LkKZHAzAwLZ05mIU+fk/ebPPGT3Udi77b1cHSfghKly+HX71/4e9dWTPMcjfZd+2DwSHckTJQIf+/ehqH9LdmzT5zKVqiMi2dPsbitVqcBnMZN0TANrQ6cOLwf40cNQd9Bw1G7YTP24NMKCY3PskkNFtvtu/VDg2atuS9jHW2ROUs2jJ0yh/9GEwWvMY64dP40xk2di0xZs+P7t6+Y4eUGmrxNnbeCnw2aWHRpVpMnAp16WvHmYFrZSJosGZbOm4GKVWujYLESPEE5fvgAJjjbo5eNA7r1H8R9JvHftVktvr+NZS9YNGmJr1+/Yv50L25n7sqtyJknPyh8xdPZHp6+i1ClZj2+l2zQt2MTVKxSCy5eM9QTEBUMmoA5D+6L08cPYe7KbWwPKpULZ8a3r18wZJQHOvToxx5z2gjtN9UTizftR7r05pjpPQ7HD+7FnJXbkCp1anwKDORJjf9sH0z3X8Njpwkk/bNtwyo42/Xl1RlbRzcUK1kGp44dhK/Xn7Ame5fx0XqJiJCPFja5SQgIAQMhIELeQAwh3TBeAtEV8laWzfHh/XtM8lui9pxqo0CbOj2cBqP3wGHo2LO/+hIKjejQoCoKFS2O4WO92ctNQp7E7JS5y1H638we5NXu36kZC3bKLkNlivtIrPD3w/zVO1CoaEmYJUyoTv+3e+t6eIy0Q//BTmjfva+6va9fPqNjo+ooVrI0ho3xQvKUqSIl5HdtWcde+iEunmjauqO6vgunT2BI306hstZQWsufP37wCsO7d29YlL559RIL1+1W36stRp6EbUghTwKYxF/1Og0xyMlNA69l05qIHz8+Ty5IfJKQd7LthaGunmje1pJDacjzPXb4QI2JSfBKwouR79qsNtpY9sQQZw8kSpSYhfeSOdM5U8uspRvZg08eapch/dG5lxWatbVUV03hQ/07NcVgp7E8EVAJ+Rbtu8Bx7GSeeAQvxOrnzx/4/es3Hty7zfauXL0O3Kb4qYV89xZ10KWvLWwdx6hvPbR3B3vIB40Yg+btu+LB3dtwGdIPmbNlh+eMRXzd+hX+7An3mhWAyv+K+5DP6Y7Na+ExYjBcJkxH3cYtcOzgXp680eQgf5FicHKfzBM/2hPy6P5dTJjpj4QJE2oI+dT/ppQML0Z+vPMQuHj+aYMmBpQlyWlgT3z79lVjBSgqbxMR8lGhJdcKASFgaAREyBuaRaQ/RkcgJkKesryQ9zN4PHRIAORN95s6Hpv+Po8s2XOq/0xid6zjILx6+QyuE305vIaE/Lpli+CzYCVy5f0v1IC8uRRbv+Xwn9Ccu7duwG24DV4+e4Ia9Rqxx5m81STOqa150yZi06F/2KutKhReM3a4LafIdJk4A2nSpY+UkKdVA/Jqz1q6CSXLllfXp22zK8V/U1gPeahpZYAmKxfPnmQveXSE/ME92zHcuhumzF2BitVra6Alb/CBXVswdrIfChUryULe3dGWx0Y8VIUmDZRVaP/5e6GezahudiWvMk1qVmw/wvsEDuzayptlqf2s2f9LNfr+7WucPPo3bBxcOfSFhHzP1hawGjoKXfv98bJTIQFPqzqnjh7EzasX8f7dO3z6+AFH/94Li8YtNYR8rzb1YU3pMPv8lw7z8oWzcLXvjxr1GmPgcFeOk/caPRxb163Axr/PcUpIt+EDcfXieSzd8jeSJkuu9ftJz1aLGmXQuFV79sBPnzgGJw7tQ4sO3bBo9lQErN/Lef0H92qHOg2bc5YfmngE98hHRshry1oz3KobTh07hH3n7kTr3SFCPlrY5CYhIAQMhIAIeQMxhHTDeAlEV8hTSMa+7Zs4M01Ni8ZhApg5yR3zZ3hhx4lr6lSLdHFUhfztG1dx9NpzdTsU/nJ4306cPPI3bzIkoUveWvKILpo1BTtPXIf5vzH1dFN0hfyKRX6YTkJ+2eZwhTyF1lC7JJopHj5XvoL48vkTyKNPBzxFR8hTWNEwq26YtWQjyleuHm0hv2bJfJx7EKgTIT/Sthen5qRVgH07NrOQr9uoRagYfNpsSqsqBf8NrdEm5J8+eoCZ3u64de0KKtesi/QZMuHt61dYvnAWatdvGqGQpwkCCfnqdRuxkKdyZP9ujLDtiT42DqhYow5ch/RH/eZt0C3YBELbw0orH7TRethoLwyz6sp7Deo0bMb1240chzRp08F5SD8+X+CvKjU47EZXQp6eEW32icxbRYR8ZCjJNUJACBgqARHyhmoZ6ZfREIiukL90/gxviKTwCxLQ/2Wf0Rw6xcJTaAPFVZP3XFUob3qX5rWQv1BRDBs9kTeRhueRDynkVR7dwPfvMH/GJJBYnea/Fo/u3YH32BEY5zMP1es2VLf39esX7i9tih3qOoE3mUYmRl7V/xHjpmikaCRvsG2PturQGgpjaVmrLJq27oSe1vY8HvLQjxsxiDdwRkfInzt1DCNte6NLXxt07DFAA2yvtg14MkTjJO94eB752BLydHgVhbL0HezIG07DKmF55GkiQPdP8F2E8pVrcDYcCo/p1bY+KlXTDK3p2coCvW2HoY/tMHUztCLgOnQAPz+qjbW0ibRjoyocC9++ez9+Nuas2MLnBIRXDu7dAVq9oM3QC2Z6w9tvKacGHTm4D9+b3jwjZ84Z7TWTV5ZEyBvNK046KgSEgAETECFvwMaRrhkHgegKecoSQmELu7esQ+fe1hzyQBs2KVyCxNjaZQt5Y+nzJ4/haNOdM43MXLIR2XPl4Wtow+rmNctYVDdvZ8mfRVbI04ZR2hzL7f38Bf/ZU7F47nSOmSdPMHlUaXOmb8B6FrlUNx18RCEXjmO9WfRpy1qjbbMrZWWx79uZN3H6rdjKIUDnTx3j2PX4CcyCCflAtKlbnsNaKIQkWbIUuPLPWbg7DUKqVGk0hPyMCWOwbOEs3l9AKRETJ0nCMdMhY+RfPHvC4vLsiSO8AZYmPRSDvypgDmZN9uDY9MFO7vygRUfI/3P2JJzt+qFpm448UaCY+yRJk3ImG20HQlFoTXCPPIXFUDjP0yePMGPRGs4GRIWy9lw8f5q98SSAwxLyJMRJyNMzUL9pK/z69Rtb16/gPRB1GjTT8MjT5luKyx/kOAbV6jbkjaUTXB04HeSSzX/DPGMm9ReOMhbRKarpzTOhWKkynPEoopNXnz1+iC7NayNT5qy4d+cmDl95wvVRXzauWsyrBf+rWFW9aTgsIb/Kfw4mjxsJt8l+vOGW9m8kTpyEN+KGFVojHnnjeFdKL4WAENA9ARHyumcqNZoYgegKecJE4S1zpnrixJED+PjhPWfk+Pr5M4J+BLFg95q1mDex7t+5hTOMPH38kGPTSYjTBkpKzdd9wGAWWSS2Kc3i+mULMXn+CuTKk19tCYqRv3/nFg5eesSfUTgBTQyyZM+FD+/e4OG9O6hh0RgDhjhx/nUKSSFPLAlNSkP4MfA9EiVOwh512jDJ7f38icXzZmDTqiXwWbiKc35T3DttlKVMOzQpUBXKQkLimfKIUw5xmkRQ5hVKvznCffKfLCxBQZyxZN2yhZw7PJ15Rjy6fweU3pDE/4K1u9T1USgQxUZTe+kzZoK1gzOq1W7AKwR0Muh0Sj/5b3w/TRrm+ExgMUz54ylE6PevXywqKeSDPqNyeP8uuA2zgevEGahSy0LdFk0ENqzwx6k7b0M92ZRr33eiG4tMCpUpXKI0ZxGi+P6uzWvBeqgLuvazVd9HQt7Fri/W7z+rztl/5sQRzPXx5JzrlDaUMs9Qmk7KauPsOY3Dqa5f/gfdWtaFzTAXTm+pKmQfmmBR9hxKp0lx55Qz/vKFM6hl0URDyNPEomipsvjy6SNvPKX87SlTpeEsOM3bW3LGHVWh57JDgyqcutTRzRstOnTlSUp4hVZUKP6fxkgbd8d4z+LLVfsAyMNPm2HrNGrOn5Pn32+qB44f3IfZyzcjVeq0/Dnllne26wPK009pNFt17ok2nXtg77aN8PF05ew+lHZUVeg5oJWJU3feROvNI6E10cImNwkBIWAgBETIG4ghpBvGSyAmQp5GTYcBUW5vSvNHh/tQPHjGLNlQoHBRTheoKpQ7m8JxyFNOmw5z5MrDwoxS81EhT/Ota5dBp8JWq2XBoSmqsmvzOo43b97+T/jGP2dOcHrJj4GBSJw4MaerJGEb/KAi2hBLgpDaS5ac2svLBxDR4UGq9sjbfufmNfaiU2gQhftQGkLytta0aKJunz4/d+ooTyZI0OUtWBhFS5bFzk1rUOavSjwJoEJtUTgMxX4nSpQI+QsX434Hvn+vFoCqSmlTLHGjCUal6rU5R/71yxeZI/WHQn9Uheq7cOYEb/gl733WbDlRomx5jXAmEq/HD+1Hhao1NbII0UZSqpPSNmorjx7cxbkTR/H58ycUKFwMJcr+xX2mNJily1Vkcf6fDW9ybvWGLdppeLjpcCPy4tMKAq2I0OZe2gCrOsSL0lRSHnWqL/ihS1Tvk0cP2J7v3r5mMUw2orAlmvxUrPZngy+ln6TNrn1sh/NntNJBhQ5rIsZ08FbIYterA+fDd5s8G4X//xyCiApN7KgdekZLlavAB2NRocnWnq0bOAsQ7QWhWHkqdP2lC2d4xYnSjdLEVFVo0kV9pHvK/lWZN27T5IYmZRWr19FYPaD8/7QaQClYo0SYVgYAACAASURBVFNEyEeHmtwjBISAoRAQIW8olpB+GC2BmAp5ox24dNxoCKiEfMisNWENgFZ8GlcuxnskaMUkrGw1RgMgnI6KkFeCFWUMQsB0CYiQN13by8h1RECEvI5ASjWxRoBj7NvUh42DC6ezjKjQCcF0sBhlVGrQrE1Elxv130XIG7X5pPNCwOQJiJA3+UdAAMSUgAj5mBKU+2ObAIUNTfVwRrM2nVCpRt0Im6P9ERTKQpuOg4d3RXijEV4gQt4IjSZdFgJCQE1AhLw8DEIghgREyMcQoNwuBOKQgAj5OIQvTQsBIRBjAiLkY4xQKjB1AiLkTf0JkPEbMwER8sZsPem7EBACIuTlGRACMSQgQj6GAOV2IRCHBETIxyF8aVoICIEYExAhH2OEUoGpExAhb+pPgIzfmAmIkDdm60nfhYAQECEvz4AQiCEBEfIxBCi3C4E4JCBCPg7hS9NCQAjEmIAI+RgjlApMnYAIeVN/AmT8xkxAhLwxW0/6LgSEgAh5eQaEQAwJiJCPIUC5XQjEIQER8nEIX5oWAkIgxgREyMcYoVRg6gREyJv6EyDjN2YCIuSN2XrSdyEgBETIyzMgBGJIQIR8DAECuH75H2xYGYAcufOhWdvOSJEylbrSc6eO4cCuLfj+7VuYDZWvXAO1GzTFrWuXsWHVYvz88YOvTZDADJmzZUeFqrVQoHAxrfc/un9XfQ+deprePGOMB3T14nlsWr0EufMVRJPWHZE8RUp1naePHcLBPdsRFPQ9zHaovzUtGqv//uzJI5w9cQS3b1zF508fkThJEhQuVgp/Va2JdOkzxLi/plyBCHlTtr6MXQgYPwER8sZvQxlBHBMQIR9zA4xzGow1S+Yje87ccPWaiXKVqqkr3bdjM1YHzMXXr1/wIygID+/fRdD3byhYtIT6mnpNWqJTTyvs3b4RJMwKFS2JJEmT4tPHQJAITpEqNSbMWIQSZcuH6uzyhbMxfcJo/P71C8PHTkKL9l1jPKDRQ62wcdVi5MyTH2O8Z6F0uYrqOndtWYe1SxfwxCSIxnPvNn78CELBIv+Np0HztmjfrS/fc+LwAUwdNwpPnzxEypSpYZ4xEx7wPT9QrGRZDHYaq8Eixp03sQpEyJuYwWW4QkBhBETIK8ygMhz9ExAhHzPmr1++QO92DUBe9R0bV6Nrv0HoMcAOCczMQlX87u0buI+wxesXz7Fw3e5Qf9+zbQML+TV7TiJfwSL89307NmHs8IFImToNNuw/i/gJEqjvI6E/1tEWZmZmOPb3HpQsWwHjZyzkSYC2QqsD29atgJWDM9KmM9d6zasXz9GtRW1UrF4HuzavRd9Bw9GplzUSBGtXdeOb168wxsEKHz+8x/w1O0PVd+fmNbgOHYDnjx/Bwc0L9Rq1UF+zcWUApowbhTJ/VcaYSbOQKk3amBnCRO8WIW+ihpdhCwGFEBAhrxBDyjDijoAI+Zix37Z+JbzdRmDqgpVYOn8me9FJmKYzDx0yEh0hT57vDg2r4PXL51i0YS/y5Cuo7vCl86fhaj8A1kOdcfHcKRzevwtjvGejaMkyWge1c9MazJ02Eb6L1yNTlmxaryFP/BT3UfBZuApL5s5gb/voSbOQWovQDk/I0+rDknm+mD/DCx7T5qNanQYa7VFoToDfNMyaPA4z/NeiYrXaMTOEid4tQt5EDS/DFgIKISBCXiGGlGHEHQER8tFnT6J98lgnjv1esHYXNq9ZBp/xzpgybwVK/a9CqIqjI+S/fP6ETo2r4+2bV+ypN8+Qiev9+fMHVgfMw7oV/pi2YBXevX0NK8uW6Gc3Am0se2n1oEck5D8GfsAEl6F49OAe5q3ajvUr/DFz0lj4BqxHkRKlQ40nPCEf+OE9RgzsCer/JL+lSJsufaj7zxw/DJch/dGoZTtYO7hE3xAmfKcIeRM2vgxdCCiAgAh5BRhRhhC3BETIR58/CXhnu36waNIS3QfY4fqVi3C268ubU+2dPWIs5APfv8OqxfOwcOZktOrYDYNHjkP8+PG53s+fP2HkwF5Ikz49hrp48mcOA7ogWbLkcJ4wHanTpAvVfkRCnjbtutj3R7M2ndG5tzWu/HOWx1e9bkMMGuEWJSFPE4/+nZpxfP1gJ3ckTZYs1P20udfFfgDSpE2LmUs2Rt8QJnynCHkTNr4MXQgogIAIeQUYUYYQtwREyEeP/+/fv7Bt/Sr4ermxCM2drwCH1YwfNQSnjv6NrUevcOx68BJZjzzfFy8efv78iaRJk6FjjwGwGabpsb5z4yr6dWqKoS4TUL9Za/bQL5s/CwtmemPh2l2cceb7928cHnP80H7uxptXL/D4wT0UKlYSiRIn4c9ad+qOeo1bcnsbVy7G3OkT2RufNXtOjn13Gz4QF86ewLYjl0PF/YfnkSch369DE1StXZ9XCRL/215wHreuX+HQoKRJk2Le6h3RM4SJ3yVC3sQfABm+EDByAiLkjdyA0v24JyBCPno2+P7tK4vcF8+ewsbBBanS/tmsuX65P1YsnI1x0+ajbqPm0RLyHXv0R5p06XHj6iXcvXkdzdpZolu/QRp1UcjL7q3rYevohjwFCvHfzp86hsnuI9HbxgFd+9lyZpk1S+fj3Mlj/PfnTx/hzs3rvME0SZI/G2IbNG+DmhZN8O3rF95U+/7dW1gNdUaKVH9SaK7yn8sZeSbM9Eet+k00+hAZIV+2YlX25tOEJGShFQzXIf2RLUcueM9dFj1DmPhdIuRN/AGQ4QsBIycgQt7IDSjdj3sCIuSjZ4PHD++hS9Na7KXOki2HOuTl7ZvX7PUuV6kqpi1cg0SJE6sbiKxHXpW15u3rV5jk5ohjB/dh9rJNKFikONf14f17tK33F+dkpxSRCRMm5M8/f/rEqR1z5s6LgI37Q2WvCS+05u6tG+jZ2gKJEidCpizZ1eMhsf7k4T1UqlEX3nOWIlGi/8YTboz8+3cYZtUNv3795ElAmrShY+SP/r0Xrvb90K3fYFAOfClRJyBCPurM5A4hIAQMh4AIecOxhfTESAmIkI+e4dYuW4gFMybxJs3gOeGptqkezrhw5gT8lm3WyCATVSFPdZ0+dhAjbHqicInSmL5oDXf24N4dGDagCwYMGYkqtSw0BrBhRQDneZ8yf0WoTDDhCfkV/n5YNm8mrB2cka9QUY06J41xxM2rF+G7eAMKFy+l/lt4Qj7o+3fOkBMwZxqmL1rN6TmDl69fPsPH05VTdi5Yswt58v+XjSd6FjHNu0TIm6bdZdRCQCkERMgrxZIyjjgjIEI+6uh//fyJxlVLIHfeAvCcsRCp02puLN2/cwuGW3XFAPtRvAk2Xrx43Eh0hDzdN7h3B5w9fpjjyPMXKgoryxa4ceUilm87hExZs2sMgCYQQ/tZokqNunD18kW8fzfH0kU7N6/FXJ8JodJPUix+4yrFUahICYyd6odUqTVzuu/ZthGjBvWGzTBX3gSrGk9EeeT/OXsSYxys8eLZY3jNXopipcryvdTeknkzsGjmFA4B6jvIkU97lRJ1AiLko85M7hACQsBwCIiQNxxbSE+MlIAI+agbjsRy77YN0GugA/rbOYWq4P3bN2hnURE58uSHp+9CdcpIij8fN2IQXj5/qvVAqH3bN3HmmVW7jqsPhKLKD+3dyR749t37oXlbS1h3bYlipf8Hr1mLQ7VNG25tu7fB7RvXELBxH3Lmyae+5uK509i7fQN6DBiiMfmg2Pp+HZvyptSe1vah6qQJSDuLCshfuBjcp8xV58h/9+Y1RjtYgbLraDsQik5vPbRnO5Yvmo0Hd29zmFGyZCnw5vVLJE+eAjXrN0GXPgO15tyPulVM8w4R8qZpdxm1EFAKARHySrGkjCPOCIiQjzr6u7eug3Kg0+mn2XPm1lrBkf278PFjICpWraUWzRRucvr4IY5tr9NQcyMsVfL44X0cPbAbFk1baxzARLHvFIKSOVt25C1QmLPQkHe7QOFiWtsmYU6nqlLYTVgHPwW/8c6Nazh3+hgqVauNrDlyaa3z0L6doHAYSq2ZKnUavoay4pw68je+ff2K2g2bhQnyycP73J9nTx/j548gJEuekicYhYuVEk981B8/jTtEyMcQoNwuBIRAnBIQIR+n+KVxJRAQIa8EK8oYTJWACHlTtbyMWwgog4AIeWXYUUYRhwREyMchfGlaCMSQgAj5GAKU24WAEIhTAiLk4xS/NK4EAiLklWBFGYOpEhAhb6qWl3ELAWUQECGvDDvKKOKQgAj5OIQvTQuBGBIQIR9DgHK7EBACcUpAhHyc4pfGlUBAhLwSrChjMFUCIuRN1fIybiGgDAIi5JVhRxlFHBIQIR+H8KVpIRBDAiLkYwhQbhcCQiBOCYiQj1P80rgSCIiQV4IVZQymSkCEvKlaXsYtBJRBQIS8Muwoo4hDAiLk4xC+NC0EYkhAhHwMAcrtQkAIxCkBEfJxil8aVwIBEfJKsKKMwVQJiJA3VcvLuIWAMgiIkFeGHWUUcUhAhHwcwpemhUAMCYiQjyFAuV0ICIE4JSBCPk7xS+NKICBCXglWlDGYKgER8qZqeRm3EFAGARHyyrCjjCIOCYiQj0P40rQQiCEBEfIxBCi3CwEhEKcERMjHKX5pXAkERMgrwYoyBlMlIELeVC0v4xYCyiAgQl4ZdpRRxCEBEvIZ8pZE8TLl4rAX0rQQEALRITDGwRprlwfA3Nw8OrfLPUJACAiBOCUgQj5O8UvjSiCwcuVKrFu3TglDkTFoIXDmzBkUKFAAqVKlEj4KJTBv3jykTJlSoaOTYQkBIaBkAiLklWxdGZsQEAIxJjBgwAAMGjQIhQsXjnFdUoEQEAJCQAgIAV0SECGvS5pSlxAQAoojIEJecSaVAQkBISAEFENAhLxiTCkDEQJCIDYIiJCPDapSpxAQAkJACOiCgAh5XVCUOoSAEFAsARHyijWtDEwICAEhYPQERMgbvQllAEJACMQmARHysUlX6hYCQkAICIGYEBAhHxN6cq8QEAKKJyBCXvEmlgEKASEgBIyWgAh5ozWddFwICIHYIHD//n3cvXsXP3/+5Op9fHzQqlUr5MiRg/8/bdq0KF68OBIlShQbzUudQkAICAEhIAQiTUCEfKRRyYVCQAiYAoGbN2+iWbNmuHbtWqjhmpmZgTz0Hh4eSJEihSngkDEKASEgBISAARMQIW/AxpGuCQEhEDcE3N3dQSf2hix58+bFnDlzULt2bcSLFy9uOietCgEhIASEgBD4l4AIeXkUhIAQEAIhCAQGBqJgwYJ49uyZ+i8JEiSApaUlpk+fLqeAyhMjBISAEBACBkFAhLxBmEE6IQSEgKER8PPzg5WVFX79+sVdo9j4VatWoW7duobWVemPEBACQkAImCgBEfImangZthAQAuETePv2LerUqYNz587xhe3atUNAQAASJ04s6ISAEBACQkAIGAQBEfIGYQbphBAQAoZG4MePHyCv/NChQ5EkSRLs3bsXZcuWNbRuSn+EgBAQAkLAhAmIkDdh48vQhYAQCJ8AZa7p0aMHC3iKjY8fP74gEwJCQAgIASFgMAREyBuMKaQjxkqAsptMn+ELs4SSV9xYbRhuv3//BiRDjSJNS4MK/PAOjx89grm5uWLHKAMTAkJAuQREyCvXtjIyPREgIZ+3THWUKV9JTy1KM/okEBT0HZQ/Pl488cbrk7u+2nLo3wXL/eeKkNcXcGlHCAgBnRIQIa9TnFKZKRIQIW+KVpcxK4WACHmlWFLGIQRMk4AIedO0u4xahwREyOsQplQlBPRMQIS8noFLc0JACOiUgAh5neKUykyRgAh5U7S6jFkpBETIK8WSMg4hYJoERMibpt1l1DokIEJehzClKiGgZwIi5PUMXJoTAkJApwREyOsUp1RmigREyJui1WXMSiEgQl4plpRxCAHTJCBC3jTtLqPWIQER8jqEKVUJAT0TECGvZ+DSnBAQAjolIEJepzilMlMkIELeFK0uY1YKARHySrGkjEMImCYBEfKmaXcZtQ4JiJDXIUypSgjomYAIeT0Dl+aEgBDQKQER8jrFKZWZIgER8qZodRmzUgiIkFeKJWUcQsA0CYiQN027y6h1SECEvA5hSlVCQM8ERMjrGbg0JwSEgE4JiJDXKU6pzBQJiJA3RavLmJVCQIS8Uiwp4xACpklAhLxp2l1GrUMCIuR1CFOqEgJ6JiBCXs/ApTkhIAR0SkCEvE5xSmWmSECEvClaXcasFAIi5JViSRmHEDBNAiLkTdPuMmodEhAhr0OYUpUQ0DMBEfJ6Bi7NCQEhoFMCIuR1ilMqM0UCIuRN0eoyZqUQECGvFEvKOISAaRIQIW+adpdR65CACHkdwpSqhICeCYiQ1zNwaU4ICAGdEhAhr1OcUpkpEhAhb4pWlzErhYAIeaVYUsYhBEyTgAh507S7jFqHBETI6xCmVCUE9ExAhLyegUtzQkAI6JSACHmd4pTKTJGACHlTtLqMWSkERMgrxZIyDiFgmgREyJum3WXUOiQgQl6HMKUqIaBnAiLk9QxcmhMCQkCnBETI6xSnVGaKBETIm6LVZcxKISBCXimWlHEIAdMkIELeNO0uo9YhARHyOoQpVQkBPRMQIa9n4NKcEBACOiUgQl6nOKUyUyQgQt4UrS5jVgoBEfJKsaSMQwiYJgER8qZpdxm1DgmIkNchTKlKCOiZgAh5PQOX5oSAENApARHyOsUplZkiARHypmh1GbNSCIiQV4olZRxCwDQJiJA3TbvLqHVIQIR85GEGfniP169eIHuO3DBLmDDyN8qVkSbw6sUzDBvQFZWq10GfQcMjfZ+pXihC3lQtL+MWAsogIEJeGXaUUcQhgdgU8mdPHMGgnu2QJGlSzFyyCQUKF1WP9OfPH/Aa7YgXz55g1HgfpDPPEIcUIm466Pt3TBo7AltWL0XApv3IV7BIxDcFu+L379949/Y1EiZMhOQpUiJevHhRul9pF//69Qvv375BosSJkSx5CjWPB3dvo1fb+qhUrQ7cpvgpbdg6H48IeZ0jlQqFgBDQIwER8nqELU0pk0BsCvljf++FVZcWMDMzQ4VqtTB++kKkTJWaQf788QNjHQfh1ctncJ3oiwyZMhs04F8/f2Lfjs04e/IoetrYwzxDpij19/Onj+jfqSnK/lUFA+xHInGSpFG6X2kXv3vzGtZdWqJanfroZeOAhIkS8RBFyEfN0iLko8ZLrhYCQsCwCIiQNyx7SG+MkIA+hHz1uo1wZP8uOE+YjubtLI1SyMfUtJ8+BqJX2wYoV7EarIe5IGnSZDGt0qjvf/v6Jfp2bIrqdRqi32BH9syLkI+6SUXIR52Z3CEEhIDhEBAhbzi2kJ4YKQF9CPnZyzbDdegAZM7yf+2dCXSN19fGH7SqppqqrRJzY6h5KKo1z1SEKhEiQUgjTYSQRJDREJIQIoSYqXmoqWZqKmIuqmbVovwrphrL173JXSS0/W7d5N7c56xldeX2Pefs89vvuus5++yz7/sIHR2HgoWL/W1E/szJnzB/Rhx2bFmvAu/DClXxRVdXlCpb4aWUjx85hOjhQzS6eyBhJ5bNn4k8ed9GR+deqNu4Bc6dPoUpMaNw9PB+1KrbCO59A5D96emADPrzuTOYEx+DAwm78Mftm6jXuCXaOrqgUOFiOqekgqxY9DU2rVkO/7AovP3Oe5Ao+4TIociZKw+atLJHfMwo7N+9A4WKFIfHgEDYlimnfdevWoYxwwbht4u/4o0sWZArd15ky5EDIyfMREGbovrMzi3rMW/GJJw5eRz58r8L+45d0cK+g2G9h/fvweTokXB298aRg3sxf8YkZM+RE/YOLmjZtgPeeCOL4dmrv13G11NjkbBzq6bzVPmoNjo498IHpT80PHNw7y5MHR8J5y+9IWMvmDkZOXK8hbadXHTeJGGd1GHdisVYMGsKLl+8gMJFS8Kxhzuqf1zXMN62jWuxYOYknD19Qk9X2jp0QzO7z1/orzXfLMLY8EBNq3ozaza8lSs3cufNh2HRU/Dw4UNNrfmodj187tgN0yeOwekTx1Gh6kfo6eWHAgVtnhvz7MmflNuOLet0rNr1GsPFvR+yZsumz125fBH9ejqifZceePjggXIpblsGYWMm484ft/WUZfWyBfj57Cm8W6AgPnfsru9L0h0I6d/X1QHdPHyQM2cutefsqRMoWaqsbkBKlCqr80wdH4Wjh/bB0y8YBQs/8am03du3IDLEHz6BI1ClRu1X/i1BIf/KkXJAEiCBVCRAIZ+KsDlV+iSQGkJ+xrKNuHk9Ef3dneDmHYCOzj3x+NHjFKk1jx89wqa1KzAswBuPHj1G+UrV8ODhA4hIv574OyLj5uDjeo1fmF/+/daNCPDsgbxv58fVK7+heq1PcSDhexWybR1csPjrqShhW1ZTOEQIy6YgfuEaZMqUCUcPH4CX8+coUuID1KrTCHfu3Mac+PGaBz9s3FS8934hSE7/9AljsGLhHIydvgjv2xRB4l853kP9vXDtf1dx6qdjyJv/HeR/twCOHEhQQTpr+WYUKf4BTh4/ip3fbcTMuGj9u06j5siaNRvqNmmJnG/lwrTYKEyODsfH9Rpp6s3BvbuxffNaOLi4oWcfP2TK9Bq2rF+NMD9PFb0yX9Van+LEsR9w7vRJhETFGUSzpKb49XZWexs0t1NWS+ZOx60bNzB5wWoVoNI2r12pnGV+Ha/mJ/jp2A84f+YkwqLj0aRVW33u4cMHGDsiCLMnx6D4B6VQwrYMDu3bg8ePHyFm1lIUtCmCyWNHKhsR0RWr1dTNzK5tm9C5hwdcevdTxs82mWfH5nWYHR+DD0qXU5/KvQHhciPxmgp5EdL3795DcdvS+PPPP3HkwF5U/7gOgiJikTvv25A7BwcTdiHM31N9KvZeT0zE2uULdSMUN3cFMr+RRfm4tGsM2zLlcfrEj2r/udMnsHD9Ht3IrFw8V+cVf4ro3r5pDYIiJ6JZ6yebENmYONs3QumyFXD86GEV7rIZkzUWLWGLwFHjUaxkKWzbuAZ+Hi4IipiA+k1aAhkyqN0jBvfTDeCyLQdMkj5GIZ8+v5e5KhKwFgIU8tbiaa7TZARSS8iXLlcJvu5d8evP51Qo2hQplkLIS/QzxPcrXL74C0bGzoRN0eK67iOH9sHd0Q5lylfC0OgpyJUnbwoeIuR7d7HXKHGfgDCUtC2DhO+3YUjfXrh//75Gc1u1c1BxNaRfL0gEefrSDRqlFkF8aN9utGzroCJNmkT0Jdou6UC16jT8WyG/deMadHH9Cp1dPTRKvmj2FIwY4oM+/qHo6OKm470stUY2FX1dO6F+01bw8g9R8SktKnQgdm7diJDIibAtW16FvESG5RKo96AwFZEiTAd790K+/O9gdPw87ffL+bMqSJu2bqcRamnbNq1Fv56d4B0wVCPTSUK+Xy9HXZt8XqR4Sd1wCC/ZjERNnqvP7dnxHQa4O+nGyDc0Uk8T7t75QzcmlarXxPkzp+HdvQOatWkPj/6Bhkj+yKABKnaDIyYYotbPOu2fUmtkA+IxIBiNW7XR04bIED9sXrsKQZETUKlaTfxx+zYiQvwgEfmw6MkaTZe2cfU3evrTZ2AY7B26GoS8CP/+geFo2KKN3tm4f+8uvt+6Ce8WKISSpcvqhufCuTMY5N1TN4OjJsx6TsjLnYY+A0P1pEZOK9avXIrgAb3h5j0Q7Z164H9XfkNvp7aoXL2Wzi3vkZyuDOrjijLlK+spjikahbwpqHJMEiCB1CJAIZ9apDlPuiWQWkL+w4pVVfwNHeiF5nbtVVgnv+x6eH8CfNwc4di9t/57tgX59MbhA3sQNnqSCtvkTYT8gC+d4BMYrqkhIsyklGGorydyvJULIc9UQJn/VxpJRLAvwsfP0GisNBF6l369oBuNe3fvagqOpGFIRZ16TVr9rZCXCO/M5ZuROfOTPO9bN66jboXCcOjmDu+AMP3sZUJebBkzdNCTNA3bJ9FyaYcPJOiGYPCIsahdv4kK+cC+veAXGoVGLdvo+qSSjkSkD+3fg8UbEp5DIsJS0kVE8J4/ewqRof7o1ccfLu599TmJyAf1d8fAsNFo0Ly1YbyQAR66cVq0YY8+NyUmAhNHD8ekeStRvnL1FNznTBmvEfsv+wY8V8lHTkO+WTALgaNiUeOTein6/ZOQL1+pOkbEzlDRLU1OZXo6tNKNwacNm6lwduv0mZ5wtLDviNeflgOVdJ3IsIFo1NxON2FJEflyFatiVNwcw3hJBt2+dUs5/X71Cm5cT9TUmezZc2DS/FX6SFJEvnqtOhgxfrphHbLp9HRuj9LlKuo7lzFjBkwcPUJPBGYt34K3cufBhtXLMHxQX00ZkhMUUzQKeVNQ5ZgkQAKpRYBCPrVIc550SyC1hHy5StVw6+YNjBk2GN8uW4B5a3YibvSI56rWSE68h1NbTXmpWLXGc8wnRYdj9ZJ5CI6Kw4cVq6Twhwh5/6+6wT9sNBo2b63//3riNU0fkVz5/kHhhj7LF85BqN9XGt1v0Owz/HHrlua3r1oyD/fv3dN8eEkpkcjrvxHyv126iGlL1j1nUyWbHGjUog3CY2fo5y8T8qOCfCFiWCL5kkKT1B48uK+fDQ4fp1FzEfIisuXvTxs0NTw3dGAfLP56GhJOX9PP7t65o3/PmjxONyRSbUfSbO7evZNCyIf5e2nFoNr1GxvGkxMROY1IGk+ekQ3FrpNXtXRm8iapRQtnT3mh/ZK2I6kw1WrVSdHvn4R88vKTv144j1a1yyE4cqJu1OTv1p9WwGuvva7lTYEn5TwfPfoTN2/eQPvO3eEbEmEQ8rXrNVFbkpr4WO4JxEaEaeRc8uclXej27VuoWKVGCiFft1ELDBkZY+gvpTMDfdx1btlsyemHpNcIP0+/INRv2hrjI0I0JUhON3Lmym2S7xAKeZNg5aAkQAKpRIBCPpVAc5r0SyA1hbxQPLR3N/w9u2kuuIgpyWFPKj+57WbjHAAACrhJREFUZ8cWeLp8Af/QSLRs5/Ac9HHhwXrRVPLBJcUmefsvQl6isDHhwfiyXwDadHDSaKpsKiQt4r8I+fpNP0NE3Oy/FfIz4qIROyoUE+eueGHEO2mdfyfk5aLq/vM39dF1K5cg1M8Tn7XrpDnq+d8rgGOHD8CpTYN/LeQXz5lqGE8uaspGY8nmfYaLv8+yjx8XgbgxwzX/XqLe/7YZI+Rb1CqrQl5SpK5cvqS575Ib7ypVb56ehiSfPykin1zIS/lL395d9a6Gh28g5MRIovwBXk8uxSaPyNdp2ExPF5La1SuX9RJtocJFdfP4Ztasenl3kJcrXnv9NQwOj8EA9674pH4TOPXy1A2HKRqFvCmockwSIIHUIkAhn1qkOU+6JZDaQl7SQSTNY970SShQsBCKlLA1CPmzp35CgJer5s/7hUUZas7LBUw3RzvNmZdqIxJhf5VCXuq7/7A/Acu+O6j50dIWzZmK8aNCXqmQd+3QUk8TpLKJ/AiStE3fLkewrwd6ePRHeydXQ+qHXPy9ceM6smXPriLw3wp5OfGYGTcWy7cd0ku60rasWwUft85GCfnVS+dj6EBvdHXz0o2BnFI8ePBAc/Hfee99bNu0Rk8K3PsNQjvHbsj0NBVGNmnyS7hyiTUpPeZZn8kFWzfH1nqnwb1fgKGu/svqyEsE/lkhL6ct/h4uOr7knz97b0J/aCpLFi3x+TIhLylUXzStiZ59/NHR2U0v5EoK0uA+PfXkIbmQtylSXCPyksqTMWNG3ejJ/NK/fZfuhtOUmJHBmDZhNNx9BmPhzHjtU81EaTXCk0I+3X41c2EkYBUEKOStws1cpCkJpLaQl7VI5LJrm4a4+MvPWrEkKSIvaSFzp01QIVSt5icoXa4y7t39A3t2bsXJH49oRFQuhb6o/ZeI/ISooYgfOwodnHtqGsiJY4exbuVSLV34qiLykuYSMqA3fjiwF83tv9CcfKmmIyJXLoZKqUi7Dl1QtkIVLc0paR8ZMmZEF1cP5M6T718LeamQEj7ER0soNmjWWlNQNqxaqnn0yXPkX5Za82xE/trvV+HdvSPOnTmJRi3sYVO0GE4dP6a+8x8ahezZc2oeuFwWFvvLlKukFXukBKhEyTt1741cufOkcJmkGgX3d8eJH48+LbP5GHYdnHD7ptTbT/nLrsmFvMwhKVqTxoxA+crVUL9Za2UppSElP19OV6Tq0MuEvOTEy+VhufwspTmzZHlTT3y2bvgWJUt9mELIS9qTbDBFlMsmRTZHsmkJjpygzyc1ubzs1kmqBQHlq3yEIeHjtIqOqRqFvKnIclwSIIHUIEAhnxqUOUe6JmBKIb97+2atyCJ15MtWqPwcRxFMcjlVLlrKZUHJp5aWVNtb6nJfOHda661Lfr1TLy/974uiu9LvYML3Gp0MGB6tlyGlvSxHXkT6IK8eGBU3W0smiqiMjRyKdSsXA48ea5WVNh2dEBUWgH6Dh+llV8k1nzMlFisWzdGc5/cK2mjEedjAPrj2+/8QO3vZc+urXDgnmtm11xMEaSLcD+/bg/BAH602I1V8hsdMw9v538WN69ew5OvpWs/80i8XNE1DLpZKmk+1j+totFhYSoUa2fTUrNPAMJfkyEsJxe3HLupnTzZDE7UOv+T7Fy5WQiPl4YH9n5SDfHrZVTY+QT7uCBw5Xn91N6lJjrcI5KTx5HMRwzLm2hWLtXZ+CdvSWue+VbtOWiZSOC+ePQXffrNIKw5lzZYVFarUUIZVanySovxkEo+9u7YhIshXx5eylZI2df/+PTjZNUC9Ji3hFxppsEuEvF2dippa0/Rpach7Unnmu41YMCte2WbOnFnX27CFHewdnHUjcfHCeXRuXU/vKwwIHmUYT8T4vl3bIZs4qdaTJ28+1G3cUisYybhxc1fqs0mXXavWqK3vn9Tvv3zpVzRsbqe/USAbr2fLa8oGw6eXI3ZsXq+/AOzqOQAZMmQ02XcIhbzJ0HJgEiCBVCBAIZ8KkDlF+iZgSiGfvslxddZAIEnIJ7/s+rK1y4ZNTkTk9xDGTJmv9etN2SjkTUmXY5MACZiaAIW8qQlz/HRPgEI+3buYC/wPBP6/Qv7ns6f1BEBq3Uu5ypddwv0PJj3XlUL+VZHkOCRAAmlBgEI+LahzznRFgEI+XbmTi3nFBORSb+fP6qFxS3v4hkb84+iz48cjevgQDB83VdODTN0o5E1NmOOTAAmYkgCFvCnpcmyrIEAhbxVu5iKNJCAXjy/99UvD2bJlf+EvCicfVirm3LiRqBV9TB2Nl7kp5I10LLuRAAmYBQEKebNwA42wZAIU8pbsPdpu7QQo5K39DeD6ScCyCVDIW7b/aL0ZEKCQNwMn0AQSMJIAhbyR4NiNBEjALAhQyJuFG2iEJROgkLdk79F2aydAIW/tbwDXTwKWTYBC3rL9R+vNgACFvBk4gSaQgJEEKOSNBMduJEACZkGAQt4s3EAjLJkAhbwle4+2WzsBCnlrfwO4fhKwbAIU8pbtP1pvBgQo5M3ACTSBBIwkQCFvJDh2IwESMAsCFPJm4QYaYckEKOQt2Xu03doJUMhb+xvA9ZOAZROgkLds/9F6MyBAIW8GTqAJJGAkAQp5I8GxGwmQgFkQoJA3CzfQCEsmQCFvyd6j7dZOgELe2t8Arp8ELJsAhbxl+4/WmwEBCnkzcAJNIAEjCVDIGwmO3UiABMyCAIW8WbiBRlgyAQp5S/Yebbd2AhTy1v4GcP0kYNkEKOQt23+03gwIUMibgRNoAgkYSYBC3khw7EYCJGAWBCjkzcINNMKSCVDIW7L3aLu1E6CQt/Y3gOsnAcsmQCFv2f6j9WZAgELeDJxAE0jASAIU8kaCYzcSIAGzIEAhbxZuoBGWTIBC3pK9R9utnQCFvLW/AVw/CVg2AQp5y/YfrTcDAhTyZuAEmkACRhKgkDcSHLuRAAmYBQEKebNwA42wZAIU8pbsPdpu7QQo5K39DeD6ScCyCVDIW7b/aL0ZEKCQNwMn0AQSMJIAhbyR4NiNBEjALAhQyJuFG2iEJROgkLdk79F2aydAIW/tbwDXTwKWTYBC3rL9R+vNgACFvBk4gSaQgJEEKOSNBMduJEACZkGAQt4s3EAjLJkAhbwle4+2WzsBCnlrfwO4fhKwbAIU8pbtP1pvBgQo5M3ACTSBBIwkQCFvJDh2IwESMAsCFPJm4QYaYckERMhv3rEbefLlt+Rl0HYSsEoCCTu+w8H9e5EvXz6rXD8XTQIkYNkEKOQt23+03gwIXLt2DYmJiWZgCU0gARIwhoCNjQ0yZcpkTFf2IQESIIE0JUAhn6b4OTkJkAAJkAAJkAAJkAAJGEeAQt44buxFAiRAAiRAAiRAAiRAAmlKgEI+TfFzchIgARIgARIgARIgARIwjgCFvHHc2IsESIAESIAESIAESIAE0pQAhXya4ufkJEACJEACJEACJEACJGAcAQp547ixFwmQAAmQAAmQAAmQAAmkKQEK+TTFz8lJgARIgARIgARIgARIwDgCFPLGcWMvEiABEiABEiABEiABEkhTAhTyaYqfk5MACZAACZAACZAACZCAcQQo5I3jxl4kQAIkQAIkQAIkQAIkkKYEKOTTFD8nJwESIAESIAESIAESIAHjCFDIG8eNvUiABEiABEiABEiABEggTQn8H9FE6PMuPdL+AAAAAElFTkSuQmCC\" width=\"754\" height=\"599\"\u003e\u003cbr\u003e\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab5\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 5\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003ePrimary and secondary endpoint outcomes:\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"2\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eEndpoints\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNumber of patients\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eComplete remission after induction therapy\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e14\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eComplete remission on Day 35\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e02\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eComplete remission on Day 45\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e07\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eComplete remission on Day 60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e05\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDisease-free survival (DFS) after 3 years/\u003c/p\u003e \u003cp\u003eEven-free survival (EFS) after 3 years\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e14\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTreatment Failure\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMortality\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRelapse\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eIn our study, the age range of patients was 20\u0026ndash;50 years, aligning with the prevailing pattern where APL is commonly diagnosed in younger adults aged 20\u0026ndash;59 years and less frequently in both pediatric and elderly populations\u003csup\u003e\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eWe observed the ratio between males and females was 1:1.5, which is consistent with findings from previous clinical trials and population-based research that showed a comparatively higher frequency of APL in women\u003csup\u003e\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e\u003c/sup\u003e. It has been suggested that estrogen, a member of the retinoid receptors' superfamily, could potentially work synergistically to impact the binding of the aberrant PML/RARA protein to the RXR receptor\u003csup\u003e\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003ePatients with APL are at high risk for thrombohemorrhagic complications such as disseminated intravascular coagulation (DIC), venous thromboembolism, and bleeding manifestations. Oral bleeding is a common finding in APL and can be an initial evidence of the disease\u003csup\u003e\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e\u003c/sup\u003e and it was also found prevalent among our patients. The majority of our patients also had DIC as a clinical finding, which was persistent with the higher prevalence of DIC associated with APL compared to other subtypes of acute leukemia\u003csup\u003e\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eHematological findings like anemia, thrombocytopenia, leukopenia, and an elevated blast count, are characteristic features of acute promyelocytic leukemia (APL). The blood test reports of our patients were consistent with these typical findings. Severe thrombocytopenia is associated with an increased risk of bleeding and was found in nearly all of our patients\u003csup\u003e\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eOur study aimed to demonstrate that the use of ATRA and arsenic trioxide in both induction and consolidation therapy is potentially superior compared to the standard ATRA and anthracycline-based chemotherapy in adults with low-to-intermediate-risk APL.\u003c/p\u003e \u003cp\u003eThe combination of ATRA and ATO has already been proven effective as a frontline treatment for APL. A study by Shen et al, where induction was done with ATRA plus ATO and consolidation by chemotherapy, resulted in complete remission (CR) in 94% of patients\u003csup\u003e\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u003c/sup\u003e. Our study replicates such favorable outcomes while eliminating the use of chemotherapy. Notably, our findings are consistent with recent studies by Lo-Coco et al and Abaza et al. These studies demonstrated the superiority of ATRA plus ATO over ATRA plus chemotherapy in low- to intermediate-risk APL patients. Besides 100% complete remission, we also report a 100% 3-year EFS where Lo-Coco et al. reported 98% and Abaza et al reported 96%, surpassing the 85% EFS observed in the chemotherapy group.\u003c/p\u003e \u003cp\u003eTo improve outcomes in high-risk patients, we followed the treatment protocol outlined by Burnett et al. To the ATRA-ATO combination, we added Daunorubicin or Mitoxantrone, resulting in a significant improvement of both CR and survival rates compared with previous reports. Mitoxantrone was added in a case involving a patient with cardiac issues, as Daunorubicin was unavailable at that time. Importantly, our high-risk patients achieved complete remission without any maintenance therapy, providing additional evidence of the superiority of this treatment regimen.\u003c/p\u003e \u003cp\u003eBeyond the therapeutic advantages, our study also verified the regimen's benefits in substantially minimizing hematological side effects. While common side effects such as differentiation syndrome and QTc prolongation were noted, they were manageable.\u003c/p\u003e \u003cp\u003eThe primary limitation of this study is its single-center, nonrandomized design. The relatively small sample size is attributed to the fact that the patients included in this pilot study have already met our primary endpoints. In the meantime, in the 2023 update to the guidelines for the management of APL, the National Comprehensive Cancer Network (NCCN) has also recommended the use of the ATRA-ATO regimen for low-risk patients, while suggesting the incorporation of Idarubicin along with the ATRA-ATO regimen for high-risk patients. Nonetheless, it's important to note that our study is ongoing, continually demonstrating the effectiveness of this regimen.\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003eIn conclusion, our pilot study demonstrates the safety and efficacy of the chemotherapy-free ATRA plus ATO approach, with or without GO. This treatment regimen ensures long-term disease-free survival across all risk-group patients while reducing the burden of maintenance medication. Recognizing the substantial impact of this treatment regimen on enhancing the quality of care for APL patients, we have decided to disseminate the results of our pilot study. Further evaluation of our research findings on a larger scale is imperative, and we are actively continuing our study to contribute to the ongoing understanding of APL management.\u003c/p\u003e"},{"header":"Limitations","content":"\u003cp\u003eThis is a single-center, nonrandomized study in nature, including the patients who were only treated at our hospital. However, the similarity of results to those reported in previous studies supports the efficacy of this regimen.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll procedures involving patient samples were approved by the Ethical Committee of Sir Salimullah Medical College Mitford Hospital, and written informed consent was obtained from all patients.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eInformed written consent was obtained from all the patients involved in the study.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and materials:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe datasets used and analyzed during the current study are available from the corresponding author upon reasonable request.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare that they have no competing interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNone.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor Contribution\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eMK conceptualized the study. SBP designed the study and wrote the manuscript. MKP and MA collected the data. MK and MSI revised the manuscript. All the authors have read and reviewed the manuscript.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eGill H, Raghupathy R, Lee CYY, Yung Y, Chu HT, Ni MY et al. Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021. BMC Cancer. 2023;23(1). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1186/s12885-023-10612-z\u003c/span\u003e\u003cspan address=\"10.1186/s12885-023-10612-z\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTallman MS, Altman JK. How I treat acute promyelocytic leukemia. Blood. 2009;114(25):5126\u0026ndash;35. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1182/blood-2009-07-216457\u003c/span\u003e\u003cspan address=\"10.1182/blood-2009-07-216457\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePaulson K, Serebrin A, Lambert P, Bergeron J, Everett J, Kew A et al. Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study. British Journal of Haematology. 2014;166(5):660\u0026ndash;6. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1111/bjh.12931\u003c/span\u003e\u003cspan address=\"10.1111/bjh.12931\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRahm\u0026eacute; R, Thomas X, R\u0026eacute;cher C, Vey N, Delaunay J, Deconinck E et al. Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients. Leukemia. 2014;28(12):2422\u0026ndash;4. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/leu.2014.240\u003c/span\u003e\u003cspan address=\"10.1038/leu.2014.240\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYohannan B, Cervoni-Curet F, Rios A. AML-156 Early deaths in patients with newly diagnosed acute promyelocytic leukemia: a Single-Center Retrospective Study from a general hospital. Clinical Lymphoma, Myeloma \u0026amp; Leukemia. 2022;22:S219\u0026ndash;20. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/s2152-2650(22)01233-2\u003c/span\u003e\u003cspan address=\"10.1016/s2152-2650(22)01233-2\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSanz M\u0026Aacute;, Fenaux P, Tallman MS, Estey EH, L\u0026ouml;wenberg B, Naoe T et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019;133(15):1630\u0026ndash;43. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1182/blood-2019-01-894980\u003c/span\u003e\u003cspan address=\"10.1182/blood-2019-01-894980\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood. 1990;75(11):2112\u0026ndash;7. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1182/blood.v75.11.2112.2112\u003c/span\u003e\u003cspan address=\"10.1182/blood.v75.11.2112.2112\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWatts JM, Tallman MS. Acute promyelocytic leukemia: What is the new standard of care? Blood Reviews. 2014;28(5):205\u0026ndash;12. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.blre.2014.07.001\u003c/span\u003e\u003cspan address=\"10.1016/j.blre.2014.07.001\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChen Y, Kantarjian HM, Wang H, Cortes J, Ravandi F. Acute promyelocytic leukemia: A population-based study on incidence and survival in the United States, 1975‐2008. Cancer. 2012;118(23):5811\u0026ndash;8. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/cncr.27623\u003c/span\u003e\u003cspan address=\"10.1002/cncr.27623\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTallman MS, Andersen J, Schiffer CA, Appelbaum FR, Feusner J, Ogden A et al. All-trans-Retinoic acid in acute promyelocytic leukemia. The New England Journal of Medicine. 1997;337(15):1021\u0026ndash;8. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1056/nejm199710093371501\u003c/span\u003e\u003cspan address=\"10.1056/nejm199710093371501\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLengfelder E, Haferlach C, Sau\u0026szlig;ele S, Haferlach T, Schultheis B, Schnittger S et al. High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia. 2009;23(12):2248\u0026ndash;58. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/leu.2009.183\u003c/span\u003e\u003cspan address=\"10.1038/leu.2009.183\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLo-Coco F, Avvisati G, Vignetti M, Thiede C, Iacobelli S, Ferrara F et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. The New England Journal of Medicine. 2013;369(2):111\u0026ndash;21. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1056/nejmoa1300874\u003c/span\u003e\u003cspan address=\"10.1056/nejmoa1300874\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKela\u0026iuml;di C, Chevret S, De Botton S, Raffoux E, Guerci A, Thomas X et al. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. Journal of Clinical Oncology. 2009;27(16):2668\u0026ndash;76. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1200/jco.2008.18.4119\u003c/span\u003e\u003cspan address=\"10.1200/jco.2008.18.4119\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBurnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. The Lancet Oncology. 2015;16(13):1295\u0026ndash;305. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/s1470-2045(15)00193-x\u003c/span\u003e\u003cspan address=\"10.1016/s1470-2045(15)00193-x\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDe Botton S, Sanz M\u0026Aacute;, Chevret S, Dombret H, Martı́N G, Thomas X et al. Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia. 2005;20(1):35\u0026ndash;41. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/sj.leu.2404006\u003c/span\u003e\u003cspan address=\"10.1038/sj.leu.2404006\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eShen ZX, Shi Z, Fang J, Gu BW, Li J, Zhu Y et al. All-trans retinoic acid/As 2 O 3 combination yields a high-quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(15):5328\u0026ndash;35. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1073/pnas.0400053101\u003c/span\u003e\u003cspan address=\"10.1073/pnas.0400053101\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJq M, Jm L, Zx S, Sj C, Chen Z. How to manage acute promyelocytic leukemia. Leukemia [Internet]. 2012;26(8):1743\u0026ndash;51. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/leu.2012.57\u003c/span\u003e\u003cspan address=\"10.1038/leu.2012.57\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRavandi F, Estey E, Jones D, Faderl S, O\u0026rsquo;Brien S, Fiorentino J et al. Effective treatment of acute promyelocytic leukemia with All-Trans-Retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. Journal of Clinical Oncology. 2009;27(4):504\u0026ndash;10. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1200/jco.2008.18.6130\u003c/span\u003e\u003cspan address=\"10.1200/jco.2008.18.6130\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRaffoux E, Rousselot P, Poupon J, Daniel M, Cassinat B, Delarue R et al. Combined treatment with arsenic trioxide and All-Trans-Retinoic acid in patients with relapsed acute promyelocytic leukemia. Journal of Clinical Oncology. 2003;21(12):2326\u0026ndash;34. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1200/jco.2003.01.149\u003c/span\u003e\u003cspan address=\"10.1200/jco.2003.01.149\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(9):3342\u0026ndash;7. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1073/pnas.0813280106\u003c/span\u003e\u003cspan address=\"10.1073/pnas.0813280106\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang G, Li W, Cui J, Gao S, Cheng Y, Jiang Z et al. An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all‐trans retinoic acid. Hematological Oncology. 2004;22(2):63\u0026ndash;71. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1002/hon.728\u003c/span\u003e\u003cspan address=\"10.1002/hon.728\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEstey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovšek S, Jones D et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006;107(9):3469\u0026ndash;73. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1182/blood-2005-10-4006\u003c/span\u003e\u003cspan address=\"10.1182/blood-2005-10-4006\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eIland H, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012;120(8):1570\u0026ndash;80. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1182/blood-2012-02-410746\u003c/span\u003e\u003cspan address=\"10.1182/blood-2012-02-410746\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAbaza Y, Kantarjian HM, Garcia-Manero G, Estey E, Borthakur G, Jabbour E et al. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017;129(10):1275\u0026ndash;83. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1182/blood-2016-09-736686\u003c/span\u003e\u003cspan address=\"10.1182/blood-2016-09-736686\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSanz M\u0026Aacute;, Lo Coco F, Martı́N G, Avvisati G, Ray\u0026oacute;n C, Barbui T et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96(4):1247\u0026ndash;53. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1182/blood.v96.4.1247\u003c/span\u003e\u003cspan address=\"10.1182/blood.v96.4.1247\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCheson BD, Bennett JM, Kopecky KJ, B\u0026uuml;chner T, Willman CL, Estey EH et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Journal of Clinical Oncology. 2003;21(24):4642\u0026ndash;9. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1200/jco.2003.04.036\u003c/span\u003e\u003cspan address=\"10.1200/jco.2003.04.036\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAvvisati G, Mele A, Ma S, Vegna ML, Pasquini P, Mandelli F. Epidemiology of acute promyelocytic leukemia in Italy. Annals of Oncology. 1991;2(6):405\u0026ndash;8. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1093/oxfordjournals.annonc.a057974\u003c/span\u003e\u003cspan address=\"10.1093/oxfordjournals.annonc.a057974\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDouer D. The epidemiology of acute promyelocytic leukaemia. Best Practice \u0026amp; Research Clinical Haematology. 2003;16(3):357\u0026ndash;67. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/s1521-6926(03)00065-3\u003c/span\u003e\u003cspan address=\"10.1016/s1521-6926(03)00065-3\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBennett JS, Lin TL, Venkatesh P, Male H, Byrd KP. Acute promyelocytic leukemia: A single institution\u0026rsquo;s experience. Journal of Clinical Oncology. 2022;40(16_suppl):e19001. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1200/jco.2022.40.16_suppl.e19001\u003c/span\u003e\u003cspan address=\"10.1200/jco.2022.40.16_suppl.e19001\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eShahmarvand N, Oak J, Cascio MJ, Alcasid M, Goodman EH, Medeiros BC et al. A study of disseminated intravascular coagulation in acute leukemia reveals markedly elevated D-dimer levels are a sensitive indicator of acute promyelocytic leukemia. International Journal of Laboratory Hematology. 2017;39(4):375\u0026ndash;83. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1111/ijlh.12636\u003c/span\u003e\u003cspan address=\"10.1111/ijlh.12636\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSalah MB, Bchir M, Berred R, Kharrat R, Abdennebi YB, Aissaou\u0026iuml; L et al. PB1802: Acute Promyelocytic Leukemia and thrombosis: How to identify the high-risk patients? HemaSphere. 2022;6:1682\u0026ndash;3. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1097/01.hs9.0000850060.85301.70\u003c/span\u003e\u003cspan address=\"10.1097/01.hs9.0000850060.85301.70\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Acute Promyelocytic Leukemia (APL), All-trans Retinoic Acid(ATRA), Arsenic Trioxide (ATO), Complete Remission","lastPublishedDoi":"10.21203/rs.3.rs-4204216/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4204216/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground:\u003c/h2\u003e \u003cp\u003eAcute promyelocytic leukemia (APL) is a distinct variant of acute myeloid leukemia (AML), comprising 5\u0026ndash;10% of all AML cases. Characterized by the t(15;17) chromosomal translocation, APL presents a unique challenge due to its associated bleeding manifestations and coagulopathy, emphasizing the need for urgent and specialized management.\u003c/p\u003e\u003ch2\u003eMethods:\u003c/h2\u003e \u003cp\u003eThis prospective open-label pilot study enrolled ten newly diagnosed APL patients, stratified based on the Sanz risk score. Low and intermediate-risk patients underwent ATRA-ATO induction therapy, followed by consolidation therapy. High-risk patients received additional Daunorubicin or Mitoxantrone alongside ATRA-ATO induction. The study evaluated patient characteristics, clinical findings, laboratory results, and treatment outcomes, focusing on complete remission (CR) after induction therapy and disease-free survival (DFS) at 3 years.\u003c/p\u003e\u003ch2\u003eResults:\u003c/h2\u003e \u003cp\u003eThe study observed a 100% CR rate after induction therapy, with favorable 3-year DFS and event-free survival (EFS). No treatment failures, mortality, or relapses were reported. Laboratory findings and clinical outcomes were consistent with established characteristics of APL. The absence of maintenance therapy minimized associated toxicities, supporting the safety and efficacy of the chemotherapy-free ATRA-ATO approach.\u003c/p\u003e\u003ch2\u003eConclusion:\u003c/h2\u003e \u003cp\u003eThis pilot study underscores the potential paradigm shift in APL management by demonstrating the safety and efficacy of a chemotherapy-free ATRA-ATO strategy. The results align with the 2023 National Comprehensive Cancer Network (NCCN) update, endorsing the ATRA-ATO regimen for APL. The ongoing nature of the research emphasizes its contribution to evolving APL management practices, encouraging further comprehensive evaluations on a broader scale.\u003c/p\u003e","manuscriptTitle":"Optimizing the Treatment of Acute Promyelocytic Leukemia: A Maintenance-Free Strategy for Complete Remission","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-04-05 07:33:51","doi":"10.21203/rs.3.rs-4204216/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"1491b113-7800-4105-b640-99ffc4a99ae0","owner":[],"postedDate":"April 5th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2024-04-09T16:15:11+00:00","versionOfRecord":[],"versionCreatedAt":"2024-04-05 07:33:51","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-4204216","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4204216","identity":"rs-4204216","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}